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ABSTRACT 
 As the fourth leading cause of cancer-related deaths, pancreatic cancer is one of the most 
lethal forms of cancers in the United States. Lymphatic vessel invasion and subsequent metastasis 
to the lymph nodes are early and significant events observed during pancreatic cancer progression 
and are used to determine patient prognosis and therapy selection. Although clinicians and 
researchers recognize the importance of lymph node involvement for patient prognosis and 
therapy selection, the biological mechanisms that govern lymphatic invasion and metastasis and 
the contributions of the pancreatic tumor microenvironment to these processes remain poorly 
understood. In this dissertation, we characterize the interactions of lymphatic endothelial cells 
with pancreatic tumor cells and pancreatic fibroblasts, showing that while both cell types 
accelerate lymphangiogenesis, pancreatic fibroblasts are the major recruiters of lymphatic 
endothelial cells. Additionally, we evaluated pancreatic tumor cell invasion of lymphatics and 
demonstrated that adhesion protein E-selectin regulates pancreatic tumor adhesion to and 
transendothelial migration across a lymphatic endothelium. Blockade of E-selectin using a novel 
glycomimetic inhibitor, GMI-1271, significantly impaired these processes if pancreatic tumor 
cells expressed the proper E-selectin ligands. E-selectin blockade in vivo significantly impaired 
pancreatic tumor metastasis to a number of organs sites including the lymph nodes. This 
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impairment of metastasis through the lymphatic vasculature by GMI-1271 was not due to changes 
in lymphatic vessel density, but rather tumor cell interactions with the lymphatic endothelium.  
 Chemokine receptor CXCR4 and its ligand CXCL12 have also been implicated in 
facilitating pancreatic tumor progression and metastasis. Using a novel small molecule inhibitor 
of both CXCR4 and E-selectin, we demonstrated that CXCR4 blockade significantly impairs 
pancreatic tumor cell adhesion and transendothelial migration across a lymphatic endothelium 
independent of tumor cell expression of E-selectin ligands. In vivo blockade of both CXCR4 and 
E-selectin moderately impaired pancreatic tumor metastasis. However, this inhibition of 
metastasis through GMI-1359 administration did not prolong animal survival even when 
administered in combination with chemotherapy and immunotherapy. Examination of pancreatic 
tumor microenvironment following GMI-1359 treatment revealed significant changes to the cell 
cellular composition: drastically reduced desmoplasia and lymphatic vascular densities. Further 
studies are ongoing to evaluate GMI-1359 efficacy in combination with immunotherapy in 
spontaneous mouse models of pancreatic cancer. Altogether, our data demonstrates that 
lymphatic biology and function is affected by both pancreatic tumor cells and pancreatic 
fibroblasts, and that factors expressed by the lymphatic endothelium ((E-selectin and CXCR4) 
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I. Pancreatic Cancer Background 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related 
deaths in the United States (1) and results in over 330,000 deaths annually worldwide (2). 
Unfortunately, the 5-year survival rate for patients with pancreatic cancer is a dismal 6% and the 
median survival time is only 6 months (3). Unlike the stable or decreasing trends of incidence and 
death rates for other cancers, the incidence of PDAC continues to rise. It is predicted that by 2030 
PDAC will become the second leading cause of cancer-related deaths in the United States (4). 
Current therapies for the treatment of PDAC are inadequate. The only curative option is surgical 
resection, but only 15% of patients present with localized, resectable disease (5, 6). Standard of 
care chemotherapy, gemcitabine, does little to extend the survival of patients with metastatic 
disease (7, 8). Combinatorial treatment of gemcitabine with other drugs such as cisplatin (9), 
capecitabine (10), and nab-paclitaxel (11) have also proven unsatisfactory. A newly developed drug 
regimen, FOLFIRINOX, has improved median survival from 6 months to 11 months; however 
severe side effects limits which patients can endure this therapy (12). These dismal facts regarding 
PDAC and PDAC therapy underscore the critical need for a better understanding of PDAC biology 
in order to develop new and effective therapies.  
  As previously mentioned, the only curative option for PDAC is surgery, but for more than 
85% of newly diagnosed patients, surgery is not an option as the disease has already spread to 
regional (i.e. lymph nodes) or distant locations (i.e. liver, lung, bone marrow) (1). The ability to 
diagnosis PDAC at early stages has proven to be quite difficult. Patients with early stage PDAC do 
not present with any obvious symptoms. Even at late stage disease, PDAC symptoms are very 
similar to those of other more common gastrointestinal maladies such as weight loss, fatigue, 
nausea, appetite loss, and abdominal/back pain; this confounds proper diagnoses (5). Multiple 
imaging modalities are used to diagnosis PDAC including endoscopic ultrasound (EUS), magnetic 
resonance imaging (MRI), computed cosmography (CT), and fluorodeoxyglucose-positron 
emission tomography (FDG-PET); however, by the time imaging is performed PDAC has already 
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metastasized (13). Many researchers are evaluating potential biomarkers within the blood and 
urine, but currently none consistently and accurately indicate the presence of PDAC especially at 
early stages (14). Even when PDAC is diagnosed at localized stages, many of these patients still 
succumb to recurrent disease suggesting that the identification of metastatic disease at diagnosis 
also requires improvement (15). Deeper examination of PDAC progression and biology will 
ultimately lead to the development of better biomarkers and imaging modalities for the early 
detection of PDAC.  
 Histological examination of PDAC progression has revealed that noninvasive precursor 
lesions known as pancreatic intra-epithelial neoplasias (PanINs) arise from the ductal epithelium 
of the pancreas. As PanIN lesions progress from benign PanIN 1 to more concerning PanIN 3 
lesions, the ductal epithelium displays increasing cellular atypia and hyperplasia (3). Genetic 
studies have demonstrated that there are accompanying genetic aberrations that drive PanIN 
progression and development of PDAC. The most common genetic aberration found in PDAC 
patients is an activating mutation within the Kras gene (16-20). This mutation is found in early, 
low grade PanIN lesions and promotes the accumulation of other genetic aberrations necessary for 
PDAC development (21-23). These Kras-accompanying mutations are often inactivation mutations 
in tumor suppressor genes p16INK4a/CDKN2A, p53, or SMAD4/DPC4, all of which are frequently 
found in PDAC patient samples (16, 24-30). Similar to mutant Kras expression, these inactivated 
tumor suppressor genes can also found in precursor PanINs and cooperate with Kras mutations to 
induce PanIN transformation and PDAC development (26, 31, 32). 
II. Lymphatic System and Pancreatic Cancer   
“Cancer metastasis into and through the lymphatic vasculature and lymph nodes occurs 
frequently (>70%) in PDAC patients (5, 28, 33) and is strongly correlated with poor prognosis (34-
37). Evaluating lymph node status has proven to be a significant factor when determining therapy 
selection for cancer patients (38-40). Furthermore, lymph nodes are often the first site of metastatic 
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growth, suggesting the importance of these organs in tumor progression (41). The lymphatic 
vasculature offers the most direct route from the primary tumor to these frequently-invaded 
draining lymph nodes during PDAC dissemination. Although lymph node involvement is a crucial 
determinant of PDAC prognosis and therapy, the role of the lymphatic system in PDAC progression 
is often overlooked. A better understanding the processes of lymphatic invasion and lymph node 
metastasis in PDAC will significantly contribute to our overall understanding of this deadly disease 
and provide the groundwork for the development of novel efficacious therapies.” 
i. Normal Lymphatic Structure and Biology  
 “The lymphatic system is responsible for maintenance of tissue fluid homeostasis, 
absorption of dietary fat, and leukocyte and antigen transport from tissues to lymph nodes for the 
initiation of immune responses (42-44). Originating in nearly all vascularized tissues, blind-ended 
lymphatic capillaries, or initial lymphatics, are specialized for the uptake of interstitial fluids, 
macromolecules, antigens, and leukocytes. They are composed of a single layer of lymphatic 
endothelial cells (LECs) with discontinuous intercellular junctions and lack a basement membrane 
(45, 46). The endothelial membrane of the initial lymphatics is attached to the extracellular matrix 
(ECM) via anchoring filaments, which facilitate the opening of the lymphatic lumen during 
increased interstitial fluid pressure (47, 48). Upon entry into the lymphatic capillaries, lymph and 
its macromolecular and cellular contents are transported to larger pre-collecting lymphatic vessels 
and then to collecting vessels, composed of not just the endothelial layer, but also smooth muscles 
to facilitate flow and bi-leaflet valves to prevent backflow (49-51). The afferent collecting 
lymphatics enter the lymph nodes where the lymph is filtered and processed for immunity purposes. 
Upon exiting the lymph nodes through the efferent collecting vessels, the lymph passes through the 
major trunks of the lymphatic system, the thoracic duct and the right lymphatic trunk, and is then 
returned to the venous circulation (43, 52).” 
 “The network of lymphatic vasculature and lymph nodes responsible for draining the 
pancreas is quite complex. In the normal pancreas, the lymphatic vessels are typically located near 
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blood vessels and are often found in the interlobular spaces of the pancreas (53). Classification of 
pancreatic nodes has not been uniformly standardized, although pancreatic lymph nodes are 
generally divided into regions based upon their location around the pancreas and the areas of 
drainage of the pancreas: head/neck, body/tail, left side, or right side (reviewed in (54, 55)). Studies 
correlating primary tumor location and lymph node involvement following resection have helped 
to identify the regional patterns and probabilities of lymph node metastasis, but more analysis will 
need to done for consistent accurate prediction of lymph node involvement (56-59).” 
ii. Lymphangiogenesis and Pancreatic Cancer 
Lymphangiogenesis is the growth of new lymphatic vessels from preexisting vessels and 
is a crucial biological process during wound healing, inflammation, and malignancy (60). Under 
pathological conditions, lymphangiogenesis is primarily driven by binding of vascular endothelial 
growth factor-A (VEGF-A), -C, and -D to respective vascular endothelial growth factor receptors-
2 (VEGFR-2) and -3 and co-receptor neuropilin-2 (Nrp-2) (61-66) and binding of angiopoietin-1 
(Ang-1) and -2 to tyrosine kinase with immunoglobulin-like and EGF-like domains-2 (TIE2) 
receptor (67, 68). Additionally, numerous other growth factors have also been implicated in 
promoting lymphangiogenesis including but not limited to fibroblast growth factor -2 (FGF-2) (69), 
hepatocyte growth factor (HGF) (70), insulin-like growth factor-1 (IGF-1) and -2 (71), nerve 
growth factor (NGF) (72), epidermal growth factor (EGF) (73-75), and platelet-derived growth 
factor-BB (PGF-BB) (76, 77). Sources for these pro-lymphangiogenic factors include LECs 
(autocrine mechanisms) as well as cells within inflammatory and tumor microenvironments 
(paracrine mechanisms) such as fibroblasts (75, 78-81), macrophages (82-85), dendritic cells (83), 
and tumor cells (86-91).  
In many malignancies, new lymphatic vessel growth occurs not only within primary tumor 
sites but also pre-metastatic lymph nodes (41, 43, 52, 92-94). The reasons for tumor-induced 
lymphangiogenesis at these sites extend beyond the simple explanation of increasing potential 
escape routes for tumor dissemination to lymph nodes. Firstly, lymphangiogenesis augments the 
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transport of tumor-derived factors, such as cytokines, antigens, growth factors, and exosomes, to 
the lymph nodes. These factors are necessary for pre-conditioning of the lymph node metastatic 
niche prior to tumor arrival (41, 95, 96). Secondly, higher lymphatic vessel densities increase 
trafficking of immune-suppressing leukocytes from tumors to lymph nodes where they inhibit anti-
tumor response (97). Thirdly, lymphangiogenesis may also serve to exacerbate immunosuppression 
as LECs cross-present scavenged tumor antigens to induce T cell tolerance, and they also express 
immune checkpoint inhibitory molecules to prevent T cell activity (98-100). Fourthly, increased 
lymphatic vessel density, strengthens the chemotactic gradients needed to guide tumor cells to 
distant organs including the lymph nodes (101, 102). Lastly, lymphangiogenic vessels exhibit 
increased expression of cell adhesion molecules, integrins, and chemokines which promote LEC-
tumor cell communication and interaction during transendothelial migration and dissemination 
(103, 104). Altogether, this suggests that lymphangiogenesis supports tumor progression, and that 
anti-lymphangiogenic therapies may be effective treatment options for cancer patients. Targeting 
the lymphatic system for the treatment of cancer progression and metastasis is discussed in greater 
details in Chapter 6.  
The incidence and significance of lymphangiogenesis in pancreatic cancer progression is a 
contested area of research. Several studies have demonstrated a correlation between lymphatic 
vascular density (LVD) at the primary site and incidence of lymphatic invasion and lymph node 
metastasis in pancreatic cancer patient samples (94, 105). Additionally, expression levels of pro-
lymphangiogenic factors VEGF-C and -D and receptor VEGFR-3 have also been shown to 
correlate with increased LVD, lymphatic invasion, and lymph node metastasis of pancreatic cancer 
(94, 106, 107), but not with hematogenous invasion and metastasis (94). Correspondingly, in vivo 
deletion of VEGF-C or -D significantly decreased LVD and impaired lymph node metastasis of 
pancreatic cancer (108, 109). However, one study by Sipos et al. did not observe overexpression 
of VEGF-C or -D in PDAC patient samples (110). Moreover, they did not find any correlation 
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between LVD or pro-lymphangiogenic factor expression and lymph node metastasis or patient 
outcome (110). Their findings suggest that PDAC metastasis is independent of lymphangiogenesis 
and that metastasis to the lymph node occurs solely through pre-existing lymphatic vessels. More 
work will need to be done to determine the role of lymphangiogenesis in tumor progression and 
whether this process can be targeted for the treatment of PDAC.  
iii. PDAC Invasion of Lymphatic Vessels and Metastasis 
a. Background 
“Lymphatic vessel invasion and subsequent metastasis to the lymph nodes are early and 
significant events frequently observed during pancreatic cancer progression (5, 28). Although 
lymphatic invasion and metastasis to the lymph nodes does not directly contribute to PDAC 
morbidity in patients, these pathologies are important indicators of the metastatic potential of this 
disease. In the clinical setting, lymph node status is used to assess disease progression, to select 
appropriate therapies, and to predict survival (39, 40). Nearly all studies concur that lymph node 
status correlates with poor prognosis for pancreatic cancer patients (34, 36, 37, 111). Studies also 
agree that invasion of lymph nodes by PDAC occurs most frequently through the lymphatic 
vasculature rather than through direct/contiguous extension of the primary tumor to the lymph node 
(112-114). However, the prognostic value of mode of lymph node invasion is arguable: some 
studies report poorer overall survival in patients with lymphatic vessel-directed metastasis as 
compared to direct invasion (114), while other reports show no survival difference between the two 
modes of lymph node invasion (112, 113). Although lymph node invasion by PDAC occurs most 
frequently through the lymphatic vasculature, the LVD at the tumor site has not been conclusively 
correlated with either lymph node metastasis or prognosis due to conflicting study results (105, 
106, 110, 115). This is also true for studies examining the expression of pro-lymphangiogenic 
factors such as VEGF-C and -D (88, 110, 116) (and in pancreatic endocrine tumors (117)). The 
lack of standardized protocols for quantifying LVD in patients makes comparative analysis among 
collected data sets difficult. Some studies enumerate only intratumoral lymphatics in whole tumor 
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sections, while others examine tumor margins for peritumoral lymphatics, and still others examine 
the sum of lymphatic vessels in both regions. In the continued absence of a standardized method, 
LVD has limited value as a metric for assessing pancreatic cancer progression. “ 
“PDAC tumors are often hypovascular with only sporadic blood and lymphatic vessels 
found among the tumor cells (81). These intratumoral lymphatic vessels are typically collapsed and 
nonfunctional due to direct compression by the tumor cells and the high internal pressure of the 
PDAC tumor microenvironment (116, 118, 119). However, even in the absence of functioning 
intratumoral lymphatic vessels, tumor cells are still capable of disseminating to lymph nodes, 
although identification of reliable sentinel lymph nodes remains challenging (56). The lymphatic 
vessels located at the tumor margins are frequently described as enlarged with open lumens capable 
of being filled with tumor cells (116, 118), and drainage studies show that these peritumoral 
lymphatic vessels are, in fact, functional (119). Sipos and colleagues demonstrated that even in the 
absence of elevated LVD values and active lymphangiogenesis, PDAC patients still frequently 
presented with lymph node metastases (110). This suggests that PDAC cells are capable of invading 
the pre-existing lymphatic vasculature, especially enlarged vessels at tumor margins, and 
necessitates examination of the mechanisms regulating lymphatic invasion.” 
b. Mechanisms/Players 
“Mechanisms regulating lymphatic invasion are not completely understood, but are gaining 
increasing research interest. Most of our knowledge of vascular invasion has come from studies of 
the blood vasculature that are now being extended to studies of lymphatic vessel properties and 
function. Initially, invasion of lymphatic vessels by tumor cells was considered a passive process 
with increased interstitial fluid pressure driving tumor cells into draining lymphatic vessels (120). 
Although increased interstitial pressure may contribute to tumor cell invasion, the concept of 
lymphatic-mediated tumor metastasis as a process that utilizes a “path of least resistance” is greatly 
oversimplified, and proteomics studies have identified distinctions between primary pancreatic 
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tumors and their corresponding lymph node lesions (121). Comparisons of pancreas tumors with 
and without lymph node metastases revealed differences in protein expression intrinsic to these two 
pathological tumor presentations (122). In an effort to better understand the potential drivers of 
lymphatic metastasis, results of studies of leukocyte intravasation into lymphatic vessels are now 
being examined for commonalities to tumor cell intravasation. Three key molecular players of 
invasion have emerged as likely candidates in the regulation of tumor-lymphatic interactions and 
metastasis: chemokine signaling, paired binding of adhesion protein partners, and alterations in 
lymphatic vessel barrier integrity.” 
1. Chemokines 
“Chemokines secreted by lymphatic endothelial cells contribute to inflammation and 
initiation of immune responses in part by regulating the chemotaxis of antigen presenting cells to 
the lymph nodes. These same molecules are also being studied for similar roles in tumor metastasis 
to lymph nodes. Two widely researched candidate chemokines are CCL21 and CXCL12 and their 
respective G-protein coupled receptors (GPCRs), CCR7 and CXCR4.” 
“During normal immune responses, lymphatic endothelial cells secrete CCL21 to increase 
migration of CCR7+ dendritic cells (DCs) toward the vessel and then to guide DCs to the lymph 
nodes (123, 124). Tumor cells, including those of pancreatic cancer, overexpress CCR7 and are 
capable of responding to CCL21 cues to facilitate their dissemination to the lymph nodes (125-
128). Guo, et al., noted a correlation between CCR7 expression in tumor cells and frequency of 
lymph node metastasis in pancreatic cancer patients (129). Sperveslage, et al., confirmed these 
results and also demonstrated that lymphatic vessels of PDAC patients had significantly higher 
expression of CCL21 compared to lymphatic vessels of the normal pancreas. Expression of CCL21 
in lymphatic vessels correlated with increased lymphatic invasion and lymph node metastasis in 
these patients, as did overexpression of CCR7 in pancreatic tumor cells in vivo (130).” 
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“The expression of CCL21 in lymphatic endothelial cells is regulated by numerous 
inflammatory cytokines including tumor necrosis factor α (TNFα) and interleukin-1β (IL-1β) and 
is also influenced by increases in transmural flow (131), both of which are often present in tumor 
microenvironments. In vitro co-culture work has demonstrated that CCR7-expressing tumor cells 
have increased chemotaxis toward CCL21-expressing lymphatic endothelial cells (104, 132, 133). 
This chemotactic axis is used by tumor cells specifically for invasion into lymphatic vessels; tumor 
cell chemoattraction to blood endothelial cells does not use this mechanism (104, 134). Blocking 
CCR7 or CCL21 expression and/or function inhibits lymphatic vessel invasion and metastasis to 
the lymph nodes in vitro and in vivo (133, 135, 136). This chemokine signaling axis appears to be 
regulated by and to work in concert with VEGF-C to synergistically promote lymphatic invasion 
of CCR7+ and VEGFR-3+ tumor cells (104).” 
“Another chemokine axis that influences lymphatic metastasis is the CXCL12-CXCR4 
axis. It has been widely documented that CXCR4-expressing tumor cells, including PDAC cells, 
home to organs with high CXCL12 expression, such as the lungs, bone marrow, and lymph nodes 
(128, 137-139). In PDAC patient tissues, high expression of CXCR4 was found in tumors, while 
lymph nodes expressed high levels of CXCL12 (137, 140). This expression pattern positively 
correlated with increased LVD values in the pancreas, lymph node metastasis frequency, and poor 
disease prognosis. Tumor-associated, but not normal uninflamed, LECs secrete ample amounts of 
CXCL12 in the tumor microenvironment and attract CXCR4+ tumor cells to lymphatic vessels and 
lymph nodes (101, 141). Blocking the CXCR4-CXCL12 signaling axis has resulted in impaired 
lymph node metastasis in numerous tumor models (142-144).  An in vitro breast cancer model 
demonstrated that CXCL12-treated LECs permitted greater transendothelial migration by breast 
cancer cells, and this permissiveness could be reversed by blocking CXCR4 in the LECs (145). An 
in vivo model of melanoma demonstrated that stem-like, dual positive CD133+/CXCR4+ tumor 
cells were strongly associated with CXCL12-producing LECs and that these cells were resistant to 
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chemotherapy (101). Combinatorial treatment with a CXCR4 antagonist relieved this resistance 
and increased the efficacy of chemotherapy thereby reducing tumor growth and metastasis. This 
study suggested that CXCL12 secretion from lymphatic vessels supported a pro-metastatic and pro-
survival niche for tumor cells. Further studies are required to elucidate whether or not these types 
of mechanisms are employed in PDAC and/or its tumor microenvironment.” 
2. Adhesion Proteins 
“Physical interactions between tumor cells and lymphatic endothelial cells may be another 
crucial regulator of tumor cell intravasation. Adhesion molecules such as E-selectin, intercellular 
adhesion molecule 1 (ICAM-1), and vascular adhesion molecule 1 (VCAM-1) are typically used 
by DCs and other immune cell types to gain entry into inflamed lymphatic vessels during migration 
toward lymph nodes (131, 146). Mounting evidence indicates that these same leukocyte adhesion 
molecules may also be important for controlling tumor cell entry into lymphatic vessels (147-149). 
In a non-inflamed state, the lymphatic endothelium does not express or only very weakly expresses 
these adhesion molecules (146, 150). Inflammatory conditions—such as those found during 
infection or tumor development—or a wound healing response quickly increase the expression of 
these molecules on the lymphatic endothelium (131, 146). Increased transmural flow, also 
characteristic of an inflamed microenvironment, upregulates ICAM-1 and E-selectin expression on 
an in vitro lymphatic endothelium resulting in increased DC binding (131). A recent report shows 
that binding and transendothelial migration of breast cancer cells is also influenced by in vitro fluid 
flow, although the mechanisms governing these behaviors have not been elucidated (150). When 
placed in co-culture with tumor cells, LECs display marked upregulation of adhesion molecules. 
Kawai, et al. (2008 and 2009) have demonstrated that invasive breast cancer cells, which express 
the αLβ2 integrin ligand for ICAM-1, are capable of inducing the expression of E-selectin and 
ICAM-1 on lymphatic endothelial cells. They also demonstrated that blocking ICAM-1 impaired 
the ability of these tumor cells to bind to a lymphatic endothelium (149, 151). Studies of the ability 
of adhesion proteins on lymphatic vessels to regulate tumor cell entry should be expanded to 
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pancreatic cancer cell lines to determine if PDAC tumor cells can use similar mechanisms to bind 
and gain access to the lymphatic vasculature.”  
3. Lymphatic Vessel Barrier Integrity 
“The intrinsic cellular and molecular organizational characteristics of lymphatic vessels 
facilitate entry of immune cells and fluids from a collecting tissue bed—properties that may also 
allow these vessels to support tumor cell metastasis. The initial lymphatic capillaries within tissues 
are composed of only a single layer of endothelial cells with loose junctions between neighboring 
cells (44, 152). Unlike the tightly-formed, continuously-arranged junctions between neighboring 
endothelial cells of the blood vasculature (153), the junctional proteins—vascular endothelial 
cadherin (VE-cadherin), platelet/endothelial cell adhesion molecule-1 (PECAM-1; CD31), 
claudins, occludins, etc.—of initial lymphatic vessels are discontinuously arranged, creating gaps 
between overlapping lymphatic endothelial cells (45). These discontinuous junctions along with 
preformed openings in the basement membrane (46) enable uptake of macromolecules, fluids, and 
cells by the initial lymphatic capillaries. As lymph and cells are transported up the lymphatic 
vasculature to the collecting lymphatic vessels, the discontinuous intercellular junctions become 
more constant and successive to prevent leakage prior to arrival at the lymph nodes (45).”  
“Data suggest that tumor cells are capable of modulating the barrier integrity of the 
lymphatic endothelium to further facilitate lymphatic vessel invasion (154). Lipoxygenase 
secretion by breast cancer cells has been shown to disrupt VE-cadherin junctions and induce 
endothelial cell repulsion, resulting in breaches in the lymphatic endothelium. Tumor-secreted 
VEGF-C also facilitates invasion by creating leaky lymphatic vasculature. VEGF-C induces the 
internalization of VE-cadherin, which, in turn, promotes tumor cell transendothelial migration 
(155, 156). In a pancreatic tumor model, inhibiting Ang-2 signaling with a soluble Tie-2 receptor 
decreased lymphatic-directed metastasis to the lymph nodes (86). This result may be explained by 
studies demonstrating that Ang-2 disrupts the barrier integrity of the lymphatic endothelium and 
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increases lymphatic permeability through phosphorylation of VE-cadherin resulting in button-
junction formation in the initial lymphatic capillaries (157).”  
III. Lymphatic Vasculature and the PDAC Microenvironment 
“The PDAC microenvironment is arguably one of the most complex of any tumor 
microenvironment, replete with cancer associated fibroblasts (CAFs), immunosuppressive 
leukocytes, tumor-associated blood/lymphatic endothelial networks, and a considerably dense 
ECM compartment (Figure 1).” Collectively referred to as stroma, these components can comprise 
up to 80-90% of the tumor (29, 158, 159). The stroma not only facilitates PDAC progression and 
dissemination, it also has the capacity to influence the normal lymphatic vasculature within the 
pancreas. 
i. Cancer-Associated Fibroblasts 
One of the most striking features of PDAC tumors is the robust desmoplastic reaction observed 
within both the primary and metastatic sites. The major cellular component of desmoplasia is CAFs, 
also known as pancreatic stellate cells (PSCs) when specifically referring to PDAC. These PSCs 
have many tumor-supporting properties. Secretion of growth factors and cytokines from PSCs 
promotes PDAC cell proliferation, survival, migration, and invasion (160, 161). Reciprocally, 
PDAC cells secrete numerous factors that promote PSC proliferation and activation creating a 
positive feedback loop between the two cell types (162).  In vivo orthotopic co-injection of PSCs 
with PDAC cells was shown to accelerate tumor growth and metastasis (160, 161, 163, 164), and 
these co-injected PSCs were also observed to accompany PDAC cells to metastatic sites (161). 
Additionally, activated PSCs secrete excessive amounts of ECM proteins which impede drug 
delivery to tumors (165). Acute pharmacological inhibition of morphogen sonic hedgehog (Shh) 
was shown to inhibit α smooth muscle actin (αSMA) + fibroblast proliferation in PDAC tumors 
which, in turn, improved tumor vascularity and chemotherapy delivery to tumors (165, 166). In 
regards to influencing tumor immunity, PSCs secrete numerous factors that suppress or modulate 








Figure 1.1 Pancreatic tumor microenvironment and lymph node metastasis.  
“Cells of the tumor microenvironment are essential contributors to tumor growth, lymphatic 
invasion, and lymph node metastasis. CAFs and TAMs secrete pro-lymphangiogenic factors and 
proteases needed for lymphangiogenesis and metastasis.  Lymphatic vessels act as conduits not 
only for tumor cell metastasis, but also for immunosuppressive cell and cytokine transport to lymph 
nodes.  Nerves are also another route for pancreatic tumor metastasis and can communicate with 




These factors also promote recruitment and differentiation of immunosuppressive immune cells 
such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) to PDAC tumor 
(80, 170). PSCs disrupt T cell recruitment to PDAC tumors and are capable of inducing T cell 
apoptosis (171-174). Depletion of fibroblast activation protein (FAP)+ fibroblasts was shown to 
significantly improve T cell infiltration and immunotherapy efficacy (171). Altogether, PSCs 
provide several mechanisms that drive tumor development and progression.  
Although initially believed to be solely tumor-supportive cells, new evidence indicates 
PSCs may possess both pro- and anti-tumor properties. Recently a handful of studies have 
demonstrated that in vivo depletion of these cells accelerated PDAC progression and shortened 
survival time. Genetic ablation of αSMA+ fibroblasts resulted in more aggressive PDAC tumors 
including increased invasion and metastasis, increased hypoxia, and enhanced immunosuppression 
leading to reduced survival (175). Rhim et al. demonstrated that genetic knockout of sonic 
hedgehog (Shh) from PDAC tumor cells reduced αSMA+ PSC activation and proliferation 
resulting in poorly differentiated tumors with accelerated growth and metastasis and significantly 
shortened animal survival (176). This group’s findings were confirmed using chronic 
administration of Shh antagonists (176). Lee et al. also confirmed Rhim’s findings demonstrating 
Shh inhibition accelerates PDAC growth and Shh activation slows PDAC growth (177). Altogether, 
these studies suggest that PSCs have anti-tumor properties and complete loss of these cells leads to 
accelerated tumor progression. Interestingly, ablation of fibroblasts in these studies exposed other 
vulnerabilities of PDAC tumors: Odzemir et al. demonstrated that fibroblast-depleted PDAC 
tumors were more susceptible to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) 
immunotherapy (175), and Rhim et al. demonstrated that VEGFR inhibitors reversed tumor 
aggressiveness following Shh-dependent depletion of fibroblasts (176). The fibroblast population 
comprising the PDAC tumor microenvironment is likely heterogeneous (178, 179). Currently the 
molecular markers of fibroblast subtype are poorly defined and are often expressed across multiple 
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types of fibroblasts as well as other cell types. The depletion or inhibition of a particular subtype 
or multiple subtypes will likely have significant consequences on tumor progression and survival 
outcomes. Much more work needs to be done to fully understand the pro- and antitumor properties 
of CAFs and CAF subtypes and whether these cells can be targeted for effective PDAC therapy.  
“Due to their abundance in the PDAC microenvironment, PSCs also exert a strong 
influence over other microenvironmental cell types including the lymphatic endothelium (180). As 
one of the main protein regulators of desmoplasia, Shh signaling is PSCs lead to the creation of a 
pro-angiogenic and pro-lymphangiogenic stromal compartment (163, 181). When Shh signaling 
was inhibited in PSCs, LVD decreased and lymph node metastasis was reduced. Data such as these 
suggest that CAFs primarily influence the lymphatic endothelium via secretion of various effector 
proteins. It has been demonstrated that CAFs of various tumor types, including PDAC, secrete a 
wide range of pro-lymphangiogenic factors such as VEGF-C, VEGF-D (78, 79), VEGF-A (80), 
EGF (75), PDGF, and FGF (81). PSCs also secrete chemokines, including CXCL12, which has 
been shown to correlate with increased tumor aggressiveness, LVD values, and lymph node 
metastases in PDAC patient tissues (137, 171). In addition to their direct action on lymphatic 
endothelia, many of these same secreted factors as well as pro-inflammatory cytokines allow CAFs 
to indirectly support lymphangiogenesis and lymphatic vessel invasion through the recruitment of 
pro-lymphangiogenic immune cells such as tumor associated macrophages (TAMs) and DCs (182, 
183). Lastly, CAFs secrete matrix metalloproteinases (MMPs) and other proteases that remodel the 
ECM of tumors (184). This remodeling promotes tumor invasion of stroma and tumor vasculature 
and releases sequestered growth factors and cytokines from the ECM for tumor growth, 
angiogenesis, and lymphangiogenesis. A recent study by Shi et al. highlights an additional protease-
related mechanism by which PSCs may influence pancreatic cancer progression and lymphatic 
metastasis. Specific pancreatic stromal compartment deletion of protease-activated receptor-2 
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(PAR-2), a GPCR highly expressed in PDAC, resulted in decreased primary tumor size (due to 
anti-angiogenesis effects) but increased LVD and lymph node metastases (185).”  
ii. Immune Cells and Immune Regulation 
PDAC tumors are highly immunosuppressed microenvironments with pro-tumor 
mechanisms greatly outweighing anti-tumor mechanisms preventing the immune system from 
mounting an anti-tumor response (186). In addition to inducing immune suppression, tumor-
infiltrating immune cells contribute to many other aspects of tumor progression including tumor 
growth, inflammation, angiogenesis, metastasis and chemoresistance (187, 188). During 
progression from precancerous PanIN lesions to invasive PDAC, there is a drastic infiltration of 
tumor-supporting MDSCs, Tregs, and TAMs (189-192), and their presence significantly correlates 
with disease stage and metastasis and negatively correlates with survival (189-191, 193, 194). 
Many of these immune-suppressing infiltrating leukocytes promote tumor immune evasion by 
impairing T cell recruitment or function. MDSCs discourage T cell recruitment to tumors, induce 
T cell apoptosis through production of nitric oxide and reactive oxygen species, activate inhibitory 
Tregs, interfere with interferon γ (IFNγ) signaling, and deplete metabolites necessary for T cell 
function and survival (195-199). Additionally, Tregs inhibit the adaptive immunity through secretion 
of immunosuppressive cytokines such as IL-10 and TGF-β and expression of high levels of co-
inhibitory ligands (200). TAMs, another prominent immune cell type in the PDAC 
microenvironment, secrete ample amounts of immunosuppressive factors that impede T cell 
function directly and indirectly through preventing DC maturation necessary for T cell activation 
(201). These cells also secrete high levels of growth factors and cytokines that stimulate tumor 
growth, invasion, and angio- and lymphangiogenesis (201-206). Noticeably absent from the PDAC 
tumor microenvironment are cytotoxic and helper T cells. The abundant amounts of 
immunosuppressive cells and cytokines exclude T cells from contact with neoplastic PDAC cells 
and retain them either in the stromal compartment or at the tumor periphery (171, 172). These T 
cells are often of a naïve phenotype or are not activated (207, 208). 
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“One of the main functions of lymphatic vessels is to transport leukocytes to lymph nodes 
for immune response initiation, uniquely positioning LECs to modulate immune responses in ways 
that may support tumor progression. As immune cell trafficking conduits, LECs are responsible for 
the transport of both antigens and antigen presenting cells (APCs), such as DCs, to the lymph nodes 
for immune response optimization (124). By regulating the expression and secretion of various 
chemokines in response to inflammation, injury, or tumor development, LECs can alter the 
recruitment of immune cells to the lymph nodes, and, as a result, influence the ensuing immune 
response (reviewed (209, 210)). Partially due to lymphatic-directed recruitment, tumor-draining 
lymph nodes demonstrate a more immunosuppressive environment as compared to normal lymph 
nodes with an increased presence of Tregs, MDSCs, immature and tolerogenic DCs, and 
immunosuppressive cytokines (97, 131, 211, 212). These immunosuppressive cells and cytokines 
accumulate in the lymph as a result of increased lymphatic drainage from the tumor site (95). 
Within the lymph nodes TGF-β, a major driver of immune suppression, supports the differentiation 
and activation of Tregs as well as promoting tolerogenic and immature phenotypes of DCs (213). As 
Tregs differentiate and accumulate, they secrete more TGF-β to further drive immune suppression. 
IL-10 is another factor that supports the accumulation of immunosuppressive cells in the lymph 
nodes by promoting Treg activity (214) and tolerogenic DC function (214, 215). Indoleamine 2,3-
dioxygenase (IDO) increases the generation of Tregs in the lymph nodes (216, 217), while 
concurrently inhibiting effector T cell activity (218). Other factors implicated in the accumulation 
of immunosuppressive cells in lymph nodes include IL-4, VEGF-A, and prostaglandin E2 (219).”  
“In addition to cellular and cytokine transport, LECs also transport tissue antigens (and in 
the case of cancer, tumor antigens) from peripheral tissues to lymph nodes. Studies have 
demonstrated that LECs, particularly those in the lymph nodes, are capable of scavenging these 
tissue and tumor antigens and cross-presenting them on major histocompatibility complex-I (MHC-
I) (98, 99). This can lead to immune tolerance through deletion of naive CD8+ T cells as LECs lack 
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co-stimulatory molecules needed to activate the T cells and instead express programmed death-
ligand 1 (PD-L1), an inhibitory signal for T cells (100). LECs can also present scavenged 
exogenous tissue/tumor antigens on MHC-II molecules and likely induce immune tolerance 
through interactions with the inhibitory lymphocyte activation gene-3 (LAG-3) protein on CD8+ T 
cells (220). These studies shed light on the phenomenon that when tumor cells are denied lymphatic 
vessel experience, such as through direct implantation into lymph nodes, tumor immunity is 
impaired through a robust CD8+ T cell response (221). LECs also modulate immune responses by 
inhibiting DC maturation (211). Binding of DCs to the lymphatic endothelium via macrophage-1 
antigen (Mac-1) and ICAM-1-mediated interactions during transendothelial migration can reduce 
the expression of co-stimulatory molecules on DCs needed for T cell activation. Studies such as 
these inspire new ideas regarding increased lymphangiogenesis at the tumor periphery and draining 
lymph nodes, suggesting that it may influence tumor progression in two ways: 1) increasing 
metastatic routes for dissemination and 2) immune suppression through increased antigen 
scavenging and decreased DC maturation leading to T cell inhibition and immune tolerance (222). 
Further investigation is needed to substantiate the immunosuppressive properties of the lymphatic 
endothelium and its specific contribution to disease progression as a component of the tumor 
microenvironment.”  
“A reciprocal concept in relation to the capacity of LECs to affect immunity is that of 
immune cells inducing effects on LECs. One such tumor infiltrating immune cell type, TAMs, can 
be found in many tumor microenvironments, including PDAC (202, 203, 223, 224), and their 
presence often correlates with poor patient prognosis (225-227). TAMs promote tumor 
lymphangiogenesis through two mechanisms: paracrine secretion of pro-lymphangiogenic factors 
and transdifferentiation into LEC-like progenitor cells. TAMs secrete high levels of VEGF-C and 
-D, which, in turn, increases LVD in and around tumors (202-205). Indeed, TAM density has been 
shown to significantly correlate with increased LVD, lymphatic vessel invasion, and lymph node 
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metastasis in many cancers (202, 205, 228-230). Inhibition or depletion of TAMs from tumor 
microenvironments significantly reduced LVD values and decreased the incidence of lymph node 
metastases compared to tumors with TAMs present (231-233). However, depletion of TAMs did 
not completely inhibit lymph node metastasis as tumor cells were still able to invade pre-existing 
lymphatic vessels. These macrophages also secrete proteases such as MMP-2, MMP-9, and 
plasmin/urokinase plasminogen activator (uPA) that remodel the extracellular microenvironment 
and release sequestered growth factors for lymphangiogenesis (234, 235). The plasmin/uPA system 
is also important for the proteolytic maturation of VEGF-C and -D increasing their affinity for 
VEGFR-3 (236). It has yet to be determined if TAMs secrete any of the other factors known to 
promote lymphangiogenesis. The second way TAMs contribute to lymphangiogenesis is by 
transdifferentiating into LEC-like progenitors both in inflammatory and tumor settings (232, 237-
239). Transdifferentiated macrophages undergo genetic reprogramming (237) with increased 
expression of lymphatic markers LYVE-1, Prox-1, podoplanin, and VEGFR-3 (232, 237, 240, 241). 
Expression of LEC markers enables TAMs to physically incorporate into the newly developing 
lymphatic vasculature. The percentage of transdifferentiated TAMs within these newly formed 
lymphatic vessels is often less than 10% (232, 240) suggesting the main mechanism by which 
TAMs promote tumor-associated lymphangiogenesis is through secretion of pro-lymphangiogenic 
factors.”  
IV. Summary 
The lymphatic system almost certainly plays a significant role in PDAC progression, as 
dissemination to the lymph nodes is seen early and frequently in PDAC patients. Lymphatic vessels 
are routes for PDAC dissemination as they directly connect the primary tumor to the draining lymph 
nodes. Additionally, these vessels transport tumor-derived factors and immune cells to lymph nodes 
in order to make these organs more hospitable for tumor metastases. Lastly, the endothelial cells 
that comprise lymphatic vessels are known suppressors of the immune system through cross 
presentation and expression of co-inhibitory ligands. All these roles promote efficient PDAC 
21 
 
growth, dissemination, and immune suppression. However, the specific mechanisms governing 
lymphatic invasion and metastasis are sorely under-researched as are the contributions of the PDAC 
microenvironment to these processes. In this dissertation, we characterized the effects PDAC cells 
and pancreatic fibroblasts have on lymphatic endothelial cells in regards to recruitment, 
lymphangiogenesis, and invasion. Using novel small molecule inhibitors, we specifically focused 
on the roles of E-selectin and CXCR4 in regulating lymphatic invasion and metastasis and whether 





Materials and Methods  
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I. Cell Lines and Cell Culture 
i. Primary Human Lymphatic Endothelial Cells 
 Adult human dermal microvascular lymphatic endothelial cells (hLECs) were purchased 
from Lonza and cultured in EGM-2MV growth medium supplemented with 5% fetal bovine serum 
(FBS), growth factors (hEGF, VEGF, hFGF-B, R3-IGF-1), ascorbic acid, hydrocortisone and 
antibiotics (GA-1000) per manufacturer's specifications. Cells were maintained in a 37⁰ C 
humidified atmosphere at 5% CO2. As an alternative source, hLECs were also purchased from 
PromoCell and maintained in culture as stated above. Primary hLEC cultures were used at passages 
5-8. For serum starvation studies, hLECs were washed and media replaced with EBM-2 basal 
media for 24 hours. 
ii. Primary Human Umbilical Vein Endothelial Cells 
 Primary human umbilical vein endothelial cells (HUVECs) were purchased from Lonza 
and cultured in EGM-2MV growth medium supplemented with recommended growth factors and 
antibiotics per manufacturer's specifications. Cells were maintained in a 37⁰ C humidified 
atmosphere at 5% CO2. Primary HUVECs were used at passages 4-9.  
iii. Human Pancreatic Cancer Cell Lines 
 All human PDAC cell lines were maintained in RPMI medium supplemented with 7% FBS 
and 100 units penicillin/100 μg of streptomycin per 1 ml of culture media. Cells were stored in a 
37⁰ C humidified incubator with 5% CO2. Human PDAC cell lines used include: S2-013, BxPC-
3, Colo357, HPAF-II, T3M4, Hs667t, Capan-1 and MiaPaca-2.  For serum starvation studies, FBS-
containing RPMI was removed, cells were washed, and media replaced with RPMI containing no 
FBS. 
iv. Mouse Pancreatic Cancer Cell Lines 
 Mouse pancreatic tumor cells KPC8060 and KPC8069 were derived from LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mouse tumors by our laboratory. KPC mice 
spontaneously develop PDAC tumors in a manner that recapitulates the human disease with 
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progression from precursor PanIN lesions to pancreatic cancer (242).  Additionally, our laboratory 
has back-crossed (10 times) the KPC mouse into the C57BL/6 background. For tumor cell isolation, 
the pancreas was minced with scissors and then digested with 2 mg/ml collagenase A (Roche, Basel 
Switzerland) for 45 minutes to 1 hour at 37⁰ C with shaking. Cells were cultured in DMEM 
containing 5% FBS and 100 units penicillin/100 μg of streptomycin per ml of media. KPC8060 
and KPC8069 cell lines were evaluated for epithelial morphology and routinely passaged to 
discourage fibroblast growth.  
v. Pancreatic Fibroblast Cells 
 Immortalized, non-transformed pancreatic fibroblast clones 13.34, 13.7, 13.8, and 13.9 
were cultured in RPMI supplemented with 7% FBS and 100 units of penicillin/100 μg of 
streptomycin per ml of media. Cells were maintained in a 37⁰ C humidified incubator with 5% 
CO2. 13.34 pancreatic fibroblasts have been previously determined to be of an activated stellate 
cell phenotype (166). Additionally, 09-06 PC pancreatic fibroblasts (isolated from a pancreatic 
cancer patient during a Whipple procedure and immortalized with hTERT) and primary LM 
fibroblasts (isolated from a liver metastasis of a pancreatic cancer patient) were a generous gift 
from Dr. Quan Ly. These cells were also cultured in RPMI supplemented with 7% FBS and 100 
units penicillin/100 μg of streptomycin per ml of media and stored in a 37⁰ C humidified incubator 
with 5% CO2. Dermal human foreskin fibroblasts (HuFF) were also cultured under the same 
conditions as above.  
II. Conditioned Media Collection and Preparation 
 To create cellular conditioned media (CM), 3.2x104 PDAC cells or pancreatic fibroblasts 
were plated per 1.0 cm2 in tissue culture-treated plasticware. Following cell adhesion, media was 
changed to RPMI or EBM-2 supplemented with 0.2% FBS. Cells were allowed to condition the 
media for 24 hour. Media was then collected and passed through a 0.45 μm filter to remove cell 
debris prior to use.  
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III. Cell Lysates and Western Blotting 
i. Whole Cell Lysates 
 Whole cell lysates were collected using a Radio Immuno Precipitation Assay (RIPA) lysis 
buffer (150 mM NaCl, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris base, pH 
8.0) supplemented with a Roche mini PMSF tablet, and 1X Halt Protease and Phosphatase Inhibitor 
Cocktail (Thermo Fisher Scientific). Collected samples were then centrifuged at 10,000 rpm for 10 
minutes at 4⁰ C. Supernatants were collected and stored at -20⁰ C.  
ii. CA19-9 Western Blot 
For CA19-9 western blotting of tumor cell lysates and conditioned media, 50 μg of protein 
or 30 μl of conditioned media were loaded onto  4-20% Tris-Glycine gradient gels (Bio-Rad 
Laboratories) under reducing conditions (2.5% dithiothreithol and 2.5% β-mercaptoethanol). Gels 
were run at 180 volts in SDS-PAGE running buffer (3 g/L Tris base, 14.4 g/L glycine, 1 g/L SDS). 
The proteins were then transferred to PVDF membranes for 1 hour at 0.35 amps in a Tris-glycine 
buffer (TBS; 1.4 g/L Tris base, 7.2 g/L glycine). The membranes were blocked for 2 hours with 
5% nonfat dry milk diluted in TBS buffer (3.0 g/L Tris base, 150 mM NaCl, 3 mM KCl) containing 
0.1% Tween-20 detergent (TBST). Following blocking, membranes were incubated with mouse 
anti-human sialyl LewisA (sLeA) (CA19-9; 1:500) or loading control mouse anti-mouse β-actin 
(1:3000, Sigma) overnight at 4⁰ C. After washing with TBST, the membranes were incubated with 
goat anti-mouse-HRP secondary antibodies (Jackson Labs) for 1 hour followed by exposure to 
chemiluminescence reagents (Thermo Scientific) for visualization.   
iii. CXCR4 Western Blot 
For CXCR4 western blots, 50 μg of protein were loaded into the wells of 10% Bis-Tris 
gels under reducing conditions in a 1X MOPS buffer (50mM Tris, 50 mM MOPS, 0.1% SDS, 1 
mM EDTA). The gel electrophoresis and membrane transfer were performed as stated above. 
Membranes were blocked for 2 hours with 5% nonfat dry milk diluted in TBST followed by 
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incubation with rabbit polyclonal CXCR4 antibody (Abcam; 1:500) overnight at 4⁰ C. After 
washing, the membranes were incubated with goat anti-rabbit-HRP secondary antibodies (Jackson 
Labs) for 1 hour followed by exposure to chemiluminescence reagents for visualization. 
iv. Phospho-ERK and Total ERK Western Blot 
Western blotting for phospho-ERK and total ERK was performed similarly to CXCR4 
western blotting except a 5% bovine serum albumin (BSA) buffer (10 mM Tris base, 100 mM 
NaCl, 0.2% Tween-20) was used for blocking and primary antibody incubations and 1% BSA 
buffer for secondary antibody incubations. Rabbit polyclonal phospho- and total ERK antibodies 
(Cell Signal) were used at a 1:1000 dilution.  
IV. Flow Cytometry 
i. In Vitro Expression Studies 
 Cells were collected using TryLE Cell Dissociation Buffer (Invitrogen) and then washed 
with PBS containing 5% FBS. Following washing, cells were incubated with primary antibodies 
for 30 minutes at room temperature. Cells were then washed 2 times with PBS+5% FBS and 
appropriate fluorescently labeled AlexFluor secondary antibodies (Invitrogen; 1:500) added. Cells 
were incubated with secondary antibodies for 30 minutes at room temperature in the dark. Cells 
were then washed again and incubated for 10 minutes with 2% neutral buffered formalin diluted in 
PBS+2% FBS. Cells were washed and resuspended in PBS and then analyzed by flow cytometry. 
Primary antibodies included rabbit polyclonal anti-CXCR4 (Novus Biologicals; 1:200), mouse 
anti-human E-selectin (Santa Cruz; 1:100), and mouse and IgG controls (Jackson Labs; 1:1000).  
ii. Immune Cell Identification  
 Cells isolated from KPC8060 orthotopic tumors were incubated with Live/Dead Aqua stain 
(Thermo Fisher Scientific) for 10 minutes in the dark then equally dispensed into the wells of a 96-
well plate. Excess Live/Dead stain was washed with PBS+2% FBS. Cells were then incubated with 
fluorophore-conjugated primary antibodies (5 µl/sample) for 30 minutes in the dark at room 
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temperature followed by washing with PBS+2% FBS. Dr. Kamiya Mehla kindly developed and 
optimized the immune cell panel for the study (Table 2.1). Following washing, cells were fixed 
with 2% paraformaldehyde (PFA) for 10 minutes in the dark at room temperature. Cells were again 
washed and then resuspended in 150 μl PBS+1% FBS and taken to the Flow Cytometry Facility 
for analysis. Unstained immune cells and compensation beads (eBiosciences) were used at controls.  
V. Methylene Blue Proliferation Assay 
 For analysis of the effects of E-selectin and CXCR4 blockade on cells, a methylene blue-
based proliferation assay was adapted from (243). Briefly, 3x103 cells were plated in the wells of a 
96-well plate along with increasing doses of GMI-1271 or GMI-1359. Five replicate wells were set 
up per dose. At designated time points (2, 24, 48, 72, and 96 hours), cells were fixed with 10% 
neutral buffered formalin then stained with 1% methylene blue for 30 minutes. After staining, cells 
were washed 4 times with 0.01 M borate buffer (pH 8.5). The methylene blue dye was then eluted 
from the cells with 1:1 (v/v) solution of ethanol and 0.1 N HCl, and the absorbance at 650 nm was 
read. Increases in the OD values were plotted as cells proliferated over time.  
VI. Inhibitor Dosing Assay 
 Cells were plated in the wells of 24-well plates and grown to 70% confluence. GMI-1271 
or GMI-1359 at various concentrations was added to the wells. Cells were imaged every 24 hours 
for 96 hours and examined for changes in morphology and cell death. GMI-1271 and GMI-1359 
are rationally designed glycomimetic small molecule inhibitors developed by GlycoMimetics, Inc. 
(Rockville, MD). GMI-1271 inhibits adhesion protein E-selectin with an IC50 of 2.4 µM. GMI-
1359 inhibits both E-selectin (IC50: 1.0 µM) and chemokine receptor CXCR4 (IC50: 0.5 µM). To 





Table 2.1 Panel of immune cell markers used for in vivo identification within tumors.  
 
Panel 1   
Marker Fluorophore Cell Type 
Live/Dead Aqua live vs. dead cells 
CD11b eFluor450 macrophages/monocytes 
CD11c PE-Cy7 DCs 
Gr-1 FITC MDSCs 
F4/80 PE macrophages 
   
Panel 2   
Marker Fluorophore Cell Type 
Live/Dead Aqua live vs. dead cells 
CD3 PE T cells 
CD8 PerCP-Cy5.5 CD8+ T cells 
CD4 APC-Cy7 CD4+ T cells 
CD19 PE-Cy7 B cells 
CD335 APC NK cells 
 
Table 2.1 lists the immune cell markers and conjugated fluorophores used to identify the immune 





VII. In Vitro Lymphangiogenesis Assays 
i. Collagen-I Three-Dimensional Matrix 
 For analysis of in vitro tubulogenesis, 5x104 hLECs were plated into the wells of a 48-well 
plate. When hLECs achieved a confluent monolayer, 100 μg/ml of rat tail collagen-I (BD 
Biosciences) was overlaid across the hLECs and allowed to form a three-dimensional matrix. Cells 
were imaged at 18 hours and tube number quantified. All treatments were performed in triplicate. 
For inhibitor studies, increasing doses of GMI-1271 or GMI-1359 were included during 
tubulogenesis.  
ii. Growth Factor Reduced Matrigel Three-Dimensional Matrix 
 As a secondary method for evaluating lymphatic tubulogenesis in vitro, we used a three-
dimensional matrigel matrix to elicit tube formation. In the wells of a 96-well plate, 55 μl of Growth 
Factor Reduced Matrigel Basement Membrane Matrix (Corning) was allowed to gelatinize for 30 
minutes at 37⁰ C in a humidified incubator. After gel formation, 1.2x104 hLECs were plated in 
designated wells. After 6 hours, hLECs formed tube-like networks and phase contrast images were 
collected. Tubulogenesis was quantified by counting the number of tubes per image. For inhibitor 
studies, increasing doses of GMI-1271 and GMI-1359 were incubated with hLECs for 30 minutes, 
after which, hLECs were added to the matrigel matrix. Each treatment was performed in triplicate. 
VIII. Live Cell Imaging of Co-cultures 
i. Co-culture Invasion Imaging Assay 
 To characterize PDAC cell and pancreatic fibroblast interactions with a lymphatic 
endothelium, hLECs were plated in the wells of a 24-well plate and grown to confluence. Once 
confluence was achieved, 4x104 S2-013, Colo357, or 13.34 cells were overlaid atop the hLEC 
monolayer. In studies examining the effects of E-selectin and CXCR4 blockade on this invasion 
process, GMI-1271 or GMI-1359 was added to hLEC monolayers 30 minutes prior to the addition 
of PDAC cells or fibroblasts. Phase contrast images at 10X or 20X magnification were collected 
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every 10 minutes using an IX81 Spinning Disk Upright Confocal Olympus Microscope. During 
image collection, cells were stored in a 37⁰ C humidified (48%) chamber with 5% CO2. Live cell 
movies were made from the images using Slikebook 5.5 software for image acquiring and 
processing. Cell types were distinguished by cell morphology. Each co-culture and/or treatment 
conditions were performed in triplicate and multiple cells per well analyzed. 
ii. Co-culture Migration Imaging Assay 
 To characterize the migration properties of a distinct cell population to another distinct cell 
population, 2-well silicone adhesive cell culture inserts were added to the wells of a 24-well plate. 
Cells were plated into designated wells at a density of 2x104/insert and allowed to adhere overnight. 
Inserts were removed once cells had adhered and washed twice to remove non-adherent cells and 
cell debris. Phase contrast images at 10X magnification were collected every 10 minutes. Each cell 
combination was performed in triplicate and assay was repeated thrice. Image analysis and front 
migration rate was performed using NIH open source Image J program. 
iii. Co-culture Lymphangiogenesis Assay 
 To evaluate how pancreatic tumor cells and fibroblasts influenced lymphangiogenesis in 
vitro, we did live cell imaging of these cells in co-cultures with LECs during collagen-I induced 
tubulogenesis. Human LECs were plated into the wells of a 48-well plate and grown to confluence. 
Once a confluent monolayer was established, 5x104 S2-013, Colo357, 13.34 cells were overlaid 
atop the hLEC monolayer along with 100 μg/ml of rat tail collagen-I.  Phase contrast images (10X 
magnification) were collected every 10 minutes. Each cell combination was performed in triplicate 




IX. Immunohistochemical Staining 
  To identify metastatic lesions, formalin-fixed (24 hours) paraffin-embedded (FFPE) mouse 
tissues were cut into 5 µm sections and deparaffinized and rehydrated using standard procedures. 
Standard hematoxylin and eosin staining was performed.  
 Staining for specific proteins, FFPE tissue sections were deparaffinized and rehydrated. 
Heat-induced antigen retrieval was performed using 10 mM citrate buffer (pH 6.0) containing 
0.05% Tween-20 for 10 minutes. Endogenous peroxidases were blocked using DAKO peroxidase 
block for 5 minutes followed by a 1% BSA protein block for 1 hour. Primary antibodies were 
incubated overnight at 4⁰ C. For secondary staining identification, DAKO polymer-labelled 
secondary was used followed by DAB substrate and a hematoxylin counterstain. Primary antibodies 
included mouse anti-mouse α-smooth muscle actin (Sigma; 1:400), rabbit polyclonal anti-CD31 
(Abcam; 1:100) and rabbit polyclonal anti-CD45 (Abcam; 1:100) antibodies. 
X. Immunofluorescence Staining 
  For immunofluorescence staining, deparaffinization, antigen retrieval and blocking were 
all performed in the same manner as the immunohistochemical staining for FFPE tissue sections. 
Rabbit polyclonal anti-LYVE-1 (Abcam; 1:100) was incubated with tissues overnight at 4⁰ C. 
After washing, appropriate Alexa Fluor secondary (1:500) antibodies were applied for 1 hour at 
room temperature. Sections were mounted with DAPI-containing mounting media (Vector Labs).  
 For staining of cells in vitro, cells were fixed with 10% neutral buffered formalin for 15 
minutes. Protein blocking and permeabilization were performed simultaneously with PBS 
containing 5% FBS and 0.1% Triton X-100 for 30 minutes. Primary antibodies were incubated at 
4⁰ C overnight. After washing, appropriate Alexa Fluor secondary antibodies were applied for 1 
hour at room temperature. Again, sections were mounted with DAPI-containing mounting media. 
Primary antibodies used included: mouse anti-human E-selectin (R&D Systems, 1:100); mouse 
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anti-human VE-cadherin (BioLegend; 1:400); mouse anti-human CA19-9 (1:100); and mouse IgG 
(Jackson Labs; 1:1000).  
XI. Boyden Chamber Migration Assays 
 For a quantifiable measure of cell migration, Boyden chamber control insert migration 
plates were used (24 well; 8 μm pore; PET membrane). In the upper chamber, cells were diluted in 
serum free media at plated at a density of 2.5x104 cells/insert (500 μl/insert). In the lower wells, 
750 μl of chemoattractant-containing media was added. After 24 hours of migration, membranes 
were washed with PBS, and non-migratory PDAC cells were mechanically removed using a Q-tip. 
Migratory cells were fixed and stained with Diff-Quick staining kit. Membranes were mounted on 
slides and divided into quadrants. Representative 10X images were collected from each quadrant 
and the numbers of cells quantified. Each experiment was performed in triplicate.  
 Several types of chemoattractants were used for various studies: undiluted PDAC 
conditioned media, undiluted fibroblast conditioned media, EGM-2MV growth media for hLECs, 
RPMI containing 7% FBS for PDAC cells and fibroblasts, or 200 ng/ml CXCL12 diluted in serum 
free media. When studies employ GMI-1271 or GMI-1359, inhibitors were added to the upper 
chamber and lower well at designated concentrations.  
XII. Live Cell Fluorescent Labeling 
 To help identify disparate cell types in co-culture assays, cells were fluorescently labeled 
with either 5 μM Vybrant CFDA-SE Cell Tracer or 10 μM Cell Tracker Orange CMRA (Invitrogen, 
Carlsbad, CA). Briefly, cells were incubated with designated concentrations of the fluorescent 
labels diluted in serum free media at 37⁰ C for 15-30 minutes. After labeling, cells were washed 
with prewarmed, serum containing media for 30 minutes at 37⁰ C. Washing media was removed 
and cells were prepped and counted for co-culture assays. 
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XIII. PDAC Adhesion Assays 
 For evaluation of the role of E-selectin and CXCR4 in PDAC cell adhesion, hLECs were 
plated in 8-well chamber slides (BD Biosciences) and grown to confluence. After establishing a 
confluent monolayer, hLECs were pretreated with increasing doses of GMI-1271 or GMI-1359 for 
1 hour. After hLEC pretreatment, 2.5x104 CFDA-SE-labeled PDAC cells were overlaid on top of 
the hLEC monolayers. Non-adhered tumor cells were washed away with PBS and adhered cells 
were fixed with a 10% neutral buffered formalin. Slides were mounted with DAPI-containing 
mounting media and images collected and quantified. Four representative fields were imaged at a 
4X magnification. Three replicate wells were analyzed per experiment, and each experiment was 
also performed in triplicate. 
XIV. Transendothelial Migration Assays 
 Using a modified Boyden chamber system (24 well; 8.0 μm pore), 3x104 hLECs were 
plated on the underside of PET membrane insert and allowed to grow to confluence. In some 
experiments, hLEC monolayers were pre-treated with 2 ng/ml recombinant human TNFα (R&D 
Systems) for 7 hours to induce inflammatory E-selectin expression. In experiments with CXCL12, 
hLECs were pretreated with 200 ng/ml recombinant human CXCL12 for 8 hours. Additionally, 
hLECs were pretreated with increasing doses of GMI-1271 or GMI-1359 or mouse anti-human 
CXCR4 neutralizing antibody (10 µg/ml) for 1 hour. After pretreatment, 5x104 CFDA-SE-labeled 
PDAC cells were diluted into serum free RPMI and added to the upper insert of the Boyden 
chamber. In the lower wells, EGM-2MV was added as a chemoattractant. PDAC cells were allowed 
to transendothelial migrate for 24 hours. Following TEM, membranes were washed with PBS, and 
non-migratory PDAC cells were mechanically removed using a Q-tip. Membranes were then fixed 
with methanol and mounted on slides using DAPI-containing mounting medium. Five 
representative images at 10X magnification were taken of every membrane and the CFDA-SE 
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fluorescent pancreatic tumor cells were quantified. Three replicate wells were analyzed per 
experiment, and each experiment was also performed in triplicate. 
XV. Transwell Co-culture and qRT-PCR 
4x105 hLECs were plated on the underside of PET membrane inserts (0.4 μm pore; 24 mm 
diameter; BD Biosciences) and incubated overnight. The next day, 6x105 PDAC cells or pancreatic 
fibroblasts were added to upper side of the membrane and co-cultured with the hLECs for 
designated times. After co-culturing, mRNA was isolated from hLECs using RNAqueous Micro 
Isolation kit (Invitrogen). 200 ng RNA was reverse transcribed using Verso cDNA Synthesis kit 
(Thermo Scientific). Triplicate qRT-PCR reactions were performed using SYBR Green Master Mix 
(Applied Biosystems) per manufacturer’s specifications. Relative fold changes were calculated 
based on normalization to GAPDH using cycle threshold values. E-selectin forward primer: 5’-
TGTGGGTCTGGGTAGGAACC-3’; reverse primer: 5’-AGCTGTGTAGCATAGGGCAAG-3’; 
GAPDH forward primer: 5’-GAAGGTGAAGGTCGGAGTC-3’; reverse primers 5’-
CAAGCTTCCCGTTCTCAGCC-3’. 
XVI. Orthotopic Implantation Models  
i. S2-013 Orthotopic Implantation  
  S2-013 (2x106 cells) were orthotopically implanted into the pancreases of female athymic 
nude mice (4-6 weeks old; Jackson Labs). Tumors were allowed to establish over the course of two 
weeks prior to the start of treatment. Following tumor development, mice were divided into 
treatment groups. For metastasis studies, mice were treated for 4 weeks then sacrificed. For survival 
studies, mice were treated until end stage disease. The criteria for end stage disease included severe 
weight loss, excessive ascites accumulation, or extreme weakness/inactivity. Primary pancreatic 
tumors and metastatic organ sites (lymph nodes, lungs, diaphragm, liver, kidneys and spleen) were 
collected at the end of each study and evaluated for tumor microenvironment composition and 
metastatic lesion presence.   
35 
 
ii. KPC8060 Orthotopic Implantation 
 For evaluation of GMI-1271 and GMI-1359 effectiveness in immunocompetent mice, 
9x104 KPC8060 mouse PDAC cells were implanted into the pancreas of syngeneic C57BL/6 mice. 
In some studies, treatments were initiated two weeks post-orthotopic implantation; in other studies, 
treatments were initiated the day after orthotopic implantation. Similar to experiments with S2-013, 
both survival and metastatic studies (2-week duration), were performed.  
iii. Inhibitor Treatment Schedules 
 All injections were administered by intraperitoneal injections. Table 2.2 describes the 
various drugs and treatment schedules performed in the in vivo tumor studies. PD-L1 was 
administered on days following gemcitabine treatment as it has been previously demonstrated that 
immunotherapy results in better responses after cytotoxic tumor killing (244).  
iv. Immune Cell Isolation from Mouse Tumors 
 For analysis of immune cell populations within KPC8060 tumors, primary tumors were 
collected and minced into small pieces. Tissue was then digested in RPMI containing 10% FBS, 2 
mg/ml Collagenase A and 0.25 units/ml DNase I for 45 minutes at 37⁰ C with shaking. Cells were 





Table 2.2 Drug schedule for in vivo treatment of mice. 
Drug Dose Frequency 
Vehicle Control (PBS) --- Daily 
GMI-1271 (low dose) 40 mg/kg Daily 
GMI-1271 (high dose) 40 mg/kg Twice daily 
GMI-1359 40 mg/kg Daily 
Gemcitabine* 60 mg/kg Every 4 days 
Gemcitabine 100 mg/kg Every 4 days 
Anti-PD-L1 antibody 160 μg/mouse Every 4 days following gemcitabine 
 
Table 2.2 lists the small molecule inhibitors and chemotherapy used in the metastasis and survival 
in vivo studies of orthotopically challenged mice as well the KPC drug enrollment study. Drugs 
were administered by intraperitoneal injection.  
 
* For initial evaluation of GMI-1271 efficacy in vivo, gemcitabine was used at 60 mg/kg. However, 









XVII. In Vivo Drug Enrollment Studies  
To evaluate GMI-1359 efficacy in a spontaneous mouse model of pancreatic cancer, LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mice were monitored by ultrasound imaging for the 
development of pancreas tumors. Enrollment eligibility was determined by the mean of the shortest 
and longest tumor diameters of the largest tumor cross section being 4 to 7 mm in diameter. Upon 
attainment of the enrollment eligibility, mice were randomized into 4 treatment groups: 1) Vehicle 
(PBS) control; 2) 40 mg/kg GMI-1359 daily; 3) 160 µg/mouse anti-PD-L1 antibody; 4) 
combination GMI-1359 and anti-PD-L1. Tumors growth was monitored weekly by ultrasound 
imaging. Mice were treated until they displayed signs of end stage disease (extreme lethargy, 
excessive ascites accumulation, and/or severe cachexia).  
XVIII. Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 5 software. Student t test was 
used for tubulogenesis assays, binding assays and transendothelial migration assays. Student t test 
was also used to evaluate statistical significance in tumor volume, weight, desmoplasia, and 
lymphatic and blood vascular densities in the in vivo studies. One-way ANOVA was used for 
proliferation assays. Statistical significance for survival studies was determined using log-rank 
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Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related 
deaths in the United States, is lethal with a median survival of 6 months and a 5-year survival rate 
of 7% (1). Very little progress has been made in improving overall patient survival (4). One of the 
factors impeding development of successful therapies for this deadly disease is the complexity of 
the PDAC microenvironment. A dense desmoplastic response is one of the defining characteristics 
of this disease and can comprise up to 80% of the tumor mass (159). Although there is debate about 
the role of fibroblasts in tumor progression, some fibroblast components of the desmoplastic 
response are significant contributors to PDAC progression through promotion of tumor growth and 
survival, immune suppression, and metastasis. These tumor-supporting fibroblasts provide 
paracrine support to tumor cells as well as other tumor-supporting cell types within the PDAC 
microenvironment including immune cells and vascular and lymphatic endothelial cells [reviewed 
in (246-248). 
Lymphatic vessel invasion and subsequent metastasis to the lymph nodes are frequently 
observed events during pancreatic cancer progression (5, 28, 33). At the time of diagnosis, more 
than 70% of pancreatic cancer patients present with lymph node involvement (56, 249-251), and 
this lymph node involvement strongly correlates with poor patient prognosis (34-37). Additionally, 
lymph node status is a significant factor in staging patients and selecting appropriate therapy (39, 
40, 111). Although clinicians and researchers recognize the importance of lymph node involvement 
for patient prognosis and therapy selection, the biological mechanisms governing lymphatic vessel 
invasion and lymph node metastasis remain poorly understood.   
Due to their prevalence within the PDAC microenvironments, pancreatic fibroblasts are 
probable effectors of lymphatic biology and function within PDAC tumors and likely promote 
PDAC invasion of lymphatic vessels. However, the mechanisms by which fibroblasts impact 
lymphatic endothelial cells, the main cell type comprising lymphatic vessels, have not been widely 
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investigated. In this paper, we describe, for the first time, evidence for intercellular communications 
and interactions between fibroblasts and lymphatic endothelial cells. We demonstrate that 
fibroblasts promote lymphatic recruitment, accelerate lymphangiogenesis, and invasion. Using a 
combination of live cell imaging and endpoint co-culture techniques, we compare the effects of 
fibroblasts or pancreatic tumor cells on lymphatic endothelial cells to elucidate the contributions 
by each cell type to the biology of lymphatic endothelial cells within the PDAC microenvironment.  
 
II. Results 
Lymphatic endothelial cells strongly migrate toward pancreatic fibroblasts in vitro. 
 We evaluated the capacity of pancreatic fibroblast and PDAC cells to recruit hLECs 
through secreted paracrine factors. Conditioned media (CM) was collected from a panel of 
pancreatic tumor cells (Colo357, S2-013, BxPC-3, T3M4, Hs766T, HPAF-II) and pancreatic 
fibroblasts derived from normal pancreas (13.34) and used as chemoattractants for hLECs in a 
Boyden chamber migration system. 13.34 pancreatic fibroblasts were determined to be of an 
activated phenotype (αSMA+) suggesting they are capable of producing abundant growth factors 
and cytokines necessary to induce cellular migration (Supplementary Figure 3.1A-D) (167). Data 
in Figure 3.1A show that CM from Colo357, S2-013, and T3M4 PDAC cells induced modest levels 
of directional hLEC migration compared to unconditioned media. Hs766T, BxPC-3, or HPAF-II 
CM did not induce significant hLEC migration compared to unconditioned control media. In 
contrast, 13.34 pancreatic fibroblast CM induced high levels of hLEC migration. In our hands, 
13.34 CM was a stronger chemoattractant for hLECs than standard endothelial growth media EGM-
2MV (positive control), which contains necessary growth factors and serum for hLEC maintenance. 
 To determine if the chemotactic effect was specific to the 13.34 line, hLEC migration 
toward CM collected from other pancreatic fibroblast lines was also evaluated.  CM from three 
separate lines of normal pancreatic fibroblasts - 13.7, 13.8, and 13.9, strongly induced directional 





Figure 3.1 Pancreatic fibroblasts strongly induce hLEC migration while PDAC cells only 
induce moderate hLEC migration.  
A) Conditioned media (CM) from pancreatic fibroblasts (13.34) or PDAC lines (Colo357, S2-013, 
T3M4, Hs766T, BxPC-3, HPAF-II) was evaluated as a potential chemoattractant for hLECs using 
a Boyden chamber migration system. EGM-2MV with 5% FBS was used as a positive control for 
hLEC migration. Graphical representation is the mean of 3 replicate membranes; experiment was 
repeated 3 times.  *p<0.05, **p<0.01; error bars = s.d. 
 
B) Conditioned media from a panel of human non-transformed pancreatic fibroblasts (13.34, 13.7, 
13.8, 13.9), PDAC-associated fibroblasts (09-06 PC), PDAC liver metastasis-associated fibroblasts 
(liver fibro), or dermal foreskin fibroblasts (HuFF) was used as a chemoattractant to induce hLEC 
migration. Graphical representation is the mean of 3 replicate membranes; experiment was repeated 
3 times.  *p<0.05, **p<0.01, ****p<0.0001; error bars = s.d. 
 
C) hLECs were plated in the lower well of a Boyden chamber to act as a chemoattractant for 13.34 
fibroblasts or S2-013, Colo357, or T3M4 cells. Graphical representation is the mean of 3 replicate 
membranes; experiment was repeated 3 times.  **p<0.01; error bars = s.d. 
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 tumor-associated fibroblast line, 09-06 PC, which also strongly attracted hLEC populations. 
Comparable results were obtained for CM from fibroblasts isolated from a liver metastasis of 
PDAC patient sample (liver fibroblast CM). CM from neonatal dermal foreskin fibroblasts 
(HuFF) consistently displayed a weaker ability to attract hLECs compared to CM from the other 
fibroblast lines; however, CM from this line consistently attracted enhanced numbers of hLECs 
compared to unconditioned media. These data demonstrate that pancreatic fibroblasts are strong 
inducers of hLEC migration, and suggest that their presence strongly supports lymphatic 
recruitment to primary PDAC tumor sites.  
As the ability of PDAC cells and fibroblasts to migrate toward lymphatic vessels is also 
key for key for successful lymphatic-directed dissemination, we evaluated the ability of hLEC 
paracrine factors to induce migration of PDAC cells and pancreatic fibroblasts. Across multiple 
replicate experiments, 13.34 fibroblasts consistently showed strong migration toward hLECs as 
compared to control wells without hLECs present (Figure 3.1C). PDAC cells did not demonstrate 
an increased ability to migrate toward hLECs compared to control wells that lacked hLECs. 
Chemotactic communication between pancreatic fibroblasts and PDAC cells is highly 
variable across PDAC lines. 
 To more fully understand cell-cell communications within the pancreatic tumor 
microenvironment, we also examined the ability of PDAC tumor cell lines to induce pancreatic 
fibroblast migration as well as the ability of pancreatic fibroblasts to induce PDAC migration. 
Figure 3.2A shows that conditioned media from BxPC-3 and Colo357 PDAC lines significantly 
increased pancreatic fibroblast migration compared to unconditioned media. HPAF-II PDAC cells 
were unresponsive to 13.34 conditioned media. Unexpectedly, the conditioned media from S2-013 







Figure 3.2 Chemotactic communication between pancreatic fibroblasts and PDAC cells is 
highly variable across PDAC lines.  
A) Boyden migration plates were used to evaluate the ability of S2-013, BxPC-3, Colo357, and 
HPAF-II CM to induce 13.34 fibroblast migration. Graph represents the mean of 3 membranes per 
conditioned media type; experiment was repeated 3 times. ***p<0.001, ****p<0.0001; error bars 
= s.d. 
B) CM from 13.34 pancreatic fibroblasts was loaded into the lower wells of a migration plate to 
act as a potential chemoattractant for S2-013, Bx-PC-3, Colo357, and HPAF-II PDAC cells. 13.34 
CM strongly induced S2-013 and Colo357 migration but did not alter on BxPC-3 or HPAF-II 
migration compared to unconditioned media. Graphical representation is the mean of 3 




 We also examined whether factors secreted from 13.34 pancreatic fibroblasts were capable 
of inducing PDAC cell migration. Although S2-013 cells do not induce pancreatic fibroblast 
migration, these cells are strongly attracted to the secreted factors found in pancreatic fibroblast 
conditioned media (Figure 3.2B). Colo357 PDAC cells were also strongly attracted to 13.34 
conditioned media compared to unconditioned media. BxPC-3 and HPAF-II PDAC cells 
demonstrated no difference in migration to 13.34 conditioned media compared to unconditioned 
media. 
Live cell imaging characterization of homogenous cell populations. 
 Boyden chamber migration systems allow for easy quantification of cell migration; 
however, these assays only capture migration of a single cell type at a fixed endpoint. Using live 
cell imaging, we examined real-time migration of PDAC cells, pancreatic fibroblasts, and/or hLECs 
in co-culture. Various cell types were plated into the wells of a 2-well silicone insert. Once the cells 
within the wells of the inserts had adhered to the bottom of the well, the insert was removed, 
creating a 500 μm gap-exclusion zone between the two cell populations. Images of cell migration 
into the gap were captured every 10 minutes for 24 hours and then the frames were stitched together. 
The use of a barrier, rather than a scratch, to create a gap between two cell populations is important 
for multiple reasons: a) it permits migration analysis of disparate cell types; b) it minimizes cell 
damage which can influence migration results, and c) it creates a uniform gap in all multiple 
experimental wells. Using live cell imaging, we followed the migration pattern and morphology 
changes of two cell types as they migrated toward one another. Figure 3.3 diagrams some of the 
terminology used to describe these assays. 
 For controls, we initially characterized the migration of identical cell populations (13.34 to 
13.34; hLEC to hLEC; S2.013 to S2.013; and Colo357 to Colo357; Figure 3.4A-D). Numerous 
similarities were seen when cells of the same type migrate toward one another. The migration fronts 
of each home population move at uniform rates, and the cells at the leading edge of the migration 







Figure 3.3 Co-culture migration illustration and terminology. 
Two-well silicone removeable inserts were adhered to the bottom of the wells of 24-well plate. 
Disparate or similar cell types were seeded into each of the wells. Following cell adhesion to the 
bottom of the well, the silicone insert was removed creating a uniform 500 µm gap between the 
two cell populations. The population where a cell type was plated prior to the start of the experiment 
is referred to as its “home” population. The “migration front” refers the edge of the population 
migrating into the gap (dashed line). The individual cells at the boundary of the migration front are 




population to traverse the gap and interact with the opposing population of cells. When migration 
fronts met at gap closure, the forward migration of each cell population stopped and the cells at the 
edge of each front integrated to form a homogenous monolayer. No cells were observed crawling 
atop the approaching cell population nor did one population drive the opposing front backward. 
 Some dissimilarities were noted among the different cell types during homogeneous cell 
migration. Human LECs populations moved as a single, connected group. The cells at the leading 
edge of the migration flattened out and formed obvious lamellipodia on the side of the cell facing 
the gap (Figure 3.4A). The cells behind the leading edge appeared to pulled along by the leading 
cells and did not form obvious lamellipodia themselves. All the cells retained a round cell shape. 
No proliferation was undergone by the hLECs at the leading front while the cells behind the front 
were observed regularly dividing. Upon gap closure, hLECs at the leading edge integrated to form 
a single cohesive population. 
 Unlike hLECs, pancreatic fibroblasts at the leading edge of the migration front significantly 
elongated toward the oncoming fibroblast population (Figure 3.4B). Fibroblasts both at the leading 
edge and behind the leading edge formed filipodia in the direction of the opposing fibroblasts. Each 
population migrated as a loosely connected group with all the cells remaining in close proximity. 
As the leading edges closed the gap, individual fibroblasts intermixed but retained their elongated 









Figure 3.4 Live cell imaging characterization of the migration patterns of identical cell 
populations. 
A-D) Live cell imaging of two cell populations of the same type migrating across a gap toward one 
another. Images were collected at 10X magnification every 10 minutes for 24 hours. Figures A-D 
contain representative steady state images collected at 10 minute, 6 hour, 12 hour, 18 hour, and 24 




 S2-013 cells displayed much more individual movements among cells within the home 
population but the movement did not appear to be directed toward the opposing S2-013 population 
(Figure 3.4C). S2-013 cells both at the migration front and behind it formed lamellipodia; however, 
the lamellipodia were not always orientated in the direction of the other S2-013 population. Similar 
to the fibroblasts, S2-013 populations migrated as a loosely connected group while closing the gap. 
Cells at both the leading edge and behind the leading edge underwent significant amounts of 
proliferation. Once the gap closed individual cell movements slowed and cells formed a single 
cohesive monolayer.  
 Colo357 gap closure was much slower compared to that of the other cell types as the gap 
did not completely close by 24 hours (Figure 3.4D). Much like the hLECs, Colo357 populations 
migrated as a single connected population with very little movement among the individual cells. 
Cell division was frequently observed behind the migration front. A significant accumulation of 
cells behind the migration front suggested that proliferation may have contributed to gap closure. 
Additionally, lamellipodia formation was not orientated in the direction of the oncoming Colo357 
population.  
Characterization of migration of disparate cell types in co-culture using live cell imaging.  
 Next, we characterized the migration patterns of cells toward a disparate cell type initially 
focusing on co-cultures of hLECs with 13.34 pancreatic fibroblasts or PDAC cells (S2-013, 
Colo357; Figure 3.5A-D). Figure 3.5A displays the migration of hLECs to hLECs as a reference 
for control migration. Assessment of migration patterns between pancreatic fibroblasts and hLECs 
revealed that, similar to homogenous migration, 13.34 elongated and formed filipodia in the 
direction of the approaching hLEC population (Figure 3.5B). Unlike migration toward an identical 







Figure 3.5 Live cell imaging characterization of the migration patterns of hLECs in co-culture 
with pancreatic fibroblasts or PDAC cells. 
A-D) Live cell imaging of the migration patterns of hLECs in A) monoculture or in co-culture with 
B) 13.34 fibroblasts, C) S2-013, or D) Colo357 PDAC cells. Images were collected at 10X 
magnification every 10 minutes for 24 hours at the exact same location. Figures A-D contain 
representative steady state images collected at the 10 minute, 6 hour, 12 hour, 18 hour, and 24 hour 
timepoints. Circles indicate examples of cells crawling atop by not invading the hLEC population. 




across the gap toward the hLEC population. 13.34 fibroblasts demonstrated a greater migration 
potential by closing more of the gap than the hLEC population. Migration of hLECs toward 13.34 
fibroblasts was relatively similar to migration toward another hLEC population: hLECs moved as 
a cohesive unit with leading edge cells forming lamellipodia in the direction of the oncoming 
fibroblasts. As the migration fronts converged, 13.34 fibroblasts and hLECs did not intermix. 
Rather, the two populations remained abutted against one another. The only exception to this was 
the occasionally observed fibroblast crawling atop the hLEC population (white circles). 
 Examination of S2-013 and hLEC migration in co-cultures revealed that leading edge 
hLECs elongated perpendicularly to the approaching S2-013 population (Figure 3.5C). These cells 
did not form lamellipodia nor did the hLEC migration front progress very far into the gap. 
Individual S2-013 cells at the leading edge of the migration front were observed very early to exit 
the home population and migrate across the gap to the opposing hLEC population. After physical 
contact was made with hLEC cells, S2-013 cells often returned to the home population. As the S2-
013 migration front got closer to the hLEC population, the hLEC front was observed to recede 
backward. Eventually the S2-013 front closed the gap between the two populations and then 
physically forced the hLEC population backward. There was no intermixing of two cell types upon 
gap closure although a handful of S2-013 were observed crawling atop the hLEC monolayer. 
 Examination of Colo357, another PDAC line, migration toward hLECs revealed that a 
small number of hLEC migrate across the gap early toward the Colo357 population (Figure 3.5D). 
However, these hLECs never fully lost contact with their home population. Unlike S2-013 
migration toward hLECs, individual Colo357 cells did not exit their home population and migrate 
across the gap toward the hLEC population. The Colo357 population moved as a single cohesive 
unit as did the majority of the hLEC population. Colo357 cells did not induce hLEC recession like 
the S2-013 cells did. Since both Colo357 and hLEC migration is relatively slow, the gap never fully 
closed between the two cell types in 24 hours.  
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Lastly, we characterized the migration patterns of pancreatic fibroblasts and pancreatic 
tumor cells toward one another (Figure 3.6A-C). Unlike migration toward hLEC cells, migrating 
S2-013 cells remained with the home population moving as a loosely connected group (Figure 
3.6B). Individual S2-013 cells were not observed to escape the home population and migrate across 
the gap toward the fibroblasts. S2-013 lamellipodia formation was not orientated in the direction 
of the approaching fibroblasts, but rather formation occurred on all sides of the cell. Similar to other 
experimental setups, 13.34 fibroblasts at the leading edge elongated and formed filipodia in the 
direction of the approaching S2-013 population. Although elongated, leading edge 13.34 cells 
remained associated with the home population. Once the two fronts met to close the gaps, progress 
forward stopped and both migration fronts remained stationary. Cells of opposing type did not 
intermix nor were they observed to crawl atop the opposing monolayer.  
Examination of 13.34 and Colo357 migration in co-culture again demonstrated 13.34 
elongation toward the approaching Colo357 cells (Figure 3.6C). However, unlike migration 
toward S2-013 cells, numerous individual 13.34 fibroblasts exited the home population and 
migrated toward the approaching Colo357 population making multiple physical contacts with the 
PDAC cells. The Colo357 cells maintained tight contact with the home population and do not 
migrate cross the gap. When the two fronts closed the gap, front progression stopped and neither 
population regressed nor intermixed with the opposing cell population.  
Analysis of the rate of gap closure and cellular migration front progression from live cell 
imaging.  
 Using the live cell images, we calculated the rates of gap closure as well as the migration 
rates of each cell front under the examined co-culture settings. The rate of gap closure was relatively 
consistent across the groups, with migration between two S2-013 populations being the fastest and 
migration between two Colo357 populations being the slowest (Figure 3.7A). As gap closure rate 
is the average velocity of two migration fronts, we also calculated the rate of migration for each 
front in each of the co-culture conditions (Figure 3.7B-E). The migration rate of hLECs  
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Figure 3.6  
 
 
Figure 3.6 Live cell imaging characterization of the migration patterns of pancreatic 
fibroblasts in co-culture with PDAC cells. 
A-C) Live cell imaging of the migration patterns of pancreatic fibroblasts in A) monoculture or in 
co-culture with B) S2-013 or C) Colo357 PDAC cells. Images were collected at 10X magnification 
every 10 minutes for 24 hours. Figures A-D contain representative steady state images collected at 







Figure 3.7 Rate of front progression during co-culture migration. 
A) Graphical representation of the mean rate of gap closure in a series of co-culture migration 
assays. Rate = d/t, where d = length of the gap and t = total time to gap closure. If the gap did not 
completely close, t = 24 hours. This is a measure of the average rate of both population fronts. n=6 
gap closure studies per co-culture setup. a.u.= arbitrary units; error bars = s.d. 
B-E) Graphical representation of the mean rate of the migration front for B) hLECs, C) 13.34 
fibroblasts, D) S2-013 or E) Colo357 PDAC cells in a series of co-culture migration assays. Rate 
= (x1-x0)/t, where x1 = area covered by a cell population at gap closure, x0 = area covered at t = 0, 
and t = time of gap closure. If the gap did not close, t = 24 hours. n=6 gap closure studies per co-
culture setup. Asterisks indicate a statistically significant change in the migration rate of a cell type 
when in co-culture with a disparate cell type compared to the migration rate when in co-culture 
with the same cell type. *p<0.05, **p<0.01; a.u.= arbitrary units; error bars = s.d.  
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was relatively similar when migration was toward other hLECs, 13.34 fibroblasts, or Colo357 cells 
(Figure 3.7B). However, the hLEC rate significantly slowed when migration was toward S2-013 
cells. The 13.34 fibroblast migration rate was slowest toward another 13.34 population, but it 
significantly increased during migration toward an hLEC or an S2-013 population (Figure 3.7C). 
The rate of S2-013 migration was fastest toward hLECs and 13.34 fibroblasts compared to 
migration toward another S2-013 population (Figure 3.7D). Lastly, Colo357 migration was slowest 
toward pancreatic fibroblasts and fastest toward hLECs (Figure 3.7E). Asterisks indicate statistical 
significance of co-culture migration compared to monoculture migration.  
Pancreatic tumor cells and fibroblasts accelerate in vitro lymphatic tubulogenesis and 
disrupt normal tube network organization. 
 Lymphangiogenesis is a crucial physiological function of lymphatic endothelial cells, 
particularly during times of wound healing, inflammation, and malignancy. To evaluate the effects 
of PDAC cells and pancreatic fibroblasts on lymphangiogenesis, we performed live cell imaging 
of collagen-I-induced hLEC tubulogenesis when co-cultured with PDAC cells or pancreatic 
fibroblasts. Figure 3.8A shows fixed timepoints of normal tubulogenesis when hLECs are in 
monoculture. At 4 hours, hLECs lost their smooth cell boundaries and developed a more dendritic 
appearance with many cellular protrusions. By 8 hours, several individual hLEC cells started to 
coalesce into an immature tube-like configuration, and by 12 hours, a network of interconnected 
tubes began to form. Tube formation was completed by 20 hours when nearly all individual hLECs 
incorporated into the network. 
 The addition of 13.34 pancreatic fibroblasts or PDAC cells (S2-013, Colo357) to hLECs 
during collagen-I-induced tubulogenesis resulted in significant changes to the tubulogenesis 
process (Figure 3.8B-D). For three different co-culture experimental designs, tube formation began 
much earlier than was observed for hLECs in monoculture. Thirty minutes following initiation, 
tube-like structures were initiated in the co-culture system; this was not seen until 8 hours in the 
monoculture model. Also unlike the monoculture system where every hLEC cell coalesced into the  
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Figure 3.8 Characterization of lymphatic tubulogenesis in the presence of PDAC cells or 
pancreatic fibroblasts. 
A-E) Live cell imaging of in vitro collagen-I-induced hLEC tubulogenesis in A) monoculture or in 
co-culture with B) 13.34 fibroblasts, C) S2-013, D) Colo357, or E) additional hLECs. Images were 
collected at 10X magnification every 10 minutes for 24 hours at the exact same location. Figures 
A-E contain representative steady state images collected at the 30 minute, 4 hour, 12 hour, 18 hour, 
and 20 hour timepoints. Scale bars = 100 µm 
F) Quantitative analysis of the mean number of hLECs tubes formed when in monoculture or in 
co-culture with 13.34, S2-013, or Colo357 cells at t=20 hours. 3 replicate wells were analyzed per 
experiment; experiment was performed 3 times. *p<0.05, **p<0.01, ****p<0.0001; error bars = 
s.d. 
G) Quantitative analysis of the mean number of disconnected or broken hLEC tubes under 
monoculture and co-culture conditions at t=20 hours. 3 replicate wells were analyzed per 
experiment; experiment was performed 3 times. **p<0.01, ****p<0.0001; error bars = s.d. 
H) Graphical representation the percentage of co-culture cell types 13.34, S2-013, or Colo357 
either associated (physical contact) or not associated (no physical contact) with hLEC tubes at t=20 
hours. *p<0.05, ***p<0.001; error bars = s.d. 
I) Representative images of 13.34, S2-013, or Colo357 cells in culture with hLECs during collagen-
I-induced tubulogenesis. 13.34, S2-013, or Colo357 were labeled with green CFDA-SE cell tracer 









tube network, many individual hLEC cells remained unincorporated at the time of tube network 
completion. Pancreatic tumor cells and fibroblasts significantly reduced the number of hLEC tubes 
formed (Figure 3.8F). Furthermore, the tubes formed in the co-culture settings had thin diameters 
and were disconnected from branch points or nodal clusters (Figure 3.8G). Examination of the 
tumor cell and fibroblast position revealed that most of these cells closely associated with hLEC 
tubes or hLEC nodes (Figure 3.8H). However, the tumor cells and fibroblasts did not incorporate 
into the tube network themselves (Figure 3.8I). To ensure that the acceleration in tubulogenesis by 
PDAC cells or pancreatic fibroblasts was not simply due to increases in total cell number during 
induction, the assay was performed with the addition hLECs commensurate with the addition of 
collagen-I. Similar to the monoculture studies described above, hLEC tube formation started 
around 8 hours and was complete at 20 hours; there was no acceleration of tuber formation with 
the addition of hLECs to the culture (Figure 3.8E). Nearly all hLECs, including those added at the 
time of induction, incorporated into the tube network. Moreover, the tubes had thick diameters and 
all were connected to network branch points or nodal clusters. Altogether these data suggest that 
pancreatic fibroblasts and tumor cells are capable of accelerating lymphatic tube formation through 
a process that leads to poorly formed lymphatic networks with decreased diameters and disjointed 
tubes in vitro.  
Characterization of pancreatic tumor cell invasion of simulated lymphatic endothelia. 
 The ability of PDAC cells to invade lymphatic endothelia is a critical step for dissemination 
to lymph nodes. We evaluated this this function in vitro through transendothelial migration (TEM) 
assays as diagramed in Figure 3.9A. Briefly, a confluent hLEC monolayer was established on the 
underside of the porous membrane of a Boyden chamber insert (Figure 3.9B). Plating the hLECs 
on the underside of the membrane orientates the basal side of the LECs toward the invading PDAC 
cells similarly to lymphatic invasion in vivo. Following monolayer formation, a chemoattractant 
was added to the lower well and PDAC cells diluted in serum free media were added to the upper 







Figure 3.9 Evaluation of the TEM capacity of PDAC cells in vitro.  
A) Diagram illustrating the setup of an in vitro transendothelial migration assay. Human LEC 
monolayers were established on the bottom of the membrane to position the basal cell surface of 
hLECs toward the invading PDAC cells; this is analogous to lymphatic invasion in vivo.  
B)  Representative immunofluorescent images of hLEC monolayers plated on the underside of a 
Boyden chamber membrane. Actin (red; top) and VE-cadherin (green; bottom) labeling was used 
to demonstrate that the hLECs formed a confluent monolayer on the underside of the membrane 
and there were no gaps between hLEC cells. Potential gaps would have allowed PDAC cells to 
cross the endothelial barrier without undergoing invasion. Cell nuclei were stained with DAPI 
(blue). Scale bar = 50 µm 
C) Graphical representation of TEM through a lymphatic endothelium by a panel of PDAC cell 
lines: S2-013, Colo357, BxPC-3, HPAF-II, T3M4, and HS766T. 3 replicate membranes/cell type; 
experiment was repeated 3 times. Error bars = s.d. 
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is shown in Figure 3.9C. Not all PDAC lines displayed the same propensity to invade a 
lymphatic endothelium: S2-013 cells demonstrated a high rate of TEM; Hs766t, BxPC-3, and 
Colo357 cells demonstrated a moderate rate; and HPAF-II and T3M4 demonstrated a low rate.  
 We collected steady state images of fluorescently labeled PDAC cells (BxPC-3, Colo357, 
HPAF-II, and S2-013) and pancreatic fibroblasts (13.34) invading a lymphatic monolayer. To 
evaluate the position of invasion within the monolayer, we used immunofluorescence staining of 
endothelial-specific adherens junction protein VE-cadherin to visualize hLEC cell boundaries 
(Figure 3.10A-F). There were three possible positions of PDAC cell invasion of a lymphatic 
monolayer: 1) where two endothelial cells came together (bicellular junction); 2) where three 
endothelial cells came together (tricellular junction); or 3) on the cell body of an endothelial cell. 
The majority of PDAC cells invaded at tricellular endothelial junctions (Figure 3.10G). 
Occasionally, PDAC cells would invade at bicellular junctions and even less often transcellularly 
through an endothelial cell body. PDAC cells caused a loss of VE-cadherin at the site of invasion; 
however, occasionally, VE-cadherin loss also occurred at sites away from invasion (arrowhead, 
Figure 3.10D).  Comparable to the invasion pattern of PDAC cells, 13.34 pancreatic fibroblasts 
also preferred to invade at tricellular junctions (Figure 3.10F, G). However, 13.34 cells also 
demonstrated the unique ability to elongate across the top of the monolayer without invading into 
it (no disruption of VE-cadherin staining). This was not seen in any of the co-cultures with PDAC 
cells. We compared the invasion pattern of PDAC cells and the 13.34 pancreatic fibroblasts to that 
of freshly isolated leukocytes (Figure 3.10H-I). Leukocytes displayed no preference for an 
endothelial junction type during adhesion or invasion of the lymphatic monolayer.  
 Live cell imaging was also used to fully characterize PDAC invasion of a simulated 
lymphatic endothelium. Examination of S2-013 PDAC invasion revealed that S2-013 cells invade 




Figure 3.10 Characterization of PDAC invasion of an hLEC endothelium. 
A) Representative image of an hLEC monolayer prior to addition of PDAC cells. 
Immunofluorescent staining with VE-cadherin (red) antibody indicates fully-matured cell junctions 
between adjacent hLEC cells. Nuclei are labeled with DAPI (blue). Asterisks represent potential 
cellular invasion sites on the hLEC monolayer: the white asterisk is an example of a tricellular 
junction; the yellow asterisk is an example of a bicellular junction; and the pink asterisks is an 
example of an endothelial cell body location. Scale bars = 50 µm 
B-E) Representative images of B) BxPC-3, C) Colo357, D) HPAF-II, and E) S2-013 invasion of 
an hLEC monolayer. PDAC cells were labeled with a CFDA-SE (green) cell tracer and hLEC 
adherens junctions were labeled with VE-cadherin (red) antibody. Nuclei were labeled with DAPI 
(blue). D) Arrowhead indicates an example of VE-cadherin loss in hLECs distant from sites of 
invasion. Scale bars = 50 µm 
F) Representative image of 13.34 fibroblasts invading an hLEC monolayer. 13.34 cells were 
labeled with CMRA cell tracer (orange) and hLEC adherens junctions were labeled with VE-
cadherin (green). Nuclei were labeled with DAPI (blue). Scale bar = 50 µm 
G) Graphical representation of the locations within an hLEC monolayer invaded by PDAC cells 
and fibroblasts: tricellular junctions, bicellular junctions, or atop endothelial cell body. 
****p<0.0001; error bars = s.d. 
H) Representative image of leukocyte entering an hLEC monolayer. Freshly isolated leukocytes 
were labeled with CMRA cell tracer (orange) and hLEC adherens junctions were labeled with VE-
cadherin (green). Nuclei were labeled with DAPI (blue). Scale bar = 50 µm 
I) Graphical representation of the locations on an hLEC monolayer where leukocytes preferred to 













Figure 3.11 Live cell imaging evaluation of PDAC invasion of an hLEC endothelium 
A) Representative live cell imaging photographs of S2-013 invasion of a lymphatic endothelium at 
10 minutes, 6 hours, 12 hours, and 24 hours. Individual images were collected at 10X magnification 
every 10 minutes for 24 hours at the exact same location. Scale bar = 100 µm 
B) Representative live cell imaging photographs of S2-013 invasion of a lymphatic endothelium at 
10 minutes, 12 hours, 24 hours, and 36 hours. Individual images were collected at 20X 
magnification every 10 minutes for 36 hours at the exact same location. Scale bar = 10 µm 
C) Representative live cell imaging photographs of Colo357 invasion of a lymphatic endothelium 
at 10 minutes, 6 hours, 12 hours, and 24 hours. Individual images were collected at 10X 
magnification every 10 minutes for 24 hours at the exact same location. Scale bar = 100 µm 
D) Representative live cell imaging photographs of 13.34 fibroblast invasion of a lymphatic 
endothelium at 10 minutes, 6 hours, 12 hours, and 24 hours. Individual images were collected at 
10X magnification every 10 minutes for 24 hours at the exact same location. Scale bar = 100 µm 
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3.11A). Rather individual S2-013 cells actively migrated to clusters to augment invasion through 
collective cell migration. Following successful invasion, S2-013 clusters expanded the opening in 
the monolayer by physically forced extension of tumor cells and endothelial retraction. 
Expanding S2-013 islands physically pushed against the surrounding endothelial cells to further 
open the monolayer. Additionally, hLECs actively retracted from the invaded S2-013 cells, 
creating larger holes in the monolayer; this retraction often occurred in the absence of contact 
between the two cell types. Human LECs at the invasive boundary displayed an elongated 
morphology. Non-invaded S2-013 cells migrated across the top of the monolayer to sites of 
successful invasion; this migration to invaded sites appeared to be directed and non-random. 
These newly recruited S2-013 cells then rapidly incorporated into the invaded S2-013 population. 
Figure 3.11B illustrates this process at a greater magnification and decreased S2-013 density. As 
seen in the steady-state immunofluorescence images, S2-013 cells were also able to induce gaps 
in the monolayer at sites distant to invasion (Figure 3.11B arrowhead).  
 Colo357 invasion was also evaluated to determine if all PDAC cells invade in the same 
manner (Figure 3.11C). Like S2-013 cells, Colo357 also invaded the monolayer as clusters (albeit 
smaller clusters compared to S2-013 cells), and single Colo357 cells migrated toward clusters to 
augment collective cell migration and invasion. Colo357 cells did not invade the monolayer as 
rapidly as S2-013 cells: by 6 hours numerous S2-013 cells had invaded the monolayer while very 
few Colo357 cells had invaded the monolayer at this same time point. Like S2-013 cells, Colo357 
formed islands within the hLEC monolayer and recruited other Colo357 cells to sites of successful 
invasion. Colo357 cells invasion was principally physical pressure to enlarge openings in the hLEC 
monolayer openings; there was less endothelial retraction induced by Colo357 cells compared to 
S2-013 cells.  
Evaluation of fibroblast entry into an hLEC monolayer revealed that 13.34 cells are much 
less invasive in this system compared to PDAC cells (Figure 3.11D). Many of the 13.34 cells 
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remained atop the endothelial layer and did not invade into it, although a small invaded cluster can 
be seen within the monolayer by 24 hours (Figure 3.11D; arrowhead). These pancreatic fibroblasts 
did not induce endothelial retraction, suggesting accompanying PDAC cells may be required to 
enhance fibroblast migration across an endothelium.  
III. Conclusions 
Very few studies have evaluated how pancreatic tumor cells interact with lymphatic 
endothelia, and even fewer studies have examined how pancreatic fibroblasts interact with 
lymphatic endothelia. We demonstrated that pancreatic fibroblasts are strong recruiters of LECs, 
while PDAC cells only moderately recruited LECs. Pancreatic fibroblasts also strongly induce 
PDAC migration, but this induction is very dependent on the PDAC cell line, as is the ability of a 
PDAC line to induce fibroblast migration. Co-culture analysis of the effects of fibroblasts and 
PDAC cells on lymphangiogenesis revealed that all these cell types accelerated lymphangiogenesis 
and led to poorly developed lymphatic networks with thin, broken vessels and defective LEC 
incorporation. Finally, evaluating PDAC invasion revealed that different PDAC lines have varying 
abilities to invade a lymphatic endothelium, but all PDAC cells preferred to invade at tricellular 
endothelial junctions. Live cell imaging uncovered many of the minute differences that allow 
different PDAC lines to invade a lymphatic endothelium. Understanding the role of LECs in the 
PDAC tumor microenvironment is still in its infancy. The work presented here lays the groundwork 









Supplementary Figure 3.1 Characterization of 13.34 pancreatic fibroblasts.  
A-C) Flow cytometry evaluating αSMA, FAP, and podoplanin fibroblast markers in 13.34 
pancreatic fibroblasts. Red histograms represent isotype control; blue histograms indicate A) 
αSMA (activation marker) B) FAP, and C) podoplanin expression. 13.34 fibroblasts demonstrated 
positive expression for αSMA and FAP and were negative for podoplanin.  
 
D) Immunofluorescence staining for αSMA (red) and FAP (green) in 13.34 fibroblasts. Mouse IgG1 
isotype antibodies (red; far right) and sheep polyclonal IgG antibodies (green; far right) were used 






A novel glycomimetic inhibitor reveals the role of E-










Excerpts from this chapter have been edited from:  
Steele, MM, Radhakrishnan, P, O’Connell, K., Mohr, AM, Caffrey, T, Grandgenett, PM, 
Grunkemeyer, JA, Mehla, K, Patil, P, Fink, DM, Hanson, RL, Fogler, WE, Magnani, JL, and 
Hollingsworth, MA.  A novel glycomimetic inhibitor reveals the role of E-selectin in lymphatic 




Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related 
deaths in the United States and has a dismal 7% 5-year survival rate (1). One of earliest and most 
frequently observed sites of PDAC metastasis is the draining lymph nodes, which also correlates 
with poor prognosis (34-36). The process of lymph node metastasis requires interactions between 
tumor cells and lymphatic endothelial cells, the primary cell type comprising lymphatic 
vasculature. The specific mechanisms that regulate PDAC invasion of lymphatic vessels are poorly 
understood. One hypothesis is that tumor cells invade lymphatic vasculature by utilizing molecular 
processes similar to those used by immune cells during lymphatic intravasation. Although not fully 
understood, it is known that leukocyte entry into lymphatics is regulated by several adhesion 
proteins including E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular adhesion 
molecule-1 (VCAM-1) (146). Many of these same adhesion proteins have also been implicated as 
regulators of tumor-endothelial interactions and vasculature invasion for many cancer types (252). 
Adhesion protein E-selectin belongs to the selectin family of proteins, which are single-
pass transmembrane glycoproteins that encode a lectin-like domain which forms an adhesive 
receptor capable of binding to carbohydrate ligands including sialyl LewisA/X (sLeA/X) motifs (253). 
E-selectin expression is restricted to endothelial cells and is known to facilitate endothelial-
leukocyte interactions during immune cell extravasation across the blood vasculature (254, 255). 
Recently, it has been determined that E-selectin plays a similar role in the lymphatic vasculature 
for leukocyte intravasation during inflammation (256). Many types of tumors, including PDAC, 
have been shown to appropriate leukocyte intra- and extravasation mechanisms for invasion of 
blood vessels during dissemination (146, 257). However, the role E-selectin in tumor invasion of 
lymphatic vessels has not been investigated.   
The investigation reported here was to determine the role of E-selectin in PDAC metastasis 
through the lymphatic vasculature. Using a novel glycomimetic, small molecule antagonist of E-
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selectin ligand binding to sLeA/X, GMI-1271, in combination with chemotherapy, we demonstrate 
that E-selectin blockade decreases metastasis to lymphatic vasculature-dependent sites in 
orthotopic models of spontaneous PDAC metastasis. Additionally, combinatorial treatment with 
GMI-1271 and gemcitabine extended survival in an immune competent model of pancreatic cancer. 
We report for the first time that inhibition of E-selectin ligand binding resulted in a significant 
reduction in metastasis to lymph nodes. Immunohistochemical staining revealed that the reduction 
in metastasis by GMI-1271 was not due to decreased lymphatic and blood vessel densities at the 
tumor site. Rather, E-selectin blockade through GMI-1217 impaired the ability of PDAC cells to 
adhere to and migrate across an endothelial barrier in vitro. Interestingly, co-culture of PDAC cells 
with lymphatic endothelial cells induced E-selectin expression in lymphatics to facilitate this 
invasion. Together, our data demonstrate that PDAC cells use E-selectin-dependent mechanisms to 
gain access to the lymphatic vasculature for dissemination to lymph nodes.  
II. Results 
PDAC cells express the E-selectin ligand sialyl LewisA. 
We examined the expression of E-selectin ligands, sLeA/X, on a panel of human PDAC cell 
lines to select lines for studies of interactions with E-selectin on lymphatic endothelial cells. 
Western blot analyses demonstrated that several PDAC lines express the sLeA including S2-013, 
Capan-2, and BxPC-3 cells (Figure 4.1A). The polydispersed migration of glycoproteins 
containing sLeA is consistent with the known expression of this glycan on multiple proteins in these 
cells. These same cell lines also had detectable levels of sLeA on proteins secreted into conditioned 
media (Figure 4.1B). PDAC lines T3M4, Colo357, Hs766t, and HPAF-II and pancreatic fibroblasts 
(13.34) showed no expression of sLeA (Figure 4.1A-B). Expression of sLeA was also confirmed by 




Figure 4.1 PDAC cells express E-selectin ligand sialyl Lewis A. 
 
A) Immunoblot (50 µg protein/lane) analysis of sLeA expression in pancreatic fibroblasts (13.34) 
and a panel of human PDAC cell line lysates (T3M4, Colo357, Capan-2, Hs766T, BxPC-3, HPAF-
II, and S2-013). β-actin expression was used as a loading control for all cell lines. Capan-2, BxPC-
3, and S2-013 demonstrate expression of sLeA. The smeared pattern indicates that sLeA is expressed 
on a multitude of PDAC proteins.  
 
B) Immunoblot (30 µl/lane) analysis of sLeA expression in pancreatic fibroblasts (13.34) and a 
panel of human PDAC cell line conditioned media. Secreted proteins from Capan-2, BxPC-3, and 
S2-013 display sLeA expression.  
 
C) Immunofluorescence staining indicating sLeA expression in S2-013, Capan-2, and BxPC-3 
PDAC cells. SLeA (green) is expressed by several individual PDAC cells, but not all cells within a 
population. Cell nuclei are stained with DAPI (blue). Scale bars = 25 µm 
 
D) Immunofluorescence staining indicating sLeA expression in non-implanted S2-013 (left) and in 
vivo implanted S2-013 (right) cells. In vivo implantation of S2-013 increases the number of cells 
expressing sLeA (green) as compared to S2-013 cells not implanted. Cell nuclei are stained with 











PDAC lines (data not shown). To ensure that PDAC cells retained sLeA expression following in 
vivo implantation, S2-013 PDAC cells were orthotopically implanted into the pancreases of 
athymic mice for 3 weeks and then isolated from the tumors. Immunofluorescence staining revealed 
that in vivo implantation increased the incidence of sLeA expression in S2-013 cells (Figure 4.1D).  
GMI-1271 in combination with gemcitabine reduces vasculature-dependent metastasis of 
PDAC. 
We evaluated the effects of blocking the binding of E-selectin to ligands (using GMI-1271) 
on PDAC metastasis in vivo with a specific focus on metastasis to the lymph nodes. S2-013 PDAC 
cells, which express sLeA and frequently metastasize to lymph nodes (258, 259) were orthotopically 
implanted into the pancreas of athymic mice. Treatment with GMI-1271 was initiated two weeks 
after tumor implantation. Mice were randomized to 6 different treatment groups: vehicle, low dose 
GMI-1271, high dose GMI-1271, gemcitabine, low dose GMI-1271 with gemcitabine, and high 
dose GMI-1271 with gemcitabine. Treatment with GMI-1271 alone (low or high dose) had no 
impact on in vivo tumor growth compared to control mice (Figure 4.2A). This result was verified 
in vitro by examining the effects of GMI-1271 on PDAC proliferation (Supplementary Figure 
4.1). As expected, mice treated with gemcitabine showed a significant reduction in tumor size 
compared to mice treated with the vehicle control; however, addition of GMI-1271 (low and high 
dose) to gemcitabine treatment did not further decrease tumor size (Figure 4.2A). Gross 
histological examination of representative sections revealed that GMI-1271 had no effect on the 
overall morphology of primary tumors or the metastatic lesions (Figure 4.2B). None of the GMI-
1271-treated mice displayed any drug-induced toxicities.  
Since E-selectin has been previously implicated in promoting tumor dissemination, we 
evaluated several candidate organs for the presence of metastases following treatment with GMI-
1271. Figure 4.3A illustrates observed lesions found in representative sections of lungs, lymph 













Figure 4.2 E-selectin blockade has no impact on PDAC growth or morphology in vivo. 
  
Human S2-013 PDAC cells were orthotopically implanted into the pancreases of athymic female 
mice and allowed to establish for 2 weeks. GMI-1271 and gemcitabine treatments were 
administered for 4 weeks, after which tumors and metastatic organs were collected. n = 15 
mice/treatment group. 
 
A) Graphical representation of tumor volume and weight for each treatment group. E-selectin 
blockade (high or low dose) had no impact on tumor size. As expected, gemcitabine significantly 
reduced tumor size, but combinatorial treatment GMI-1271 and gemcitabine did not further 
decrease tumor size.  ****p<0.0001  
 
B) Representative histological sections of S2-013 primary tumors, lung lesions, and lymph node 
lesions from mice treated with vehicle control (PBS) or GMI-1271. High dose GMI-1271 did not 








Figure 4.3. E-selectin blockade reduces pancreatic cancer metastasis in vivo. 
 
A) Representative histological sections of spontaneous lung, lymph node, and liver lesions from 
GMI-1271-treated mice. Arrows indicate metastatic lesions. Scale bars = 200 µm for lung and 
lymph node. Scale bar = 50 um for liver. n=15 mice/treatment group. 
 
B) The presence of spontaneous metastatic lesions was identified in lymph nodes, liver, lungs, 
diaphragm, kidney, spleen, and peritoneum using histological staining of multiple representative 
sections. Graphs represent the absolute percentage of mice per group exhibiting spontaneous 
metastases in the indicated organs. n= 15 mice/group 
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lymph nodes, lungs, liver, diaphragm, spleen, and peritoneum (Figure 4.3B).  We observed a 
reduction in metastatic incidence to the liver in mice treated with high dose GMI-1271. Treatment 
with GMI-1271 alone (low or high dose) did not significantly affect the incidence of metastasis to 
other organs. 
Gemcitabine monotherapy moderately decreased metastatic incidence to all organs 
examined when compared to vehicle-treated mice (Figure 4.3B). Interestingly, combinatorial 
treatment with gemcitabine and low dose GMI-1271 resulted in a significant reduction in metastatic 
incidence within all examined organs, except spleen, compared to mice treated with gemcitabine 
only (Figure 4.3B). In groups receiving gemcitabine and high dose GMI-1271, metastatic 
incidence to most organs was also reduced compared to the gemcitabine only treatment group, 
though not to levels greater than that observed with low dose GMI-1271. Examination of lesion 
size revealed that GMI-1271, alone or in combination with gemcitabine, had no impact on lesion 
growth if tumor cells reached a distant site (Supplementary Figure 4.2).  
As E-selectin regulates immune cell trafficking, we sought to determine if E-selectin 
blockade was impeded immune cell trafficking to tumors. Immunohistochemical staining revealed 
total numbers of CD45+ leukocytes within the tumors remained relatively similar across all 
treatment groups (Figure 4.4A-B). Also, there was no effect of the treatments on the presence of 
tertiary lymphoid aggregates within primary tumors (Figure 4.4C-D).  
GMI-1271 significantly prolongs survival in an immune competent model of PDAC. 
 We evaluated survival of immune deficient mice challenged with S2-013 following 
treatments with PBS, low dose GMI-1271, gemcitabine (100 mg/kg) or a combination of 
gemcitabine and GMI-1271. There was no difference in survival of animals treated with GMI-1271 
either as a monotherapy or in combination with gemcitabine (Figure 4.5A). Histological 







Figure 4.4 GMI-1271 does not affect total numbers of CD45+ leukocytes within orthotopic 
PDAC tumors. 
 
A) Representative immunohistochemical staining of CD45+ (brown) immune cells within PDAC 
primary tumor sections. Arrows indicate CD45+ immune cells. Sections were counterstained with 
hematoxylin (blue). Scale bar = 50 µm  
 
B) Quantification of the number of CD45+ leukocytes per field within the tumors. Four sections 
from four different mice were examined; at least 4 fields at 20X magnification were collected per 
section. GMI-1271 did not affect total numbers of CD45+ immune cells within the primary tumor. 
Error bars = s.d. 
 
C) Quantification of the number of CD45+ tertiary lymphoid aggregates (TLAs) per tumor section. 
15 sections examined/treatment group. Error bars = s.d. 
 
D) Representative staining of a CD45+ (brown) TLAs. Asterisk indicates a TLA.  Sections were 








Figure 4.5 GMI-1271 does not improve animal survival in an immune incompetent model of 
PDAC. 
 
A) Kaplan-Meier survival curve for S2-013-challenged athymic mice treated with PBS, GMI-1271, 
gemcitabine, or Gem+1271. Arrow indicates treatment start day. n = 10 mice/group. Log-rank tests 
determined no statistical significance between the GMI-1271 treatment groups.  
 
B) Graphical representation of the absolute metastatic incidence in KPC-challenged mice at end 





resulted in decreased metastasis to the lymph nodes, lungs, and liver at end stage disease compared 
to the gemcitabine treated group (Figure 4.5B).  
 We also evaluated the effects of GMI-1271 on survival in immune competent mice using 
transplanted KPC tumors.  A tumor line isolated from the KPC pancreatic cancer mouse model was 
implanted into the pancreases of C57BL/6 mice. After two weeks to establish tumors, mice were 
treated with GMI-1271, gemcitabine, or both. The GMI-1271 monotherapy did not prolong survival 
compared to untreated mice (Figure 4.6A). Interestingly, in this immune competent model, GMI-
1271, when used in combination with gemcitabine, significantly improved animal survival 
compared to mice treated with gemcitabine only (p=0.0302).  All mice were evaluated at end stage 
disease, and mice treated with both GMI-1271 and gemcitabine demonstrated a slightly lower 
incidence of metastasis to the lungs, diaphragm, kidney and spleen compared to mice treated with 
only gemcitabine (Figure 4.6B).  
GMI-1271 does not decrease PDAC metastasis to the lymph nodes by reducing lymphatic 
vascular density in vivo. 
Our results demonstrated that E-selectin blockade significantly reduced PDAC metastasis 
to the lymph nodes. We next evaluated the lymphatic vessel density (LVD) within primary tumors 
to determine if changes in LVD following gemcitabine and GMI-1271 treatment might explain the 
reduction in metastatic incidence within the lymph nodes. Immunofluorescent staining revealed 
that GMI-1271-treated mice had similar numbers of LYVE-1+ lymphatic vessels within primary 
tumors compared to tumors from control mice (Figure 4.7A-B). Moreover, gemcitabine and 
combinatorial treatment with GMI-1271 did not alter LVD within primary tumors.  
We further verified that E-selectin blockade did not impact lymphatic growth by examining 
the effects of GMI-1271 on hLEC proliferation and tubulogenesis in vitro. Treatment with 
increasing concentrations of GMI-1271 did not impair hLEC proliferation in culture over the course 









Figure 4.6 GMI-1271 improves survival when used in combination with gemcitabine in an 
immune competent model of PDAC. 
 
A) Kaplan-Meier survival curve for KPC-challenged C57BL/6 mice treated with PBS, GMI-1271, 
gemcitabine, or Gem+1271. Arrow indicates treatment start day. n = 10 mice/group. Log-rank test: 
p = 0.0302 between gemcitabine vs gem+1271.  
 
B) Graphical representation of the absolute metastatic incidence in KPC-challenged mice at end 




Figure 4.7 GMI-1271 does not decrease lymphatic vascular density within the primary site 
nor does it impact LEC growth. 
 
A) Representative immunofluorescent staining of LYVE-1+ (red) lymphatic vessels within the 
primary tumor. Nuclei are stained with blue DAPI. Arrows indicate LYVE-1+ lymphatic vessels. 
Scale bars = 50 µm  
 
B) Quantification of the number of LYVE-1+ lymphatic vessels within the primary tumor site. n=4 
mice/treatment group; 4 images (20X magnification) were collected per tumor section. Error bars 
= s.d.  
 
C) hLECs were treated with increasing concentrations of GMI-1271 and proliferation monitored 
for 96 hours. n=6 technical replicates/treatment and per timepoint; experiments were repeated 3 
times. GMI-1271 did not affect hLEC proliferation in vitro. Error bars = s.d. 
 
D) Quantification of the number of hLEC tubes formed in a three-dimensional (3D) collagen-I 
matrix following treatment with GMI-1271. n=3 replicate wells; 3 separate experiments performed. 
*p<0.05; **p<0.01; error bars = s.d. 
 
 E) Representative images of hLEC tube networks in a 3D collagen-I matrix following GMI-1271 
treatments. Scale bars = 100 µm 
 
F) Quantification of the number of hLEC tubes formed in a 3D matrigel matrix following treatment 
with GMI-1271. n=3 replicate wells; 3 separate experiments performed. *p<0.05; error bars = s.d. 
 
G) Representative images of hLEC tube networks in a 3D matrigel matrix following GMI-1271 










µg/ml) had no impact on hLEC tube formation (Figure 4.7D-E). However, high concentrations of 
GMI-1271 (100-200 µg/ml) slightly decreased hLEC tubulogenesis but did not completely block 
the process. High levels of GMI-1271 reduced hLEC tube formation by approximately 15%. This 
study was repeated using another extracellular matrix to induce hLEC tubulogenesis, matrigel. 
Again, high concentrations GMI-1271 slightly decreased Matrigel-induced hLEC tubulogenesis 
(approximately 38%); however, it did not completely block the process (Figure 4.7F-G). Taken 
altogether, these results suggest that E-selectin blockade by GMI-1271 does not reduce lymph node 
metastasis by inhibiting lymphangiogenesis or lymphatic endothelial proliferation.  
Lymphatic vessels are not the only escape route for tumor dissemination and many tumors 
are known to invade blood vessels; thus, we also evaluated blood vessel densities in primary PDAC 
tumors. Immunohistochemical staining for CD31 revealed no difference in vascular densities 
among control and GMI-1271-treated tumors and no difference among gemcitabine and 
combinatorial gemcitabine and GMI-1271 treated tumors (Figure 4.8A-B). We confirmed this 
finding by demonstrating GMI-1271 has no impact on vascular endothelial cell proliferation in 
vitro (Figure 4.8C).  
GMI-1271 inhibits the ability of E-selectin ligand -expressing PDAC cells to adhere to and 
transendothelial migrate across a lymphatic endothelium. 
Since decreased PDAC metastasis to lymph nodes was not attributed to a diminished 
presence of lymphatics in the primary tumor, we examined whether E-selectin blockade impaired 
tumor-lymphatic interactions. We performed a series of in vitro experiments to evaluate PDAC 
adhesion to and migration across a lymphatic endothelium in the presence of GMI-1271. We 
examined the response to E-selectin blockade of both E-selectin ligand expressing (S2-013, BxPC-
3) and non-expressing (Colo357, HPAF-II) PDAC lines.  
Treatment of hLECs with GMI-1271 significantly inhibited the adhesion of sLeA-











Figure 4.8 GMI-1271 does not decrease the number of blood vessels at the primary tumor 
site. 
 
A) Representative immunohistochemical staining of CD31+ (brown) blood vessels within primary 
tumors of mice orthotopically challenged with S2-013 PDAC cells and treated with GMI-1271 for 
4 weeks. Sections were counterstained with hematoxylin (blue). Arrows indicate CD31+ blood 
vessels.  Scale bars = 50 µm. 
 
B) Quantification of the number of CD31+ blood vessels per field within the primary tumor. Five 
(20X magnification) representative images were collected per tumor section from 4 mice within 
each treatment group. Error bars = s.d. 
 
C) Vascular endothelial cells (HUVECs) were treated with increasing concentrations of GMI-1271 
and proliferation monitored for 96 hours using a methylene blue assay. n=6 technical 





manner (Figure 4.9A). However, blocking E-selectin had no impact on the ability of non-sLeA-
expressing Colo357 or HPAF-II PDAC cells to adhere to a lymphatic endothelium (Figure 4.9B).   
We also evaluated whether E-selectin blockade impaired PDAC transendothelial migration 
(TEM) across a lymphatic endothelium using an in vitro model of TEM. Figure 4.10A shows that 
GMI-1271 significantly decreased the TEM of sLeA -expressing PDAC cells (S2-013, BxPC-3) in 
a dose dependent manner. However, GMI-1271 had no significant impact on the TEM of PDAC 
cells not expressing the E-selectin ligands (Colo357, HPAF-II; Figure 4.10B). It is of note that the 
sLeA-expressing PDAC cells had a stronger capacity to undergo lymphatic TEM compared to 
PDAC cells not expressing sLeA.  
We sought to determine if E-selectin blockade also inhibited PDAC TEM across a 
lymphatic endothelium under inflammatory conditions. Human LECs were stimulated with 
inflammatory cytokine TNF-α, a known inducer of E-selectin expression in endothelial cells, and 
this significantly increased the TEM of E-selectin ligand-expressing PDAC S2-013 cells (Figure 
4.10C).  Additional treatment with GMI-1271 restored TNFα-induced PDAC TEM rates to control 
levels. TNFα did not increase the TEM rate of PDAC cells not expressing E-selectin ligands 
(Colo357) and GMI-1271 was ineffective at inhibiting TEM for this cell line (Figure 4.10D).  
PDAC cells are capable of inducing expression of E-selectin in hLECs. 
Uninflamed hLECs are reported to express very little to no E-selectin (5), yet E-selectin 
blockade inhibited PDAC TEM. We therefore investigated the hypothesis that PDAC cells were 
capable of inducing E-selectin expression in hLECs in co-culture. Using a transwell system, we co-
cultured hLECs with PDAC cells S2-013 and Colo357 for varying lengths of time and then 
evaluated E-selectin mRNA expression in hLECs. TNFα-treated hLECs were used as a positive 
control for induction of E-selectin expression. After only 1 hour of co-culturing S2-013, E-selectin 
mRNA was substantially increased in hLECs compared to hLECs in monoculture (Figure 4.11A). 








Figure 4.9 GMI-1271 inhibits the binding of sLeA-expressing pancreatic tumor cells to 
lymphatic endothelia under steady state conditions. 
 
A) Human LEC monolayers were pretreated with increasing concentrations of GMI-1271. 
Fluorescently-labeled sLeA-expressing (S2-013, BxPC-3) PDAC cells were overlaid atop the 
monolayer and allowed to adhere to the LEC monolayer for 1 hour in the presence of GMI-1271. 
n=3 replicate wells; 4 images/well were collected for quantification. *p<0.05; **p<0.01; error 
bars=s.d. 
 
B) Human LEC monolayers were pretreated with increasing concentrations of GMI-1271. 
Fluorescently-labeled non-sLeA-expressing (Colo357, HPAF-II) PDAC cells were overlaid atop 
the monolayer and allowed to adhere to the LEC monolayer for 1 hour in the presence of GMI-










Figure 4.10 GMI-1271 inhibits the ability of sLeA-expressing PDAC cells to transendothelial 
migrate across a lymphatic endothelium both under uninflamed and inflamed conditions. 
 
A-B) Human LEC monolayers were established on the underside of Boyden chamber membranes 
and then pretreated with increasing concentrations of GMI-1271. Fluorescently labeled A) sLeA-
expressing (S2-013, BxPC-3) or B) non-sLeA-expressing (Colo357, HPAF-II) PDAC cells were 
plated in the upper insert and allowed to undergo TEM for 20-24 hours in the presence of GMI-
1271. n=3 replicate wells; 5 image collected/well for quantification. *p<0.05; **p<0.01; error 
bars=s.d. 
 
C) hLEC monolayers were pretreated with TNFα to induce inflammatory E-selectin expression and 
TEM experiments repeated. n=3 replicate wells; 5 image collected/well for quantification. *p<0.05; 
**p<0.01; ***p<0.001; error bars=s.d.  
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Colo357 cells, which are not dependent on E-selectin for invasion of lymphatic endothelia, also 
upregulated E-selectin mRNA in hLECs. (Figure 4.11A), but E-selectin mRNA levels began to 
decrease following just 1 hour of co-culturing. Pancreatic fibroblasts also induced E-selectin 
mRNA expression in hLECs but to a lesser extent as the PDAC lines (Figure 4.11B).  
Normalization based on TNFα-induced E-selectin expression revealed that S2-013 and Colo357 
induce E-selectin mRNA expression in hLECs at similar levels for the first hour (Figure 4.11C). 
However, after the first hour Colo357 and 13.34-induced E-selectin rapidly declined, while S2-
013-induced E-selectin expression levels remained substantially elevated for longer periods of 
time.   
Induction of E-selectin expression in hLECs by S2-013 and pancreatic fibroblasts was also 
evaluated at the protein level. Flow cytometry indicated a slight increase in the extracellular 
expression of E-selectin in hLECs following 6 hours of co-culture with S2-013 cells (Figure 
4.11D). Pancreatic fibroblasts showed no induction of E-selectin protein in hLECs. 
Immunofluorescence staining of hLEC and S2-013 co-cultures confirmed upregulation of E-
selectin expression at the protein level (Figure 4.11E-I). Unstimulated monocultures of hLECs 
displayed very low E-selectin expression (Figure 4.11E), while TNFα stimulation markedly 
increased E-selectin expression in hLECs (Figure 4.11F). Co-culturing with S2-013 cells for 2 
hours produced a slight increase in hLEC expression of E-selectin (Figure 4.11G). As co-culturing 
time was increased to 4 (Figure 4.11H) and 6 hours (Figure 4.11I), hLEC expression of E-selectin 
significantly increased. Taken altogether, these results indicate that PDAC cells are capable of 





Figure 4.11 PDAC cells induce E-selectin expression in lymphatic endothelial cells. 
 
A-B) Human LECs were plated on the underside of a transwell system membrane (pore: 0.4µm) 
and human PDAC lines A) S2-013 or Colo357 or B) pancreatic fibroblasts (13.34) were plated on 
the upper side. At the designated timepoints, mRNA was collected from hLECs and analyzed for 
E-selectin expression by qRT-PCR. E-selectin mRNA expression was normalized to GAPDH. 
Controls included E-selectin expression in hLECs in monoculture and hLECs treated with 2 ng/ml 
TNFα-treated for 6 hours. Monoculture hLEC expression of E-selectin mRNA was set equal to 1. 
n=3 technical replicates and each experiment co-culture performed thrice. ***p<0.001; 
****p<0.0001; error bars=s.d. 
 
C) TNFα-induced E-selectin mRNA expression was normalized across plates to compare E-
selectin induction in hLECs by PDAC tumor cells and fibroblasts.  
 
D) Flow cytometry analysis examining the expression of E-selectin in non-permeabilized hLECs 
following co-culturing with S2-013 (left) or pancreatic fibroblasts (right). Red histogram indicates 
E-selectin expression in monoculture hLECs (negative control); green histograms indicate TNFα-
induced E-selectin expression in hLECs (positive control); blue histograms indicate E-selectin 
expression in hLEC following 2.5 hours of co-culturing; and orange histograms indicate E-selectin 
expression in hLEC following 6 hours of co-culturing.  
 
E-I) Immunofluorescence staining indicating E-selectin (red) expression in permeabilized hLECs 
following co-culture with S2-013 PDAC cells. E) Control hLECs display very low to no expression 
of E-selectin while F) TNFα stimulation significantly increased E-selectin expression. Coculturing 
with S2-013 cells increased E-selectin expression in hLECs at G) 2 hours, H) 4 hours, and I) 6 
hours with 6 hours of co-culturing displaying the highest level of expression. Cell nuclei are stained 






















Adhesion protein E-selectin has been shown to regulate metastasis in a variety of cancers 
(146, 257, 260). However, its direct role in the metastasis of pancreatic cancer in vivo has not been 
fully evaluated. Using a novel glycomimetic small molecule antagonist of E-selectin, we 
demonstrated that E-selectin influences PDAC dissemination via the vasculature systems, and that 
blocking its ligand binding function decreased PDAC metastasis. Although it is known that E-
selectin plays a role in vascular invasion of tumor cells, we demonstrated for the first time a role 
for E-selectin in facilitating tumor cell invasion of the lymph nodes via the lymphatic vasculature. 
Using GMI-1271, we showed that blockade of E-selectin significantly impairs PDAC adhesion to 
a simulated lymphatic endothelium and subsequent transendothelial invasion. In vivo, this blockade 
led to a significant decrease in lymph node metastasis. This inhibition of transendothelial invasion 
was contingent upon the expression of E-selectin ligands on PDAC cells. Lastly, we showed that 
PDAC cells can directly regulate the expression of E-selectin in order to undergo TEM. Novel E-
selectin antagonist GMI-1271 holds promise as a potential treatment for PDAC and other metastatic 










Supplementary Figure 4.1 GMI-1271 does not alter PDAC proliferation in vitro.  
 
S2-013 and Colo357 PDAC cells were treated with increasing concentrations of GMI-1271 and 
proliferation monitored for 96 hours using a methylene blue assay. n=6 technical 








Supplementary Figure 4.2 E-selectin blockade does not impair lesion growth following 
colonization at a distant site.  
 
Evaluation of the size distribution of metastatic lesions. Numbers above bar indicate total number 







Effects of E-selectin and CXCR4 Dual Inhibition by 
Novel Inhibitor, GMI-1359, on Pancreatic Cancer and 





 CXCR4 is the most frequently overexpressed chemokine receptor in malignancy (261, 
262). High expression of CXCR4 and its predominant ligand, CXCL12, frequently correlates with 
advanced tumor stage and poor patient prognosis in many types of cancer including pancreatic 
(140, 263, 264), breast (128, 265-267), lung (268-270), renal (271), melanoma (101), colorectal 
(272), brain (273), and prostate cancers (274). In the setting of PDAC, CXCR4 first becomes 
upregulated in early stage precursor PanINs and expression continues to increase as PanINs 
progress to malignancy (264). Pancreatic tumor cells themselves express high levels of CXCR4 but 
very low levels of its ligand. CXCL12 is mainly secreted by the cellular components of the tumor 
microenvironment such as activated fibroblasts and endothelial cells (275, 276). CXCL12-CXCR4 
signaling within the primary tumor has been shown support PDAC progression by promoting tumor 
cells proliferation (277), invasion (278), angiogenesis (137, 279, 280), chemoresistance (281), and 
immune evasion (171). 
 Studies have also indicated that CXCR4 and CXCL12 are significant players in the 
regulation of tumor metastasis. CXCR4-expressing tumor cells often follow CXCL12 gradients to 
distant organs sites during dissemination. Organs that most highly express CXCL12, the lungs, 
liver, and bone marrow, are frequent sites for tumor dissemination (128, 282-284). CXCL12-
CXCR4 has also been shown to promote angio- and lymphangiogenesis which increases the 
number of potential routes tumor cells can use to escape the primary site (280, 285). CXCL12 
expression by lymphatic and vascular endothelial cells attracts CXCR4+ tumor cells to the 
lymphovascular niche where CXCR4 enables transendothelial invasion (101, 286-288). 
Additionally, this CXCL12+ lymphovascular niche within the primary and metastatic tumor sites 
provides chemoprotection to CXCR4+ tumor cells and inhibits therapy-induced cell death (101). 
The role of CXCR4 in promoting metastasis as well as other pro-tumor mechanisms makes it an 
interesting target for cancer therapy.  
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Our studies examine the role of CXCL12-CXCR4 in facilitating intercellular 
communications and interactions among cells of the PDAC microenvironment: tumor cells, 
fibroblasts, and lymphatic endothelial cells. Specifically, we focus on potential roles it may have 
in lymphatic-directed metastasis. Using a novel small molecule antagonist of both CXCR4 and E-
selectin, GMI-1359, our results demonstrate that GMI-1359 is an effective inhibitor of previously 
described CXCR4-dependent mechanisms in vitro. Additionally, we performed side-by-side 
studies with GMI-1359 and GMI-1271, an E-selectin only antagonist, to elucidate the CXCR4-
dependent effects from the E-selectin-dependent effects of this dual inhibitor. Our results indicate 
that CXCL12 secretion from pancreatic fibroblasts facilitates the recruitment of LECs, and 
blockade of CXCR4 abrogates this recruitment. Moreover, CXCR4 expression facilitates the ability 
of hLECs to support PDAC adhesion and transendothelial migration across a lymphatic barrier. 
These in vitro studies demonstrate an essential role for CXCR4 in supporting lymphatic recruitment 
and invasion for PDAC invasion and metastasis. Examination of in vivo antagonism of CXCR4 in 
PDAC orthotopic mouse models resulted in delayed metastasis of PDAC and a significant 
reorganization of the PDAC microenvironment. Unfortunately, in vivo treatment with GMI-1359 
did not result in prolonged animal survival when used alone or in combination with chemo- and 
immunotherapies in both immune incompetent and immune competent mice. However, alterations 
to the dosage and treatment schedule of GMI-1359 in combination with other PDAC therapies may 
improve survival in future studies.  
II. Results 
Characterization of CXCR4 and CXCL12 expression in cellular components of the PDAC 
tumor microenvironment. 
To understand the potential effects of GMI-1259 on PDAC tumor cells, we examined the 
expression of CXCR4 in a panel of human PDAC cell lines. Western blot analysis demonstrated 
that all examined PDAC cell lines expressed CXCR4, albeit at varying levels (Figure 5.1A). Flow 




Figure 5.1 Pancreatic tumor cell express CXCR4 in culture. 
 
A) Western blot (50 µg protein/lane) analysis demonstrating CXCR4 expression in a panel of 
human PDAC cell line lysates: HPAF-II, S2-013, Hs766t, T3M4, Capan-2, BxPC-3, MiaPaca-2, 
and Colo357. β-actin expression was used as a loading control for all cell lines.  
 
B) Flow cytometry confirming expression of CXCR4 in a panel of non-permeabilized human 
PDAC cell lines: S2-013, Colo357, BxPC-3, Capan-2, MiaPaca-2. Rabbit polyclonal IgG was used 
as an isotype control. Blue histograms represent the IgG isotype control and red histograms 
represent CXCR4 labeling.  
 
C) Immunofluorescence staining indicating CXCR4 expression in human PDAC cell lines. CXCR4 
(red) is diffusely expressed across the cell surface. Cell nuclei are stained with DAPI (blue). Rabbit 
polyclonal isotype control was used as a negative control (red; bottom row, far right image). Scale 












 CXCR4 is expressed on the PDAC cell surface (Figure 5.1B). Lastly, immunofluorescence 
staining revealed that CXCR4 is distributed uniformly across the cell surface of PDAC cells 
(Figure 5.1C).  
Cell types of the PDAC tumor microenvironment were also evaluated for CXCR4 
expression. Western blot analysis revealed that pancreatic fibroblasts (13.34) and lymphatic 
(hLECs) and vascular (HUVECs) endothelial cells express measurable levels of CXCR4 (Figure 
5.2A). Human neonatal foreskin fibroblasts (HuFF) were used a negative control for CXCR4. Flow 
cytometry confirmed expression of CXCR4 in the pancreatic fibroblasts and hLECs (Figure 5.2B). 
Immunofluorescence staining revealed that pancreatic fibroblasts express CXCR4 across the cell 
surface while hLECs and HUVECs have more nuclear expression of CXCR4 (Figure 5.2C). LECs 
also demonstrated low levels of CXCR4 across the cell surface.  
To characterize the expression of the CXCR4 ligand, CXCL12, ELISA analysis was 
performed on both conditioned media (secreted CXCL12) and whole cell lysates (cell-bound 
CXCL12) from PDAC cells, pancreatic fibroblasts (13.34), and hLECs. In culture, only pancreatic 
fibroblasts constitutively secrete CXCL12 into conditioned media (Figure 5.3A). CXCL12 was not 
detected by ELISA in the conditioned media of PDAC cells S2-013 and Colo357 nor was it detected 
in hLEC conditioned media. ELISA analysis on whole cell lysates revealed expression of CXCL12 
in PDAC cells, pancreatic fibroblasts, and hLECs suggesting that CXCL12 may be bound to the 
cell surface or sequestered within intracellular compartments (Figure 5.3B). Flow cytometry on 
permeabilized samples confirmed the intracellular expression of CXCL12 within these same cell 
types (Figure 5.3C).  
GMI-1359 effects on PDAC tumor cell, fibroblast, and endothelial cell proliferation. 
We evaluated the effects of GMI-1359 on PDAC cells, fibroblasts, and endothelial cell 
proliferation. Both of the examined PDAC lines, S2-013 and Colo357, showed little response to 







Figure 5.2 Expression of CXCR4 in cell types of the PDAC microenvironment. 
 
A) Western blot (30 µg protein/lane) analysis demonstrating CXCR4 expression in human 
lymphatic endothelial cells (LECs), vascular endothelial cells (HUVECs), and pancreatic 
fibroblasts (13.34) lysates. Human neonatal foreskin fibroblasts (HuFF) lysates were used as a 
negative control for CXCR4 expression.  β-actin expression was used as a loading control for all 
cell lines.  
 
B) Flow cytometry confirming expression of CXCR4 in human lymphatic endothelial cells 
(hLECs), and pancreatic fibroblasts (13.34). For hLECs, the red histogram indicates IgG isotype 
control labeling and the blue histogram indicates CXCR4 labeling. For pancreatic fibroblast, the 
blue histogram indicates IgG isotype control labeling and the red histogram represents CXCR4 
labeling.  
 
C) Immunofluorescence staining indicating CXCR4 expression in 13.34 pancreatic fibroblasts, 
hLECs, and HUVECs. CXCR4 (red) is diffusely expressed across the cell surface of 13.34 cells 
while mainly nuclear staining is seen in the hLECs and HUVECs. Cell nuclei are stained with DAPI 
(blue). Rabbit polyclonal isotype control was used as a negative control (lower left image). Scale 











Figure 5.3 CXCL12 secretion and expression in PDAC cells and tumor microenvironment 
cell types. 
 
A) ELISA-based quantification of CXCL12 within conditioned media of PDAC cells (Colo357, 
S2-013), pancreatic fibroblasts (13.34), or hLECs. Media was conditioned for 24 hours by equal 
numbers of cells in equal volumes of serum free media. Unconditioned serum free media was used 
as a control. 3 replicate wells were analyzed per experiment and experiments were performed 
thrice. Error bars = s.d. 
 
B) ELISA-based quantification of CXCL12 within whole cell lysates (2000 µg/ml) of PDAC cells 
(Colo357, S2-013), pancreatic fibroblasts (13.34), or hLECs. Lysis buffer was used as a control. 3 





Figure 5.4 Effect of GMI-1359 on PDAC, fibroblast, and endothelial cell proliferation and 
morphology.  
 
Methylene blue assay measuring the proliferation of A) S2-013, B) Colo357, C) 13.34 pancreatic 
fibroblasts, D) hLECs, or E) HUVECs treated with increasing concentrations of GMI-1359 or 
GMI-1271 (0, 10, 100, 1000 µg/ml). Line graphs represent cell numbers collected at 2, 24, 48, 72, 
or 96 hours. OD values were read at 650 nm. 5 replicate wells were performed at each inhibitor 
concentration and each time point. Experiment was repeated 3 times. Error bars = s.d. Phase 
contrast images (10X magnification) are of S2-013, Colo357, 13.34, and hLEC treated with 100 












concentrations, proliferation appeared normal for the first 24 hours for S2-013 cells. However, by 
72-96 hours, S2-013 proliferation significantly decreased with increasing concentrations of GMI-
1359. Examination of cell morphology revealed that GMI-1359-treated S2-013 PDAC cells had an 
elongated morphology compared to untreated cells. Similar to S2-013 cells, 10 µg/ml GMI-1359 
had little effect on Colo357 proliferation (Figure 5.4B). However, at 100 and 1000 µg/ml, GMI-
1359 completely impaired Colo357 proliferation after 24 hours. GMI-1271 did not affect Colo357 
at any of the examined concentrations.  Examination of cell morphology revealed the Colo357 cells 
were undergoing cell death after 72 hours of treatment with 100 µg/ml GMI-1359. GMI-1271 had 
no impact on S2-013 or Colo357 proliferation at any of the tested concentrations (Figure 5.4A-B). 
The effects of GMI-1359 on pancreatic fibroblast and endothelial cell proliferation were 
also evaluated. Treatment with 10 µg/ml GMI-1359 had no effect on 13.34 proliferation (Figure 
5.4C). At 100 µg/ml, GMI-1359 slightly reduced pancreatic fibroblast proliferation, but not 
significantly. By 1000 µg/ml GMI-1359, 13.34 proliferation was completely inhibited. GMI-1271 
had no significant impact on 13.34 proliferation. Morphologic examination revealed that treatment 
with 100 µg/ml GMI-1359 for 72 hours had no impact on 13.34 morphology. LEC proliferation 
was unaffected by GMI-1359 or GMI-1271 treatment even at high concentrations (Figure 5.4D). 
Increasing concentrations of GMI-1359 moderately inhibited HUVEC proliferation (Figure 5.4E). 
Even at high concentrations of GMI-1359 (1000 µg/ml), HUVEC still proliferated but at a reduced 
rate. GMI-1271 had no impact on HUVEC proliferation.  
GMI-1359 inhibits CXLC12-induced signaling and CXCL12-directed migration by 
blocking CXCR4. 
To verify that GMI-1359 blocks CXCR4 function, we examined its ability to inhibit 
CXCL12-induced ERK1/2 phosphorylation and CXCL12-induced migration. We used hLECs as a 
model cell type as it has been previously reported that CXCL12 induces these effects in hLECs 
(285). In agreement with these reports, CXCL12 induced phosphorylation of ERK 1/2 within 5 
minutes of stimulation (Figure 5.5A). By 30 minutes, phospho-ERK1/2 levels returned to steady 
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state levels. Total ERK1/2 levels remained unchanged during CXCL12 stimulation. CXCR4 
blockade with GMI-1359 significantly decreased, but did not completely inhibit, CXCL12-induced 
ERK1/2 activation in hLECs. Blockade of E-selectin alone with GMI-1271 had no effect on 
ERK1/2 activation during CXCL12 simulation. These data suggest that GMI-1359 blocks CXCR4 
function resulting in inhibition of CXCL12-induced ERK1/2 phosphorylation (Figure 5.5B).  
The impact of GMI-1359 on CXCL12-induced migration of hLECs was also examined. 
When present in the lower wells of a Boyden chamber system, increasing concentrations of 
recombinant CXCL12 induced a strong upregulation of hLEC migration (Figure 5.6A). 
Pretreatment of hLECs with GMI-1359 significantly impaired hLEC migration toward CXCL12. 
Regardless of CXCL12 concentration, 10 µg/ml GMI-1359 was sufficient to return hLEC 
migration to control levels. To verify that GMI-1359 impaired only CXCL12-induced migration 
and was not a general inhibitor of migration process, we evaluated its effects on hLEC migration 
using endothelial growth media EGM-2MV containing FBS and growth factors as the 
chemoattractant. GMI-1359 had no impact on hLEC migration toward FBS/growth factor-
containing media (Figure 5.6B). Combined these results demonstrate that GMI-1359 inhibits 
CXCL12-induced migration and is not a general inhibitor of the hLEC migration process.  
We also evaluated the ability of GMI-1359 to impair CXCL12-induced migration of 
another CXCR4-expressing cell type, S2-013 PDAC cells. At 100 ng/ml, CXCL12 moderately 
increased S2-013 directional migration; however, increasing the concentration to 500 ng/ml did not 
further increase in S2-013 migration (Figure 5.6C). Pretreatment with GMI-1359 reduced S2-013 
migration toward CXCL12 but did not return migration to control levels. Similar to hLECs, GMI-
1359 did not affect S2-013 migration toward FBS-containing media (Figure 5.6D), again, 
demonstrating that GMI-1359 specifically inhibits the CXCL12-directed migration and is not a 









Figure 5.5 Blockade of CXCR4 by GMI-1359 reduced ERK1/2 activation in hLECs. 
A) Western blot analysis of phopho-ERK1/2 activation in hLECs following stimulation with 200 
ng/ml human recombinant CXCL12 for 5, 10, or 30 minutes. Designated hLECs were pretreated 
with 10 µg/ml GMI-1359 30 minutes prior to CXCL12 stimulation.  
B) Western blot analysis of phopho-ERK1/2 activation in hLECs following stimulation with 200 
ng/ml human recombinant CXCL12 for 5, 10, or 30 minutes. Designated hLECs were pretreated 









Figure 5.6 CXCR4 blockade by GMI-1359 inhibits CXCL12-induce migration of hLECs and 
S2-013. 
 
A) The lower wells of a Boyden chamber plates were loaded with serum free media containing 
either 0, 100 or 500 ng/ml CXCL12. Human LECs were diluted in serum free media and added to 
the upper inserts. Designated hLECs were pretreated with 10 µg/ml GMI-1359 for 30 minutes prior 
to plating in the upper inserts. Migration was stopped after 16 hours and quantified. CXCL12 
induced hLEC migration. Treatment with GMI-1359 significantly inhibited CXCL12-induced 
hLEC migration. Quantification is the average of 3 replicate membranes; experiment was repeated 
3 times.  *p<0.05, **p<0.01, error bars = s.d. 
 
B) The lower wells of a Boyden chamber plates were loaded FBS/growth factor-containing EGM-
2MV. Human LECs or were diluted in serum free media and added to the upper inserts. Designated 
hLECs were pretreated with 10 µg/ml GMI-1359 for 30 minutes prior to plating in the upper inserts. 
Migration was stopped after 16 hours and quantified. Quantification is the average of 3 replicate 
membranes; experiment was repeated 3 times. Error bars = s.d. 
 
C) Migration plates were set up as described in Figure 5.6A except with S2-013 cells. CXCL12 
moderately increased S2-013 migration. Quantification is the average of 3 replicate membranes; 
experiment was repeated 3 times.  *p<0.05, error bars = s.d. 
 
D) The lower wells of a Boyden chamber plates were loaded FBS-containing RPMI. S2-013 cells 
were diluted in serum free media and added to the upper inserts. Designated S2-013 cells were 
pretreated with 10 µg/ml GMI-1359 for 30 minutes prior to plating in the upper inserts. Migration 
was stopped after 16 hours and quantified. Quantification is the average of 3 replicate membranes; 




CXCR4 blockade through GMI-1359 completely inhibited CXCL12-induced hLEC 
migration but did not completely suppress CXCL12-stimulated ERK1/2 activation. The other 
known receptor for CXCL12, CXCR7, has been shown to induce ERK1/2 signaling, but has no 
known role in migration (289, 290). Therefore, we hypothesized that hLECs may express CXCR7. 
Flow cytometry revealed that hLECs do, in fact, express CXCR7 and that may explain why GMI-
1359 did not completely suppress ERK1/2 activation following CXCL12 stimulation 
(Supplementary Figure 5.1).  
Pancreatic fibroblasts induce hLEC migration via the CXCL12-CXCR4 chemokine axis.  
Previously, we demonstrated that pancreatic fibroblasts strongly induced hLEC migration 
and also secrete abundant amounts of CXCL12. We evaluated whether fibroblast-induced hLEC 
migration was dependent on a CXCL12 gradient secreted by the fibroblasts. Using 13.34 
conditioned media as a chemoattractant in a Boyden migration assay, hLECs were pretreated with 
either dual E-selectin/CXCR4 antagonist GMI-1359 or E-selectin only antagonist GMI-1271. 
Treatment with GMI-1359 completely abrogated fibroblast- induced hLEC migration (Figure 
5.7A). In the presence of 10 µg/ml GMI-1359, hLEC migration to pancreatic fibroblast conditioned 
media returned to the same level as that induced by unconditioned media. Blockade of E-selectin 
alone through GMI-1271 had no significant impact on hLEC migration to fibroblast conditioned 
media. These results demonstrate that pancreatic fibroblasts strongly induce hLEC migration 
through secretion of CXCL12 and blockade of the CXCL12 receptor, CXCR4, complete abolishes 
this fibroblast-induced hLEC migration.  
We also hypothesized that S2-013 and Colo357 PDAC cell migration toward pancreatic 
fibroblast conditioned media may also be dependent on the CXCL12-CXCR4 axis. Pretreatment 
with GMI-1359 moderately reduced (38.7%) S2-013 migration toward pancreatic fibroblast 
conditioned media (Figure 5.7B). However, fibroblast-induced S2-013 migration did not return to  
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Figure 5.7 Pancreatic fibroblast strongly induce hLEC, but not pancreatic tumor cell, 
migration through CXCL12 secretion and this migration can be inhibited by GMI-1359. 
 
A-C) 13.34 pancreatic fibroblasts conditioned media (CM) was loaded into the lower wells of a 
Boyden chamber plate. 2.5 x 104 A) hLECs, B) S2-013, or C) Colo357 cells were diluted in serum 
free media and added to the upper inserts. Designated cells were pretreated with 10 µg/ml GMI-
1359 for 30 minutes prior to plating in the upper inserts. Migration was stopped after 16 hours and 
quantified. Graphical representation is the mean of 3 replicate membranes; experiment was 
repeated 3 times.  *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 error bars = s.d. 
 
D) Lower wells of Boyden chamber plates were loaded with FBS-containing media to induce 
cellular migration. 2.5 x 104 Colo357 cells were diluted in serum free media and added to the upper 
inserts. Designated cells were pretreated with 0, 10, 100 µg/ml GMI-1359 for 30 minutes prior to 
plating in upper inserts. Migration was stopped after 16 hours and quantified. Graphical 
representation is the mean of 3 replicate membranes; experiment was repeated 3 times. Error bars 
= s.d.  
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the same levels as migration induced by unconditioned media. Blockade of CXCR4 had even less 
of impact on Colo357 migration to pancreatic fibroblast conditioned media (Figure 5.7C). 
Blockade of E-selectin with GMI-1371 had no impact on S2-013 or Colo357 migration toward 
pancreatic fibroblast conditioned media. Similar to previously described experiments with S2-013 
cells, Colo357 migration toward FBS-containing growth media was not impacted by CXCR4 
inhibition (Figure 5.7D) These data suggest that PDAC migration toward pancreatic fibroblasts is 
only partially dependent on CXCL12 and that other factors contribute to this migration.  
CXCR4 faciliates PDAC adhesion to and transendothelial migration across lymphatic 
endothelial barriers. 
CXCR4 has been shown to play a role in promoting lymphatic-leukocyte interactions 
during intravasation (276). We hypothesized that CXCR4 may also facilitate PDAC-lymphatic 
interactions during tumor cell invasion. To examine the role of CXCR4 in facilitating PDAC 
adhesion to a lymphatic endothelium, a confluent monolayer of hLECs was established and 
pretreated with increasing concentrations of GMI-1359. Following pretreatment, either S2-013 or 
Colo357 PDAC cells were overlaid atop the monolayer and allowed to adhere for one hour. 
Treatment with GMI-1359 significantly impaired S2-013 adhesion to an hLEC endothelium 
(Figure 5.8A). Since S2-013 cells express E-selectin ligands, the ability of GMI-1359 to inhibit 
S2-013 adhesion may have been due to E-selectin blockade by this dual inhibitor. Therefore, to 
determine if CXCR4 may also contribute to endothelial adhesion, we examined the ability of GMI-
1359 to suppress adhesion of a PDAC cell line that does not express E-selectin ligands, Colo357. 
Interestingly, blockade of CXCR4 through GMI-1359 significantly inhibited the ability of Colo357 
to adhere to a lymphatic endothelium in a dose-dependent manner (Figure 5.8A). We performed 
similar PDAC adhesion assays using vascular endothelial cells (HUVECs) in place of hLECs. 
GMI-1359 moderately inhibited the adhesion of both E-selectin ligand-expressing and non-
expressing PDAC cells to a vascular endothelium, though these studies with HUVECs never 
achieved statistical significance (Figure 5.8B).  
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Figure 5.8 Blockade of CXCR4 by GMI-1359 inhibits PDAC adhesion and transendothelial 
migration across a lymphatic endothelium. 
 
A) Human LEC monolayers were pretreated with increasing concentrations of GMI-1359 for 1 
hour. Fluorescently-labeled S2-013 or Colo357 PDAC cells were overlaid atop the monolayer and 
allowed to adhere to the LEC monolayer for 1 hour in the presence of GMI-1359. Non-adherent 
PDAC cells were washed away and adherent cells were quantified. Graphical representation is the 
mean of 3 replicate wells. Four representative images (4X magnification) were collected per well. 
*p<0.05; **p<0.01; error bars = s.d. 
 
B) HUVEC monolayers were pretreated with increasing concentrations of GMI-1359 for 1 hour. 
Fluorescently-labeled S2-013 or Colo357 PDAC cells were overlaid atop the monolayer and 
allowed to adhere to the HUVEC monolayer for 1 hour in the presence of GMI-1359. Non-adherent 
PDAC cells were washed away and adherent cells were quantified. Graphical representation is the 
mean of 3 replicate wells. Four representative images (4X magnification) were collected per well. 
Error bars=s.d. 
 
C) Human LEC monolayers were established on the underside of Boyden chamber membranes and 
then pretreated with increasing concentrations of GMI-1359 for 1 hour. Fluorescently-labeled S2-
013 or Colo357 PDAC cells were plated in the upper insert and allowed to undergo TEM for 20-
24 hours in the presence of GMI-1359. Non-transmigrated PDAC cells were mechanically removed 
and transmigrated cells were quantified. Graphs represent the mean of 3 replicate membranes; 
experiment was repeated 3 times. *p<0.05; **p<0.01; error bars = s.d. 
 
D) Human LEC monolayers were established on the underside of Boyden chamber membranes 
and then pretreated with 10 µg/ml anti-CXCR4 blocking antibody for 1 hour. Fluorescently-
labeled S2-013 cells were plated in the upper insert and allowed to undergo TEM for 20-24 hours 
in the presence of GMI-1359. Non-transmigrated PDAC cells were mechanically removed and 
transmigrated cells were quantified. Graphs represent the mean of 3 replicate membranes; 











As tumor cell adhesion to an endothelium does not directly translate to invasion, we set 
up a series of PDAC transendothelial migration (TEM) assays to determine if CXCR4 blockade 
could inhibit tumor invasion of an endothelium. LEC monolayers were established on the 
underside of Boyden chamber membranes and pretreated with increasing concentrations of GMI-
1359. Following pretreatment, CFDA-SE-labeled S2-013 were added to the upper insert and 
allowed to undergo TEM for 20-24 hours. S2-013 TEM across a lymphatic endothelium was 
markedly reduced in the presence of GMI-1359 (Figure 5.8C). To determine if this inhibition 
was due to E-selectin, CXCR4, or both, we again evaluated the effects of GMI-1359 on the TEM 
of PDAC cells not expressing E-selectin ligands. Similar to S2-013 TEM, TEM across a 
lymphatic endothelium by Colo357 cells was significantly reduced in the presence of GMI-1359 
(Figure 5.8C). As further verification of the role of CXCR4 in PDAC TEM, we also performed 
TEM assays in the presence of a CXCR4 blocking antibody. Similar to GMI-1359, the CXCR4 
blocking antibody significantly reduced the TEM of S2-013 cells across a lymphatic endothelium 
(Figure 5.8D). The data from these experiments demonstrate that CXCR4 plays a considerable 
role in the interactions between PDAC cells and lymphatic endothelium and that blockade of this 
receptor significantly impairs the adhesion and TEM of PDAC cells across a lymphatic 
endothelium.  
CXCR4 ligand CXCL12 promotes the ability of hLECs to facilitate PDAC TEM. 
To evaluate the role for the CXCR4 ligand, CXCL12, on PDAC TEM, we stimulated hLEC 
monolayers with 200 ng/ml human recombinant CXCL12 for 8 hours, washed the monolayer, and 
then added PDAC cells. In some experiments, hLEC monolayers were pretreated with GMI-1271 
or 1359 for 1 hour and then washed prior to the addition of S2-013 PDAC cells. Neither GMI-1271 
nor 1359 was present during the TEM process to elucidate the effects of blocking E-selectin and 
CXCR4 only on the hLEC monolayers during PDAC TEM.  In inhibitor-only-treated hLECs, 
pretreatment of monolayers with GMI-1271 or 1359 significantly impaired the ability of hLECs to 
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facilitate S2-013 TEM (Figure 5.9A). Since neither GMI-1271 nor 1359 was present during the 
TEM process, these results suggest that expression of E-selectin and CXCR4 by hLECs facilitates 
PDAC cell TEM. This was not unexpected for E-selectin as E-selectin expression is restricted to 
endothelial cells. However, CXCR4 is expressed by both PDAC cells and hLECs and blockade of 
CXCR4 in only the hLECs significantly impaired PDAC TEM.  
We also evaluated the role of CXCL12 in hLEC-facilitated TEM. CXCL12 stimulation of 
hLECs resulted in a significant increase in the ability of hLECs to facilitate S2-013 TEM (Figure 
5.9A). As expected, blockade of CXCR4 in hLECs through GMI-1359 abrogated this CXCL12-
enhanced TEM of S2-013 cells. Unexpectedly, GMI-1271 pretreatment of hLECs also suppressed 
CXCL12-enhanced S2-013 TEM. Under E-selectin blockade only, the ability of CXCL12-
stimulated hLEC to facilitate S2-013 TEM was returned to control levels. This suggests a link 
between CXCL12 stimulation and E-selectin. Similar results with CXCL12 and GMI-1359 were 
seen using Colo357 cells (Figure 5.9B). Lastly, we evaluated whether a cellular of source of 
CXCL12 could stimulate hLEC-facilitated TEM similarly to recombinant CXCL12. Lymphatic 
monolayers were pretreated with conditioned media from 13.34 pancreatic fibroblasts. Some 
monolayers were also pretreated with GMI-1271 or 1359. Pancreatic fibroblast conditioned media 
moderately increased the ability of hLECs to facilitate PDAC TEM (Figure 5.9C). The fold 
increase in TEM was similar to treatment with recombinant CXCL12 (1.5 times control levels). 
Pretreatment with GMI-1271 or 1359 again returned S2-013 TEM to control levels.  
GMI-1359 delays metastasis in an in vivo orthotopic model of pancreatic cancer. 
Our in vitro studies demonstrated that the CXCL12-CXCR4 axis plays a significant role in 
facilitating PDAC-endothelial interactions during invasion, and that blockade of both E-selectin 
and CXCR4 through GMI-1359 significantly impairs TEM of PDAC cells. We next evaluated 
whether GMI-1359 could impair this invasion in vivo and prevent spontaneous PDAC metastasis. 









Figure 5.9 CXCL12 stimulation of lymphatic endothelial cells enhances pancreatic tumor 
transendothelial migration.  
 
A-B) Human LEC monolayers were stimulated with 200 ng/ml CXCL12 for 8 hours and either 
10 µg/ml GMI-1271 or GMI-1359 for 1 hour. Monolayers were washed three times prior to the 
addition of migratory cells so that only hLECs would be affected by CXCL12 and inhibitors. 
Fluorescently-labeled A) S2-013 of B) Colo357 cells were plated in the upper insert and allowed 
to undergo TEM for 20-24 hours. Non-transmigrated PDAC cells were mechanically removed 
and transmigrated cells were quantified. Graphs represent the mean of 3 replicate membranes; 
experiment was repeated 3 times. *p<0.05; **p<0.01; error bars = s.d. 
 
C) Human LEC monolayers were stimulated with pancreatic fibroblast conditioned media (CM) 
for 8 hours and either 10 µg/ml GMI-1271 or GMI-1359 for 1 hour. Monolayers were washed 
three times prior to the addition of migratory cells so that only hLECs would be affected by CM 
and inhibitors. Fluorescently labeled S2-013 cells were plated in the upper insert and allowed to 
undergo TEM for 20-24 hours. Number of transmigrated cells were quantified. Graphs represent 
the mean of 3 replicate membranes; experiment was repeated 3 times. *p<0.05; ***p<0.001; 





 distributed the mice among 6 treatment groups with 15 mice per group: 1) vehicle control (PBS), 
2) GMI-1271, 3) GMI-1359, 4) gemcitabine (Gem), 5) Gem+1271, or 6) Gem+1359. We chose to 
investigate the effects of using GMI-1359 in combination with gemcitabine because CXCR4 has 
been implicated in promoting gemcitabine resistance in pancreatic tumor cells (291). GMI-1271 
was used in this study to elucidate E-selectin-dependent and CXCR4-dependent effects. Mice were 
treated for 4 weeks after which they were sacrificed and organs collected for metastatic analysis. 
Analysis of tumor size among the treatment groups revealed that monotherapy with GMI-
1359 had no impact on PDAC tumor size in these mice (Figure 5.10A-B). In accordance with our 
previous studies, GMI-1271 monotherapy also did not reduce tumor size, but gemcitabine did 
significantly reduce tumor size. When used in combination with gemcitabine, GMI-1359 treatment 
did not further reduce tumor size compared to mice treated with gemcitabine monotherapy (Figure 
5.10A-B). Histological examination of the tumors both at the primary site and metastatic sites 
revealed that neither GMI-1271 nor 1359 treatment affected the morphology of the tumor cells 
(Figure 5.10C). None of the mice displayed any drug-induced toxicities when treated with GMI-
1359.  
Next, we surveyed several representative organ sections from spleen, lymph nodes, liver, 
lung, kidney, and diaphragm for presence of metastatic lesions by gross microscopic analysis. 
Results from this metastatic study are displayed in Figure 5.11A. In accordance with our previous 
studies, GMI-1271 monotherapy did not significantly reduce the incidence of metastasis to any of 
the organs sites examined when compared to the vehicle control treatment group. Gemcitabine 
monotherapy reduced metastasis to all examined sites compared to control mice. This reduction in 
metastasis by gemcitabine is likely due to inhibition of primary tumor growth. The combination of 
gemcitabine and GMI-1271 further reduced the incidence of metastasis to all organ sites except 
lungs when compared to mice receiving gemcitabine only. Assessment of metastatic sites also 








Figure 5.10 GMI-1359 does not affect in vivo tumor growth or morphology in an immune 
incompetent orthotopic model of pancreatic cancer. 
 
Human S2-013 PDAC cells were orthotopically implanted into the pancreases of athymic female 
mice and allowed to establish for 2 weeks. Treatments were given for 4 weeks, after which 
tumors and metastatic organs were collected. n = 15 mice/treatment group. 
 
A-B) Graphical representation of A) tumor volume (based on length, width, height 
measurements) and B) weight for each treatment group. ****p<0.0001  
 
C) Representative histological sections of S2-013 PDAC tumors, lung lesions, and lymph node 









Figure 5.11 GMI-1359 delays metastasis in an immune incompetent orthotopic model of 
pancreatic cancer. 
 
A) The presence of spontaneous metastatic lesions was identified in spleen, lymph nodes, liver, 
lungs, kidney, and diaphragm of all mice using histological staining of representative sections. 
Graphs represent the absolute percentage of mice per treatment group exhibiting spontaneous 
metastases in the indicated organs. n = 15 mice/group 
 
B) The presence of spontaneous metastatic lesions was identified in spleen, lymph nodes, liver, 
lungs, kidney, and diaphragm of only mice completing the study. Graphs represent the absolute 
percentage of mice per treatment group exhibiting spontaneous metastases in the indicated organs. 
Vehicle n = 8; GMI-1271 n = 7; GMI-1359 n = 8; Gemcitabine, Gem + 1271 and Gem + 1359: n 
= 15.  
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within the lungs and kidneys compared to control mice. Surprisingly, the addition of gemcitabine 
to GMI-1359 therapy had no impact on the incidence of metastasis when compared to mice 
receiving gemcitabine only. A couple of sites (liver and lung) even demonstrated a slightly 
increased percentage of mice having metastases when treated with GMI-1359 and gemcitabine. 
Approximately half of the mice in the vehicle control, GMI-1271, and GMI-1359 
monotherapy groups succumbed to disease prior to the end of the 4-week study. Since these mice 
most likely would have had advanced disease at death, their results may have obscured any small 
effect or delay GMI-1359 may have had on S2-013 metastasis. Excluding the mice that died prior 
to treatment completion, Figure 5.11B displays the absolute incidence of metastasis in only the 
mice surviving to the end of the study. Mice treated with GMI-1359 monotherapy demonstrated 
significantly reduced metastasis to the spleen, lung, kidney, and liver as compared to vehicle control 
mice. GMI-1271 had no impact on the incidence of metastasis when only examining the mice that 
completed the study. This suggests that at the tested dose and treatment schedule, GMI-1359 may 
delay PDAC metastasis but it does not completely inhibit metastasis in vivo.  
Blockade of CXCR4 significantly alters the cellular organization of the PDAC tumor 
microenvironment. 
As several cell types comprising the PDAC tumor microenvironment express CXCR4 and 
use this receptor to facilitate intercellular communications, we evaluated how CXCR4 blockade 
alters the cellular organization of the tumor microenvironment. Staining for αSMA, a marker for 
activated fibroblasts, revealed that treatment with GMI-1359 significantly reduced the amount of 
desmoplasia within the primary tumor (Figure 5.12A). Quantification revealed that GMI-1359 
resulted in a 2.8-fold reduction in desmoplasia within the primary tumors compared to control 
tumors (Figure 5.12B). This same result was also found among the gemcitabine and GMI-1359 
combinatorial treated group: tumors treated with gemcitabine and GMI-1359 had significantly 
reduced levels of desmoplasia (2.2-fold) compared to tumors treated with gemcitabine alone. 








Figure 5.12 In vivo treatment with GMI-1359 significantly reduces tumor desmoplasia in an 
S2-013 orthotopic model of pancreatic cancer. 
 
A) Representative immunohistochemical staining of αSMA (brown) in primary tumors of mice 
orthotopically challenged with S2-013 PDAC cells and treated with either, PBS, GMI-1271, GMI-
1359, and/or gemcitabine for 4 weeks. Counterstaining was performed with hematoxylin (blue).  
Scale bars = 50 µm. 
 
B) Graphical representation of morphometric quantification of desmoplasia within primary 
orthotopic tumors following treatment. Grids (1400 pixel2/box; total of 825 grid boxes/field) were 
superimposed over 20X images of representative tumor sections. Number boxes containing 
+αSMA staining was divided by the total number of grid boxes and multiplied by 100 to calculate 
percent desmoplasia/field. Two to three representative images were collected per section from 4 
mice/treatment group. Primary tumors from mice treated with GMI-1359 had a marked reduction 




CXCL12-CXCR4 axis plays a significant role in the recruitment and/or activation of fibroblasts 
within PDAC primary tumors. 
Next, lymphatic (LVD) and blood (BVD) vessel densities within the primary tumor site 
were evaluated. Immunofluorescence staining of LYVE-1, a marker of LECs, in primary tumor 
sections revealed that neither gemcitabine nor GMI-1271 affected LVD (Figure 5.13A-B). 
However, tumors from mice treated with GMI-1359 had drastically fewer lymphatic vessels within 
the primary tumor site. Reduced LVD was also found in mice treated with both gemcitabine and 
GMI-1359. Unexpectedly, immunohistochemical staining for CD31, an endothelial marker, 
revealed no difference in BVD among any of the treatment groups (Figure 5.14A-B). These data 
suggest that the CXCL12-CXCR4 chemokine axis may be a critical player in the recruitment of 
lymphatic vessels to tumor sites through either direct or indirect mechanisms. Additionally, these 
data demonstrate that blood vessel recruitment is not necessarily regulated by the same mechanisms 
as lymphatic vessel recruitment. 
Lastly, we evaluated the presence of CD45+ leukocytes within the primary tumors of the 
various treatment groups. Immunohistochemical staining and quantification revealed no difference 
in the total number of immune cells present within the primary tumors (Figure 5.15A-B). 
Intratumoral tertiary lymphoid aggregates (TLAs) were also quantified (Figure 5.15C-D), and 
analysis revealed there was no difference in the total number of TLAs present per tumor section 
among the 6 treatment groups.  
GMI-1359 does not prolong survival of orthotopically-challenged athymic mice. 
Although GMI-1359 demonstrated only a slight delay in PDAC metastasis, it resulted in a 
significant reorganization of the PDAC tumor microenvironment. We next investigated whether 
GMI-1359 treatment and the reduction in desmoplasia may extend animal survival. We performed 
similar in vivo experiments as described earlier, but rather than stopping the study at 4 weeks, we 









Figure 5.13 Orthotopically challenged mice treated with GMI-1359 demonstrate a marked 
reduction in lymphatic vessel densities. 
 
A) Representative immunofluorescent staining of LYVE-1+ (red) lymphatic vessels within primary 
tumors of mice orthotopically challenged with S2-013 PDAC cells and treated with either, PBS, 
GMI-1271, GMI-1359, and/or gemcitabine for 4 weeks. Nuclei are stained with DAPI (blue). 
Arrows indicate LYVE-1+ lymphatic vessels. Scale bars = 50 µm. 
 
B) Quantification of the number of LYVE-1+ lymphatic vessels per field within the primary tumor. 
Five (20X magnification) representative images were collected per tumor section from 4 mice 
within each treatment group. GMI-1359-treated tumors displayed a significant reduction in 











Figure 5.14 Orthotopically challenged mice treated with GMI-1359 demonstrate no change 
in blood vessel densities. 
 
A) Representative immunohistochemical staining of CD31+ (brown) blood vessels within primary 
tumors of mice orthotopically challenged with S2-013 PDAC cells and treated with either, PBS, 
GMI-1271, or GMI-1359 for 4 weeks. Sections were counterstained with hematoxylin (blue). 
Arrows indicate CD31+ blood vessels.  Scale bars = 50 µm. 
 
B) Quantification of the number of CD31+ blood vessels per field within the primary tumor. Five 
(20X magnification) representative images were collected per tumor section from 4 mice within 
each treatment group. GMI-1359 treatment had no impact on blood vessel densities within the 




Figure 5.15 Orthotopic tumors treated with GMI-1359 demonstrate no change in immune 
infiltration compared to control mice. 
 
A) Representative immunohistochemical staining of CD45+ (brown) leukocytes within primary 
tumors of mice orthotopically challenged with S2-013 PDAC cells and treated with either, PBS, 
GMI-1271, GMI-1359, and/or gemcitabine for 4 weeks. Sections were counterstained with 
hematoxylin (blue).  Scale bars = 50 µm. 
 
B) Quantification of the number of CD45+ leukocytes per field within the primary tumors. Five 
(20X magnification) representative images were collected per tumor section from 4 mice within 
each treatment group. GMI-1359 treatment had no impact on immune cell infiltration within the 
primary tumor. Error bars = s.d. 
 
C) Representative immunohistochemical staining of CD45+ (brown) tertiary lymphoid aggregates 
(TLAs) within primary tumors of mice orthotopically challenged with S2-013 PDAC cells and 
treated with either, PBS, GMI-1271, GMI-1359, and/or gemcitabine for 4 weeks. Arrow indicates 
a TLA. Sections were counterstained with hematoxylin (blue).  Scale bars = 100 µm 
 
D) Quantification of the number of CD45+ TLAs per primary tumor section for all orthotopically-
challenged mice. GMI-1359 treatment had no impact on immune cell infiltration within the 











 nor 1359 prolonged animal survival as compared to the control group (Figure 5.16A). We also 
performed these same treatments in combination with gemcitabine since GMI-1359 reduced 
desmoplasia in the tumors and that might result in improved chemotherapy to the tumor. 
Unfortunately, combinatorial treatment of GMI-1271 or 1359 with gemcitabine also did not 
prolong survival when compared to mice receiving gemcitabine only (Figure 5.16B). Comparison 
of tumor weight and volume revealed no significant difference in tumor size among the mice treated 
with GMI-1271 or GMI-1359 compared to vehicle-treated mice (Figure 5.16C). Mice treated with 
gemcitabine had significantly smaller tumors at end stage disease compared to vehicle control- 
treated mice. Combinatorial treatment of GMI-1271 or GMI-1359 with gemcitabine did not further 
reduce tumor size.  
GMI-1359 does not prolong survival of orthotopically-challenged immune competent mice. 
CXCR4 signaling has been shown to inhibit T cell responses in pancreatic cancer (171). 
We next evaluated if GMI-1359 may prolong survival in immune competent mice where T cell 
responses may be impacted by CXCR4 blockade. For initial studies, we chose to orthotopically 
implant PDAC cells isolated from primary tumors of LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre 
(KPC) mice into syngeneic immune competent C57BL/6 mice. To determine if isolated KPC 
PDAC cells would respond to GMI-1271 or 1359 treatments, we evaluated two lines, KPC8060 
and KPC8069 for CXCR4 expression and E-selectin binding. Flow cytometry (Figure 5.17A), 
immunofluorescence staining (Figure 5.17B), and immunoblotting (Figure 5.17C) all confirmed 
that these KPC lines express CXCR4. GlycoMimetics, Inc. assessed the ability of KPC8060 and 
KPC8069 to interact with E-selectin using mouse E-selectin-Fc chimeric proteins. Employing flow 
cytometry as a readout, they demonstrated that both KPC lines had an enhanced ability to bind to 
the E-selectin chimeras as compared to IgG-Fc negative control chimeras (data not shown). 
Initial in vivo studies with the KPC 8060 mouse PDAC line were performed in a similar 







Figure 5.16 GMI-1359 does not prolong survival of orthotopically challenged immune 
incompetent mice whether administered as a monotherapy or in combination with 
chemotherapy. 
A) Kaplan-Meier survival curve of immune incompetent mice orthotopically challenged with S2-
013 PDAC cells. Following tumor establishment, mice were treated with vehicle control (PBS), 
GMI-1271, or GMI-1359 until end stage disease. Arrows specify treatment start day. Tables denote 
median survival (in days) for each treatment group. Log-rank tests indicate no survival benefit for 
mice treated with GMI-1271 or GMI-1359 compared to vehicle control. n = 15 mice/treatment 
group 
B) Kaplan-Meier survival curve of immune incompetent mice orthotopically challenged with S2-
013 PDAC cells. Following tumor establishment, mice were treated with vehicle control 
gemcitabine (Gem), Gem+1271, or Gem+1359 until end stage disease. Arrows specify treatment 
start day. Tables denote median survival (in days) for each treatment group. Gemcitabine 
significantly extended survival compared to vehicle control mice (p<0.0001). Log-rank tests 
indicated no survival benefit for mice treated with Gem+1271 or Gem+1359 compared to mice 
receiving only gemcitabine. n = 15 mice/treatment group.  
C) Graphical representation of tumor weight and tumor volume for each treatment group. *p<0.05, 
****p<0.0001; error bars = s.d. 
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Figure 5.17  
 
 
Figure 5.17 PDAC cells isolated from KPC mice express CXCR4. 
A) Flow cytometry confirming expression of CXCR4 in mouse PDAC cell lines KPC8060 and 
KPC8069. The upper histograms indicate IgG isotype control labeling and the lower histograms 
indicate CXCR4 labeling. Both KPC cell lines demonstrate CXCR4 expression. 
 
B) Immunofluorescence staining indicating CXCR4 expression in mouse PDAC cell lines 
KPC8060 and KPC8069. CXCR4 (red) is diffusely expressed across the cell surface. Cell nuclei 
are stained with DAPI (blue). Rabbit polyclonal isotype control was used as a negative control (red; 
far right images). Scale bars = 25 µm 
 
C) Western blot (50 µg protein/lane) analysis demonstrating CXCR4 expression in a panel of 





of syngeneic C57BL/6 mice. Tumors were allowed to establish for 2 weeks prior to the initiation 
of treatment. Unexpectedly, KPC 8060 cells demonstrated very rapid and aggressive growth in 
vivo. By the treatment start day, some mice were already showing signs of advanced disease such 
as cachexia or death. Neither GMI-1271 nor 1359 monotherapies prolonged animal survival 
(Figure 5.18A). Treatment with gemcitabine alone nearly doubled animal survival compared to 
control mice (p=0.0124; Figure 5.18B). Unexpectedly, combinatorial treatment with gemcitabine 
and GMI-1271 resulted in a statistical increase in animal survival compared to mice receiving 
gemcitabine only (p=0.0302). Combinatorial treatment with gemcitabine and GMI-1359 had no 
impact on animal survival when compared to the gemcitabine group. Histological staining revealed 
no significant difference in tumor morphology among the treatment groups (Figure 5.18C), and all 
mice had similarly sized primary tumors at death regardless of treatment (Figure 5.18D).   
Due to the aggressive growth of KPC8060 tumors in vivo, we repeated the survival study 
but with treatments beginning the day following orthotopic challenge. Similar to the previously 
described study, GMI-1271 and GMI-1359 monotherapies failed to prolong animal survival even 
when treatments were administered during early stage disease (Figure 5.19A). Additionally, 
combinatorial treatment of GMI-1271 or GMI-1359 with gemcitabine also failed to prolong animal 
survival compared to mice receiving gemcitabine alone (Figure 5.19B). Analysis of tumor size 
revealed that mice treated with gemcitabine either alone or in combination with GMI-1271 or 1359 
succumb to PDAC with statistically larger tumors than their control or monotherapy counterparts 
(Figure 5.19C).  
Incidence of metastasis in the KPC8060 orthotopic model with GMI-1271 or GMI-1359 
treatment. 
To determine the effects of GMI-1271 and 1359 on metastasis in immune competent mice, 
a pilot study was performed in the KPC8060 orthotopic model. KPC8060 cells were implanted into 
the pancreases of C57BL/6 mice. Treatments were initiated the day after implantation. After 2 
weeks of treatment, mice were sacrificed and tissues collected and processed for microscopic 
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Figure 5.18 GMI-1359 does not prolong survival of orthotopically challenged immune 
competent mice with aggressive late stage disease, but GMI-1271 does when used in 
combination with gemcitabine. 
A) Kaplan-Meier survival curve of immune competent mice orthotopically challenged with 
KPC8060 PDAC cells. Following tumor establishment, mice were treated with vehicle control 
(PBS), GMI-1271, or GMI-1359 until end stage disease. Arrows specify treatment start day. Tables 
denote median survival (in days) for each treatment group. Log-rank tests indicate no survival 
benefit for mice treated with GMI-1271 or GMI-1359 monotherapies compared to vehicle control. 
n = 10 mice/treatment group 
B) Kaplan-Meier survival curve of immune competent mice orthotopically challenged with 
KPC8060 PDAC cells. Following tumor establishment, mice were treated with vehicle control 
gemcitabine (Gem), Gem+1271, or Gem+1359 until end stage disease. Arrows specify treatment 
start day. Tables denote median survival (in days) for each treatment group. Gemcitabine 
significantly extended survival compared to vehicle control mice (p=0.0124). Log-rank tests 
indicate a survival benefit for mice treated with Gem+1271 compared to mice treated with 
gemcitabine only (p=0.0302). There was no survival benefit for mice treated with Gem+1359 
compared to mice receiving only gemcitabine. n = 10 mice/treatment group.  
C) Representative histological sections of KPC8060 orthotopic tumors treated with vehicle control 
(PBS), GMI-1271, or GMI-1359. Scale bars = 50 µm.  
 













Figure 5.19 GMI-1359 does not prolong survival of orthotopically challenged immune 
competent mice with early stage disease. 
A) Kaplan-Meier survival curve of immune competent mice orthotopically challenged with 
KPC8060 PDAC cells. Treatments began the day after PDAC cell implantation and continued until 
mice reach end stage disease. Tables indicate median survival (in days) for each treatment group. 
Log-rank tests indicate no survival benefit for mice treated with GMI-1271 or GMI-1359 compared 
to vehicle control. n = 10 mice/treatment group 
B) Kaplan-Meier survival curve of immune competent mice orthotopically challenged with 
KPC8060 PDAC cells Treatments began the day after PDAC cell implantation and continued until 
mice reach end stage disease. Tables indicate median survival (in days) for each treatment group. 
As expected, gemcitabine significantly extended survival compared to vehicle control mice 
(p<0.0001). Log-rank tests indicate no survival benefit for mice treated with Gem+1271 or 
Gem+1359 compared to mice receiving only gemcitabine. n = 10 mice/treatment group.  
C) Graphical representation of tumor weight and tumor volume for each treatment group. KPC8060 
orthotopically challenged mice treated with gemcitabine, Gem+1271, or Gem+1359 had 
statistically larger tumors than their non-gemcitabine treated counterparts (GMI-1271 vs Gem+ 












identification of metastases. All mice survived to the end of the 2-week treatment period; 
however, many of the mice were demonstrating signs of advanced disease such as lethargy and 
significant weight loss. Similar to previous studies, in vivo treatment with GMI-1271 or 1359 had 
no impact on tumor size (Figure 5.20A). Examination of organs for metastatic lesions revealed 
that very few organs contained metastatic lesions after 2 weeks of tumor progression in the 
KPC8060 orthotopic model even though the animals demonstrated symptoms of advanced stage 
disease (Figure 5.20B). This suggests that KPC8060 orthotopic challenge may not be a good 
model for metastatic studies. Treatment with either GMI-1271 or 1359 had no significant impact 
on the incidence of metastasis in these mice. Flow cytometry revealed that treatment with GMI-
1271 or 1359 had no impact on the immune cell subtypes (T cells, B cells, NK cells, 
macrophages, MDSCs, or dendritic cells) present within the primary tumors (Figure 5.20C).  
In vivo efficacy of GMI-1271 and 1359 in combination with chemo- and immunotherapies. 
Ozdemir et al. demonstrated that although loss of αSMA+ CAFs in PDAC tumors resulted 
in more aggressive tumors, it also made these tumors susceptible to immunotherapy (175). 
Additionally, another recent study demonstrated that ablation of FAP+ CAFs in KPC mice also 
improved checkpoint antagonist immunotherapy (171). To go along with this, they also 
demonstrated that treatment with AMD3100, a CXCR4 antagonist, also improved immunotherapy 
efficacy, resulting in significant tumor regression in KPC mice. This study examined tumor 
regression for only a short period (6 days) and did not examine the results of chronic inhibition of 
CXCR4. Therefore, we evaluated whether CXCR4 blockade with GMI-1359 could improve 
immunotherapy efficacy and impair PDAC progression over an extended period of time. For initial 
studies that could be done rapidly, we evaluated the efficacy of GMI-1359 and anti-PD-L1 
combinatorial therapy in our orthotopic model with KPC8060 PDAC cells. Seven treatment groups 
were set up with 10 mice per group: 1) Vehicle, 2) anti-PD-L1, 3) anti-PD-L1 + 1271, 4) anti-PD-
L1 + 1359, 5) anti-PD-L1 + Gem, 6) anti-PD-L1 + Gem + 1271, and 7) PD-L1 + Gem + 1359. 
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Mice were treated until end stage disease and then necropsies performed. The survival curves 
indicate that the addition of GMI-1271 or 1359 to anti-PD-L1 immunotherapy did not result in 
extended survival compared to PD-L1 treatment alone (Figure 5.21A). Treatment with both 
gemcitabine and anti-PD-L1 significantly improved survival compared to anti-PD-L1 therapy alone 
(p<0.0001; Figure 5.21B). However, the addition of GMI-1271 or GMI-1359 did not result in 
significantly improved survival compared to mice receiving the PD-L1/gemcitabine combination 





Figure 5.20 GMI-1359 does not impact metastasis of KPC cells orthotopically implanted into 
immune competent mice. 
A) Graphical representation of tumor volume and tumor weight for mice treated with vehicle 
control, GMI-1271 or GMI-1359 for 2 weeks following KPC8060 tumor implantation in C57BL/6 
mice. Treatment began the day after implantation and continued for 14 days. n = 5 mice/group; 
error bars = s.d. 
 
B) The presence of spontaneous metastatic lesions was identified in lungs, lymph nodes, spleen, 
kidney, diaphragm, and liver of all mice using histological staining of representative sections. 
Graphs represent the absolute percentage of mice per treatment group exhibiting spontaneous 
metastases in the indicated organs. n = 5 mice/group 
C) Flow cytometry analysis of immune cell subtypes within KPC8060 primary tumors of mice 













Figure 5.21 GMI-1359 does not prolong survival of orthotopically challenged immune 
competent mice whether administered in combination with chemotherapy or 
immunotherapy. 
A) Kaplan-Meier survival curve of immune competent mice orthotopically challenged with 
KPC8060 PDAC cells and treated with GMI-1271 or GMI-1359 and immunotherapy anti-PD-L1. 
Treatments began the day after PDAC cell implantation and continued until mice reach end stage 
disease. Tables denote median survival (in days) for each treatment group. Log-rank tests indicate 
no survival benefit for mice treated with a combination of PD-L1 and GMI-1271 or GMI-1359 
compared to receiving the vehicle control or anti-PD-L1 only. n = 10 mice/treatment group. 
B) Kaplan-Meier survival curve of immune competent mice orthotopically challenged with 
KPC8060 PDAC cells and treated with GMI-1271 or GMI-1359 and immunotherapy anti-PD-L1. 
Treatments began the day after PDAC cell implantation and continued until mice reach end stage 
disease. Tables denote median survival (in days) for each treatment group. Log-rank tests indicate 
no survival benefit for mice treated with a combination of PD-L1 and gemcitabine with GMI-1271 
or GMI-1359 compared to receiving PD-L1 and gemcitabine only. Addition of gemcitabine to PD-
L1 treatment significantly improved survival in this KPC orthotopic model (p<0.0001). n = 10 
mice/treatment group. 
C) Graphical representation of tumor volume and tumor weight for mice treated with GMI-1271 
or GMI-1359 in combination with chemotherapy (gemcitabine) and/or immunotherapy (anti-PD-









Our results indicate that the CXCL12-CXCR4 chemokine axis mediates interactions 
between cellular components of the PDAC microenvironment including tumor cells, fibroblasts 
and endothelial cells. Using a novel dual inhibitor of E-selectin and CXCR4, GMI-1359, we 
demonstrate that pancreatic fibroblast secretion of CXCL12 strongly induces hLEC migration and 
that when CXCR4 is blocked through GMI-1359 treatment, this migration is completely abrogated. 
Additionally, we show for the first time that CXCR4 on lymphatic endothelial is capable of 
mediating pancreatic tumor cell adhesion and transendothelial migration during invasion of a 
lymphatic endothelium. GMI-1359 treatment blocked both these processes regardless of E-selectin 
ligand expression on the PDAC cells demonstrating a role for CXCR4 during endothelia invasion.  
In vivo studies in athymic mice using an S2-013 pancreas orthotopic model demonstrated 
that blockade of CXCR4 with GMI-1359 moderately delays PDAC metastasis. However, this GMI-
1359 delay in metastasis did not result in prolonged animal survival. Animals treated with GMI-
1359 demonstrated significant reorganization of the primary tumor microenvironment: drastically 
decreased desmoplasia and reduced lymphatic vascular densities. Interestingly, blood vascular 
density and immune cell infiltration remained unaffected by GMI-1359 and CXCR4 blockade. As 
CXCR4 is a negative regulator of T cell function in PDAC tumors (171), we investigated the 
efficacy of GMI-1359 in an immune competent model by orthotopically implanting KPC8060 
PDAC cells into the pancreases of C57BL/6 mice. Unfortunately, GMI-1359 did not prolong 
animal survival even when in used in combination with chemotherapy and/or immunotherapy under 
the tested treatment schedule. GMI-1359 holds promise as a tool for investigating the role of 
CXCR4 in in vitro studies; however, more work needs to be done to improve its in vivo efficacy in 









Supplementary Figure 5.1 CXCR7 expression in lymphatic endothelial cells  
Flow cytometry showing positive CXCR7 expression in hLECs. The red histogram indicates IgG 
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Cancer metastasis into and through the lymphatic vasculature and lymph nodes occurs 
early and frequently during PDAC development and progression (5, 28, 33) and is strongly 
correlated with poor patient prognosis (34-37). This suggests the lymphatic system is likely a 
substantial contributor to PDAC progression and metastasis. Although clinicians and researchers 
recognize the importance of lymph node involvement as a determinant of PDAC prognosis and 
therapy selection, the mechanisms governing lymphatic-directed metastasis are almost completely 
unknown. Furthermore, very few studies have examined the contributions of the PDAC 
microenvironment in promoting lymphatic invasion and metastasis. In this dissertation, we set out 
to characterize how PDAC cells and pancreatic fibroblasts, major cellular components of the PDAC 
microenvironment, communicate and interact with lymphatic endothelial cells, the main cell type 
comprising lymphatic vessels. Our studies went on to explore the roles of adhesion protein E-
selectin and chemokine receptor CXCR4 in lymphatic invasion in vitro and how targeting these 
proteins impacts metastasis and survival in mice orthotopically challenged with PDAC.  
II. Characterization of PDAC Cells and Pancreatic Fibroblasts Impact Lymphatic Biology 
The pancreatic tumor microenvironment is arguably one of the most complex of any 
malignancy. Due to their prevalence in pancreatic tumor tissues, pancreatic fibroblasts exert a 
prominent influence over many cell types of the PDAC microenvironment including lymphatic 
endothelial cells, the cells responsible for facilitating PDAC dissemination to the lymph nodes. 
Through work presented in this chapter, we demonstrate for the first time the cell biology of in 
vitro interactions between pancreatic tumor cells, pancreatic fibroblasts, and lymphatic endothelial 
cells during processes that included cellular recruitment and tubulogenesis.  
We showed that several PDAC cell lines display a moderate ability to induce directional 
hLEC migration; however, pancreatic fibroblasts, through the secretion of soluble paracrine factors, 
strongly induce hLEC migration (we would later identify one of these paracrine factors to be 
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CXCL12). Additionally, pancreatic fibroblasts co-cultured with hLECs accelerated lymphatic 
tubulogenesis resulting in poorly formed tube networks. The ability of fibroblasts to facilitate hLEC 
recruitment and tubulogenesis at the cellular level was anticipated as studies have demonstrated 
that fibroblasts secrete a number of pro-lymphangiogenic factors such as VEGF-C, VEGF-D, 
VEGF-A, PDGF, EGF, and FGF (75, 78-81). Immunohistochemical studies have demonstrated that 
lymphatic vessel densities are highest in the stromal compartment of tumors and lowest in the 
intratumoral compartments, suggesting that there is an intimate association between fibroblasts and 
lymphatics within tumors (79). Specific to PDAC, Bailey et al., demonstrated that depletion of 
activated fibroblasts within the PDAC tumors of orthotopically challenged mice led to a significant 
reduction in lymphatic vessel density and metastasis to lymph nodes (163).  This groups findings 
were corroborated by our in vivo studies demonstrating that elimination of αSMA+ fibroblasts from 
PDAC tumors (through CXCR4 blockaded) correlated with significantly reduced lymphatic vessel 
density within pancreatic tumors. 
Our studies suggest that pancreatic fibroblasts are key to the recruitment and formation of 
new of lymphatic vessels within PDAC tumors. Other non-tumor cell types of the tumor 
microenvironment have also been implicated as contributors of lymphatic recruitment and 
lymphangiogenesis within tumors, such as tumor associated macrophages (202-205, 232), mast 
cells (292-294), and dendritic cells (83, 295). The studies reported here as well as others support 
the hypothesis that malignancies exploit the pro-lymphangiogenic mechanisms of tumor 
microenvironment cells to augment tumor invasion of lymphatic vessels and subsequent 
dissemination to lymph nodes, a common site of metastasis for many tumors including PDAC. 
Further research is needed to define the specific molecules that mediate the influence of tumor-
associated fibroblasts on lymphatic biology and function. 
 Our studies also demonstrate that paracrine factors secreted from several PDAC lines 
induce moderate hLEC migration, albeit not as strongly as pancreatic fibroblasts. Furthermore, 
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these same PDAC lines (S2-013, Colo357) also accelerated tubulogenesis in co-culture with 
hLECs. This accelerated tubulogenesis resulted in poorly formed lymphatic networks replete 
broken tubes and dissociated LECs. These poorly structured lymphatic networks support previous 
studies that described intratumoral lymphatic vessels from both clinical and in vivo samples as 
being disorganized, collapsed, and non-functional (118, 119, 296) and suggest that tumor cells are 
a significant contributor to malformed lymphatics within overall tumor structure. Studies have 
demonstrated that PDAC cells secrete a number of pro-lymphangiogenic factors and therefore are 
capable of influencing tumor-associated lymphangiogenesis (107, 116, 297, 298). In support of this 
conclusion, numerous studies have correlated the expression of pro-lymphangiogenic within 
primary tumors (both tumor-secreted and stromal-secreted) with LVD and lymph node metastasis 
including in the setting of PDAC (107, 116, 137, 297-300). However, many previous studies relied 
on immunohistochemical staining to correlate the expression of pro-lymphangiogenic factors with 
LVD and lymph node metastasis rather than studies showing direct effects by specific cell types, 
which are demonstrated by the results presented in this manuscript. Further work is needed to 
elucidate the specific paracrine signaling mechanism induced by PDAC cells use to promote tumor-
associated lymphangiogenesis.  
 We also for the first time report on PDAC and pancreatic fibroblast invasion of a simulated 
lymphatic endothelium. Chemotactic-directed TEM assays demonstrated that both PDAC cells and 
pancreatic fibroblasts are capable of crossing a lymphatic endothelial barrier albeit at differing 
rates. Steady state images of invasion revealed that PDAC cells primarily invade a lymphatic 
monolayer at tricellular junctions between LECs suggesting that PDAC cells mainly undergo 
paracellular routes during endothelial invasion as opposed to transcellular invasion. These results 
coincide with previous studies demonstrating that PDAC cells also invade vascular endothelia at 
tricellular junctions (301). Additionally, the preference of PDAC cells to invade tricellular 
junctions indicates invasion is not a random process in which PDAC cells invade the most proximal 
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lymphatic location. Rather PDAC cells showed preference for specific sites to attach to and invade 
the lymphatic vasculature.  It was also notable that tumor cells preferred a pattern of collective 
migration during invasion, suggesting that the formation of invasive sites produces a local 
chemotactic environment that recruits other cells to the invading cell mass.  Definition of the 
molecular factors that produce this effect requires further investigation, but is likely important 
given emerging reports in the literature of the potential importance of collective migration of cells 
during invasion and metastasis (302, 303). Only a handful of studies have examined the 
mechanisms regulating transmigration at tricellular junctions, and these studies evaluated vascular 
endothelial junctions. It has been proposed that tricellular junctions express a discontinuous pattern 
of adherens junctions that enables greater cell TEM (304, 305). Another study demonstrated that 
vascular endothelial tricellular junctions have enriched expression of adhesion proteins (306). 
Further investigation will be needed to determine if these same mechanisms enable PDAC invasion 
of lymphatic tricellular junctions.  
 Pancreatic fibroblasts also interacted with hLECs at tricellular junctions. However, unlike 
PDAC cells, pancreatic fibroblasts demonstrated the ability to remain atop the hLEC monolayer 
without invading, as seen in steady state images and live cell imaging. This implies that the 
fibroblasts seek to establish a stable interaction with and along the LECs, in contrast to tumor cells.  
TEM assays demonstrated that fibroblasts are capable of invading lymphatic endothelia; however, 
the capacity of these to form higher order structures (e.g. tubes surrounded by fibroblasts) were not 
addressed in the studies presented here. Although tumor-associated fibroblasts have been shown to 
accompany tumor cells to distant metastatic sites (161, 307), our results raise the possibility that 
pancreatic fibroblasts’ interactions with tumor cells facilitate fibroblast invasion of endothelial 
layers during dissemination, a process that may also contribute to the disorganization of lymphatics 
that is observed in tumors.  
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Few studies have evaluated the paracrine mechanisms by which pancreatic tumor cells 
communicate and interact with lymphatic endothelial cells, and even fewer studies have evaluated 
the paracrine mechanisms by which pancreatic fibroblasts influence the biology of LEC and 
lymphatics. The work presented here lays the groundwork for understanding the biological impact 
of interactions between pancreatic tumor cells, fibroblasts lymphatic endothelial cells. A better 
understanding of the processes of lymphatic invasion and lymph node metastasis in PDAC will 
significantly contribute to our overall understanding of this deadly disease and provide insights for 
the development of novel efficacious therapies for pancreatic cancer.  
III. Blockade of E-selectin and Implications for PDAC Therapy 
Adhesion protein E-selectin has been shown to regulate metastasis in a variety of cancers 
(146, 252, 257, 260). However, its direct role in the metastasis of pancreatic cancer in vivo has not 
been fully evaluated. Using a novel glycomimetic small molecule antagonist of E-selectin, we 
demonstrated that E-selectin influences PDAC dissemination via the vasculature systems, and that 
blocking its ligand binding function decreased PDAC metastasis. Although it is known that E-
selectin plays a role in vascular invasion of tumor cells, we demonstrated for the first time a role 
for E-selectin in facilitating tumor cell invasion of the lymph nodes via the lymphatic vasculature. 
The normal role of E-selectin is to initiate the tethering of circulating leukocytes to vascular 
endothelia during extravasation (254, 255, 308). Previous studies demonstrated that tumor cells 
expressing the E-selectin ligands sLeA/X exploit the function of E-selectin for dissemination (146, 
252, 257, 260, 309). However, very few studies have examined the functional role of E-selectin in 
lymphatics especially in regards to tumor invasion. It has been demonstrated that activated LECs 
upregulate E-selectin expression (146, 310) which enables leukocyte TEM and trafficking to the 
lymph nodes (131, 256). Using GMI-1271, we demonstrated for the first time that blockade of E-
selectin significantly impairs PDAC adhesion to a simulated lymphatic endothelium and 
subsequent transendothelial invasion. In vivo, this blockade led to a significant decrease in lymph 
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node metastasis. These results are consistent with studies showing PDAC cells and other tumor 
cells use E-selectin to facilitate invasion of blood vessels for dissemination (311-313).  
Corresponding to our in vitro results, blockade of E-selectin in vivo reduced PDAC 
metastasis to lymph nodes in an orthotopic model of pancreatic cancer. No prior reported in vivo 
studies have examined tumor metastasis specifically to the lymph nodes during E-selectin blockade. 
We demonstrated that this reduction in lymph node metastasis by E-selectin blockade was not due 
to inhibition of tumor growth nor decreased LVD at the primary tumor site. In patient samples from 
several cancer types, it has been noted that there is a potential correlation between high expression 
of E-selectin/E-selectin ligands and presence of lymph node metastases (314-319). In the setting of 
PDAC, only one study has examined this relationship, and they found no correlation between the 
expression of E-selectin/E-selectin ligands and lymph node metastases (320). Thus, further 
investigation is warranted to determine if there is a correlation between the expression of E-
selectin/E-selectin ligands and lymph node metastasis in clinical samples of pancreatic cancer and 
whether E-selectin a major contributor to lymph node metastasis. 
Our in vivo results demonstrated that E-selectin blockade by GMI-1271 resulted in 
decreased metastasis to the lymph nodes and other organs: liver, lungs, diaphragm, and kidney. 
Metastasis to these sites would be dependent on PDAC cell trafficking through the vasculature 
systems and necessitate interactions between E-selectin on endothelial cells and E-selectin ligands 
on tumor cells. Confirming the posited role of E-selectin in vasculature-dependent metastasis, 
previous studies demonstrated a strong correlation between high expression of E-selectin/E-selectin 
ligands and increased metastatic burden and poor prognosis in patient tumor samples (321-323). 
Additionally, prior studies have demonstrated that metastasis specifically to the liver and lungs is 
often regulated by E-selectin, suggesting that E-selectin may influence organ selectivity during 
tumor dissemination (324-327). However, other studies presented contrasting results that found E-
selectin dispensable for tumor homing to the liver and lungs (328).  Our results support the 
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hypothesis that E-selectin regulates organ selectivity during PDAC dissemination, as PDAC 
metastasis to the liver and lung were the sites most highly impacted by E-selectin blockade. It is 
unknown but possible that E-selectin influences tumor selectivity to other sites (i.e. lymph nodes, 
diaphragm, kidneys) as well.  
Not all PDAC cell lines examined in our study used E-selectin-dependent mechanisms for 
invasion of lymphatic endothelia in vitro and these were predictably resistant to GMI-1271 
treatment. Additionally, E-selectin blockade did not completely prevent PDAC dissemination in 
vivo. These suggest that additional mechanisms contribute to PDAC invasion of endothelial 
barriers. Other proteins have been implicated in tumor invasion of endothelia including ICAM-1, 
VCAM-1, platelet endothelial cell adhesion molecule-1, chemokine receptors CXCR4 and 
CXCR7, integrins, and others (reviewed in (260)). Additionally, immune cells can act as an 
intermediate linker cell type between tumor cells and endothelial cells to facilitate endothelial 
invasion (329, 330). This multicellular process could render non-E-selectin ligand-expressing 
tumors susceptible to E-selectin blockade in vivo, as immune cells are known to use E-selectin for 
intra- and extravasation across endothelia. Colo357 cells, which were shown to use E-selectin-
independent mechanisms for TEM, were capable of upregulating E-selectin expression in hLECs. 
Investigation as to whether PDAC cells upregulate E-selectin to promote leukocyte-assisted TEM 
or for an alternative mechanism, would provide additional insight into the mechanisms driving 
tumor cell transendothelial invasion. It was interesting that PDAC cell lines using E-selectin-
independent mechanisms directly for TEM had reduced capacities to invade a lymphatic 
endothelial barrier compared to E-selectin ligand-expressing PDAC cell lines. This suggests that 
direct E-selectin-independent mechanisms of invasion may be less efficient compared to E-selectin- 
dependent mechanisms. More work needs to be done to fully elucidate the mechanisms that 
underlie the process of lymphatic invasion by tumor cells.  
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GMI-1271 was particularly effective at reducing metastasis and extending survival when 
used in combination with chemotherapy. The improved efficacy of combination therapy with 
gemcitabine is of biological interest and clinical importance. As an anti-proliferative agent, 
gemcitabine significantly reduces the number of potentially metastatic PDAC cells within the 
tumor. Additional treatment with GMI-1271 effectively inhibited the dissemination of the 
remaining metastatic-capable tumor cells. Alternatively, E-selectin has been shown to promote 
chemoresistance by facilitating tumor interactions with a protective vascular niche (331). 
Following GMI-1271 administration, it is possible that PDAC cells were forced to exit the vascular 
niche and enter blood and lymphatic vessels where gemcitabine effectively destroyed more of these 
transiting tumor cells.  It is also possible that inhibition of E-selecting ligand binding disrupted 
other cell-cell interactions in the tumor microenvironment which thereby improved the delivery of 
gemcitabine.  As E-selectin has other biological functions, it is possible that unknown mechanisms 
contributed to the enhanced efficacy of GMI-1271 and gemcitabine when administered together. 
E-selectin is crucial for leukocyte trafficking to inflamed tissues including tumor sites. 
Immune cells within tumor microenvironments are often significant contributors to tumor cell 
killing, survival, proliferation, immune suppression, and metastasis (180, 212, 332). Although our 
results showed no change in the total numbers of immune cells present within the primary tumor 
following GMI-1271 treatment, it is possible that GMI-1271 modified the composition of specific 
immune cell subtypes within the PDAC microenvironment and that this contributed to decreased 
metastasis. Concordant with this possibility, we showed that GMI-1271 (in combination 
chemotherapy) improved survival of immunocompetent mice (but not immune compromised mice) 
following orthotopic challenge. This suggests a link between E-selectin and immune cell-dependent 
mechanisms that modulate tumor progression. Further analysis is warranted to elucidate the effects 
of E-selectin blockade on immune cell recruitment to tumors and how GMI-1271 may work in 
combination with immunotherapies. 
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Our studies demonstrate for the first time the effectiveness of using a glycomimetic small 
molecule antagonist of E-selectin, GMI-1271, in the setting of solid tumors. Until now, GMI-1271 
has mainly been evaluated in hematological malignancies specifically acute myeloid leukemia 
(AML) (333, 334). These AML studies demonstrated that GMI-1271 enhanced leukemic stem cell 
mobilization, resulting in improved efficacy of chemotherapy and prolonged animal survival in 
vivo. Similar to our findings, successful treatment of AML in vivo was dependent on combinatorial 
treatment with an anti-tumor therapy and GMI-1271. Currently, this E-selectin antagonist is in 
phase 1/2 clinical trials for AML (NCT02306291). Additional studies should evaluate the 
effectiveness of GMI-1271 in other solid tumors and as well as its ability to inhibit metastasis in 
early diagnosed tumors. 
In the clinic, PDAC patients are most often diagnosed with advanced metastatic disease. 
However, approximately 15-20% of patients are diagnosed with localized resectable disease (1, 6). 
For these patients, GMI-1271 may be an effective therapy for slowing or reducing PDAC 
dissemination prior to surgical resection. Moreover, unclean resection margins pose a substantial 
risk for disease recurrence (15). GMI-1271 treatment along with chemotherapy may prevent this 
recurrence and improve patient survival.   
In summary, we demonstrate E-selectin is important regulator of lymphatic-directed 
metastasis of pancreatic cancer. The novel glycomimetic E-selectin antagonist GMI-1271 impairs 
PDAC interactions with endothelial cells resulting in decreased tumor dissemination. GMI-1271 is 
a promising agent for inhibiting metastasis in solid tumors. Further work needs to be done to 
determine the effectiveness of GMI-1271 in other solid tumors, its effects on immunity, and its 
ability to improve chemotherapy efficacy.  
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IV. Dual Blockade of CXCR4 and E-selectin and Implications for PDAC Therapy 
i. CXCR4 contributes to invasion of a lymphatic endothelium by PDAC cells 
Very few studies have investigated the role of the CXCL12-CXCR4 chemokine axis in 
lymphatic endothelial cells. The studies that have examined this axis demonstrated it contributes to 
lymphatic migration and lymphangiogenesis (285, 335). We confirmed the finding that hLEC 
migration is stimulated by recombinant CXCL12 as well as CXCL12 secreted from pancreatic 
fibroblasts. Blockade of CXCR4 on hLECs through treatment with GMI-1359 completely 
abrogated CXCL12-induce migration. As GMI-1359 is a dual inhibitor of both CXCR4 and E-
selectin, we demonstrated that the effects were due to CXCR4 antagonism, as E-selectin only 
antagonism did not abrogate CXCL12-induced hLEC migration.   
The CXCL12-CXCR4 axis has also been implicated in facilitating vascular extravasation 
by immune cells and vascular invasion by tumor cells including those of PDAC (277, 286-288, 
336-339). However, a role for CXCR4 in lymphatic invasion has not been fully elucidated. Our in 
vitro results demonstrated that the CXCL12-CXCR4 chemokine axis supports PDAC adhesion to 
and TEM across a lymphatic endothelium and that blockade of CXCR4 significantly impairs these 
processes. Since GMI-1359 antagonizes both CXCR4 and E-selectin, a protein we previously 
showed regulated PDAC TEM, we evaluated the effects of GMI-1359 on two types of PDAC cells: 
ones that express E-selectin ligands (S2-013) and ones that do not express E-selectin ligands 
(Colo357). Not only did GMI-1359 inhibit the TEM of E-selectin ligand-expressing PDAC cells 
(S2-013) but also inhibited the TEM of PDAC cells that do not express E-selectin ligands 
(Colo357). These results were also confirmed using neutralizing antibody specific to CXCR4. Our 
findings are consistent with one other study that demonstrated the CXCL12-CXCR4 axis 
contributes to the TEM of DCs across an inflamed lymphatic endothelium (276). Altogether, our 
results demonstrated that CXCR4 plays a role in the invasion of lymphatic endothelia by PDAC 
cells and by blocking its function we can inhibit PDAC TEM. 
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To further dissect the role of CXCL12-CXCR4 in lymphatic invasion, we pretreated only 
the hLEC monolayer with GMI-1359 and demonstrated that blocking hLEC CXCR4 significantly 
impaired PDAC TEM. Furthermore, pretreatment of the hLEC monolayer with CXCL12 
significantly enhanced the ability of hLECs to facilitate PDAC TEM. Additional pretreatment with 
GMI-1359 returned CXCL12-enhanced TEM to below unstimulated levels. This is the first study 
demonstrating that endothelial expression of CXCR4 plays a role in enabling PDAC TEM. 
Previous studies have focused on the role of CXCR4 in the invading cell type (i.e. immune cells or 
tumor cells) enabling TEM (277, 286-288, 336, 340). If CXCR4 on hLECs regulates PDAC TEM, 
then PDAC cells would need to express the ligand, CXCL12. Indeed, ELISA of whole cell lysates 
indicated PDAC cells express CXCL12; however, it is not constitutively secreted from PDAC cells 
as we did not detect it in PDAC conditioned media. Non-secreted, immobilized CXCL12 has been 
shown to contribute to immune cell TEM across a vascular endothelium (340). To solidify our 
findings, cell-specific knockdown of CXCR4 in hLECs, PDAC cells, or both cell types is needed 
to accurately determine which CXCR4-expressing cell type is regulating PDAC invasion. It would 
not be surprising if CXCR4 in both the endothelial cells and the PDAC cells was contributing to 
lymphatic invasion. Similar studies should also be performed using CXCL12 knockdown 
strategies. It would also be interesting to determine if the other receptor for CXCL12, CXCR7, also 
contributes to lymphatic invasion of PDAC cells. CXCR7 expression in pancreatic tumors 
correlates with lymph node metastasis (341) and has been shown to accelerate tumor invasion in 
vivo (342). 
Unexpectedly, our in vitro results also revealed that E-selectin antagonism (using GMI-
1271) returned CXCL12-enhanced hLEC facilitation of PDAC TEM to control levels. This 
suggests that CXCL12 may upregulate E-selectin expression in lymphatic endothelial cells. A 
previous set of studies did demonstrate that CXCL12 could induce E-selectin expression in vascular 
endothelial cells to facilitate diabetic wound healing (343). More studies are needed to verify the 
152 
 
ability of CXCL12 to induce E-selectin expression in hLECs and what mechanisms regulate this 
induction.  
ii. In vivo blockade of CXCR4 and E-selectin in PDAC challenged mice 
Based on our in vitro results, we decided to evaluate whether dual inhibition of CXCR4 
and E-selectin reduced PDAC metastasis and improved overall survival. Similar to our GMI-1271 
studies, we performed our in vivo studies with athymic mice that were orthotopically challenged 
with the human PDAC line S2-013. Our findings demonstrated GMI-1359 monotherapy decreased 
metastatic incidence within the spleen, liver, lungs, and kidneys compared to treatment with the 
vehicle control. However, this was only apparent when we excluded the mice that did not complete 
the 4-week treatment regimen. When used in combination with gemcitabine, GMI-1359 failed to 
reduce PDAC metastasis when compared to mice treated with gemcitabine alone. Consistent with 
our previous in vivo studies, GMI-1271 in combination with gemcitabine was the most effective at 
reducing PDAC metastasis. Although the reduction in metastasis with GMI-1359 was not 
substantial, it is consistent with studies showing CXCR4 expression in pancreatic cancer patient 
samples correlates with metastatic burden (137, 140).  
Due to its efficacy in reducing metastatic incidence, we anticipated that GMI-1359 would 
prolong animal survival. However, GMI-1359 failed to improve overall animal survival when used 
as either a single agent or in combination with gemcitabine in our immunocompromised orthotopic 
model. Obfuscating our results is the gemcitabine treatment. We suspect that prolonged treatment 
with gemcitabine contributed to animal death as all mice treated with gemcitabine were severely 
cachexic at end stage and died with much smaller tumors compared to mice not treated with 
gemcitabine. For future studies requiring extended treatment, we recommend treating athymic mice 
with a lower dose of gemcitabine.  
Being a chemokine receptor, CXCR4 regulates the recruitment of various cell types to the 
PDAC microenvironment. We, therefore, evaluated the effects GMI-1359 had on the cellular 
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composition of the PDAC microenvironment. Unexpectedly, immunohistochemical staining 
revealed that GMI-1359 treatment significantly decreased the desmoplastic reaction within primary 
tumors as determined by loss of activated (αSMA+) fibroblasts. This was the result of blocking 
CXCR4 as blockade of E-selectin alone had no impact on activated fibroblast presence. In the past, 
researchers hypothesized that reducing the desmoplastic barrier would result in improved drug 
perfusion into the tumor (165).  However, more recent studies suggest that pancreatic fibroblasts 
may constrain tumor growth and progression as depletion of tumoral fibroblasts led to the 
development of both highly aggressive and highly proliferative undifferentiated tumors (175-177). 
This may explain why GMI-1359 did not prolong overall animal survival as we may have 
inadvertently promoted tumor growth and aggressiveness by eliminating fibroblasts from the 
PDAC microenvironment.  
For future studies, we would like to determine the mechanism by which blockade of 
CXCR4 decreases the presence of αSMA+ fibroblasts in PDAC tumors. The most obvious 
hypothesis would be that blocking the CXCL12 chemokine gradient impairs recruitment of 
fibroblasts to the tumor. However, an alternative hypothesis would be that CXCR4 regulates the 
activation status of fibroblasts and that antagonism of this receptors reverts fibroblasts to a 
quiescent state (αSMA-). Currently, there are no specific markers for identifying quiescent 
fibroblasts in tumor sections. Most studies rely upon in vitro stimulation to evaluate the ability of 
protein or drug to induce or inhibit fibroblast activation (167). A third hypothesis pertains to the 
regulation of Shh. This morphogen is one of the major drivers of desmoplasia in pancreatic cancer 
(166). PDAC-secreted Shh promotes desmoplasia through paracrine signaling in pancreatic 
fibroblasts. It was recently uncovered that Shh expression in PDAC cells is regulated by the 
CXCL12-CXCR4 axis (344). GMI-1359 may indirectly suppresses desmoplasia by inhibiting 
PDAC cell secretion of Shh thus preventing its paracrine signaling in pancreatic fibroblasts which 
is necessary to drive desmoplasia.  
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 We also noted a reduction in LVD within the primary tumors of mice treated with GMI-
1359. There are a handful of explanations for this finding. CXCL12 is a known lymphangiogenic 
factor (285, 335) and blockade of its receptor, CXCR4, would inhibit lymphangiogenesis and 
reduce tumor LVDs. In agreement with this hypothesis, we demonstrated that CXCL12 is a strong 
chemoattractant for lymphatic endothelial cells and blockade of CXCR4 potentially impairs 
recruitment of lymphatic vessels to the primary tumor. Alternatively, CXCL12 is a chemoattractant 
for many cell types within the PDAC microenvironment. Blockade of CXCR4 may have impaired 
the recruitment of cells known to secrete pro-lymphangiogenic factors such as CAFs and TAMs, 
and, this, in turn, reduced lymphatic vessel numbers within the tumor. In line with this, GMI-1359 
drastically reduced the number of αSMA+ fibroblasts within primary tumors, and without these 
fibroblasts to induce lymphatic migration and stimulate lymphangiogenesis, LVD remained low in 
GMI-1359-treated tumors. Further research is needed to determine the mechanisms by which GMI-
1359 reduces lymphatic vessel densities, although one can predict it is likely a combination of 
direct and indirect mechanisms.  
GMI-1359 significantly reduced LVD within primary tumor sites, but it did not suppress 
PDAC metastasis to the lymph nodes. This finding is likely due to disruption of the PDAC 
microenvironment including the reduction in desmoplasia following GMI-1359 treatment. 
Although we did not see a change in the total number of immune infiltrates, it is likely GMI-1359 
altered the immune cell composition of the tumor as well. By disrupting the “normal” PDAC 
microenvironment, it is possible that tumors acquired a more aggressive phenotype enabling 
successful metastasis the lymph nodes despite decreased lymphatic densities. The mechanisms 
contributing to tumor aggressiveness following GMI-1359 treatment and stromal disruption are 
likely to be complex and dependent upon the functions of multiple cell types.  
 Although GMI-1359 significantly reduced the presence of lymphatic vessels within the 
primary tumor, we saw no change in blood vessel densities. This is surprising considering the 
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overlap of mechanisms that contribute to both lymphangiogenesis and angiogenesis. The 
discrepancy in lymphatic vessel and blood vessel densities suggests that the mechanisms promoting 
lymphatic vessel growth within PDAC tumors are not necessarily the same as those promoting 
blood vessel growth. This idea of differential mechanisms regulating lymphatic and vascular 
growth is supported by studies examining lymphangiogenesis within tumor draining lymph nodes. 
These lymph nodes undergo massive lymphangiogenic remodeling prior to the arrival of tumor 
cells but the blood vasculature remains unchanged (95, 345-347). Adding to the complexity is that 
these lymph nodes contain an abundance of both pro-lymphangiogenic and pro-angiogenic factors, 
yet only lymphangiogenesis occurs. More work needs to be done to determine the differential 
factors regulating lymphatic and vascular growth within PDAC tumors.  
The CXCL12-CXCR4 axis has been shown to be a negative regulator of anti-tumor T cell 
responses within PDAC tumors (171). Therefore, we investigated CXCR4 blockade in an immune 
competent mouse model. To accelerate our studies, we orthotopically challenged C57BL/6 mice 
with a KPC cell line (KPC8060) derived by our laboratory.  In our first set of studies, tumors were 
allowed to establish for two weeks after which treatments were initiated. Unexpectedly, KPC cells 
display a very aggressive phenotype following orthotopic implantation: just two weeks after 
implantation, mice began to show signs of end stage disease (lethargy, extreme cachexia, and/or 
significant accumulation of ascites). We consulted with Dr. David Tuveson whose laboratory 
developed the KPC mouse and they have observed a similar aggressiveness when orthotopically 
implanting KPC cell lines into syngeneic mice. Despite demonstrating late stage disease, we 
proceeded with the survival study. Unfortunately, GMI-1359 treatment failed to improve the 
survival of mice with advanced disease. These studies were repeated except treatment regimens 
began the day following KPC cell implantation. Even in animals with early stage disease, GMI-
1359 failed to prolong overall animal survival. In future studies, we would like to profile the tumor 
microenvironments of GMI-1359-treated immune competent mice just as we did with the 
156 
 
immunocompromised mice. In these mice, we will also evaluate changes to the immune cell 
compartment. We expect that the tumors from GMI-1359-treated immunocompetent mice will 
similarly display a significant reduction in desmoplasia and LVD. We also expect that GMI-1359 
will significantly alter the immune cell subtypes found within the tumor.  
Ozdemir et al. demonstrated that depleting the fibroblasts from the PDAC tumor 
microenvironment makes these tumors susceptible to immunotherapy (175). Additionally, Feig et 
al. demonstrated that CXCR4 blockade (with AMD3100) significantly improved immunotherapy 
efficacy resulting in tumor regression in KPC mice (171). We evaluated if blockade of CXCR4 and 
the ensuing depletion of pancreatic fibroblasts improves the efficacy of anti-PD-L1 immunotherapy 
in KPC-challenged C57BL/6 mice. Unfortunately, in our study GMI-1359 did not improve survival 
when used in combination with gemcitabine and/or anti-PD-L1 immunotherapy. Feig et al. 
observed approximately a 15% reduction in tumor size after only 6 days of treatment with CXCR4 
inhibitor AMD3100 and anti-PD-L1 antibodies. Although not investigated in their study, one would 
suspect that tumor regression would translate to improved overall survival. Contrarily, our studies 
demonstrated that chronic blockade of CXCR4 failed to improve anti-PD-L1 efficacy and did not 
prolong overall animal survival.  
iii. Ongoing future studies: Combinatorial treatment of KPC mice with GMI-1359 and anti-
PD-L1 immunotherapy 
Our results demonstrated that CXCR4 blockade improved neither the efficacy of 
immunotherapy nor overall survival in orthotopically challenged mice. However, orthotopic tumor 
models often do not recapitulate the human disease nor do these tumors respond appropriately to 
therapies. Therefore, we are currently evaluating GMI-1359 efficacy in combination with 
immunotherapy for the treatment of pancreatic cancer in KPC mice. We have designed a drug 
enrollment study that uses ultrasound imaging to identify PDAC tumors and track their growth in 
vivo. Pancreatic tumors are typically identifiable by ultrasound at 4 mm in diameter. Enrollment 
eligibility is determined by the mean of the shortest and longest tumor diameters of the largest 
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tumor cross section being 4 to 7 mm in diameter. Upon attainment of the enrollment eligibility, 
mice are randomized into 4 treatment groups: 1) Vehicle (PBS) control; 2) 40 mg/kg GMI-1359 
daily; 3) 160 µg/mouse anti-PD-L1 antibody; 4) combination GMI-1359 and anti-PD-L1. Tumors 
growth is monitored weekly by ultrasound imaging. Mice are treated until they display signs of end 
stage disease.  
Although this investigation is still ongoing, we have some preliminary data. Figure 6.1A 
illustrates the relative change in tumor size across the various treatment groups. For effective 
evaluation of tumor growth, a minimum of three images are needed: an image at the time of 
enrollment; an image following 1 week of treatment; and an image following 2 weeks of treatment. 
At this point in the trial, we see no significant effect of GMI-1359 inhibiting KPC tumor growth. 
The same is true for combinatorial treatment with GMI-1359 and anti-PD-L1. Treatment with PD-
L1 alone appears to be slightly increasing PDAC tumor growth. By plotting the tumor growth for 
each enrolled mouse, we can see that individual mice respond to therapy relatively similarly within 
a treatment group (Figure 6.1B). Plotting the relative change in tumor size as a waterfall plot, we 
can evaluate the relative change in tumor size for individual mice after 2, 3, or 4 weeks of treatment 
(Figure 6.1C). Mice treated with GMI-1359 alone or in combination with anti-PD-L1 demonstrate 
similar tumor growth rates as control mice, while anti-PD-L1-treated mice demonstrate slightly 
elevated tumor growth rates. With only 2-4 total mice enrolled per group, significantly more mice 
will need to be enrolled before any accurate conclusions can be made regarding the effects of GMI-
1359 and immunotherapy in KPC mice. 
In this trial, we are also evaluating post-enrollment animal survival. Based on median 
survival time, GMI-1359 may be prolonging animal survival compared to vehicle-treated mice 
(Figure 6.1D). Mice treated with anti-PD-L1 alone demonstrate the longest post-enrollment 
survival time while mice treated with both GMI-1359 and anti-PD-L1 demonstrate a slightly shorter 
survival time. Table 6.1 indicates the post-enrollment survival time for each individual mouse and  
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Figure 6.1 Tumor growth and post-enrollment survival time for KPC mice treated with 
GMI-1359 and/or immunotherapy.  
A) Line graph showing the relative average change in KPC tumor size (diameter) following 
enrollment into the GMI-1359 drug study. Upon attainment of enrollment criteria, mice are 
randomized into four treatment groups: 1) vehicle control (black line), 2) 40 mg/kg GMI-1359 
daily (blue line), 3) 160 μg/mouse anti-PD-L1 every 4 days (green line), or 4) GMI-1359 + PD-
L1 (red line). Tumors are image every week by ultrasound to follow tumor growth. Initial tumor 
size was normalized to 1 to account for starting size variations. Error bars = s.d. 
B) Line graph demonstrating change in tumor growth for each KPC mouse. Tumors are image 
every week by ultrasound to follow tumor growth. Initial tumor size was normalized to 1 to 
account for starting size variations. Asterisks indicates mice is still enrolled in the trial.  
Error bars = s.d. 
C) Waterfall plots demonstrating final tumor volume changes after 2 weeks of treatment (left) or 
3 weeks of treatment (right).  Each bar represents a single mouse.  
D) Kaplan-Meier survival curve demonstrating survival post-enrollment (days) for KPC mice 









Table 6.1 KPC Drug Enrollment Mouse Identification List 
 
Table 6.1 lists all the KPC mice that have been enrolled in the drug study along with the 
treatment group, total number of survival days post-enrollment, and the current status of the 
mouse. Asterisks indicates mice currently enrolled in the trial.   
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illustrates the variability in survival times within each treatment group. Again, too few animals 
have been enrolled in the study, and, therefore, no accurate conclusions can be made at this time.  
V. Targeting the Lymphatic System as Treatment for PDAC 
i. Potential lymphatic-targeted therapies 
“Due to advanced stage at diagnosis and its complex microenvironmental organization, 
pancreatic ductal adenocarcinoma has proven to be very difficult to treat. Surgical removal of the 
tumor is the most effective option, but only approximately 15% of cases are considered resectable 
(348, 349). Of those cases in which resection is an option, incomplete removal of microscopic 
disease (R1 residual margin status) only slightly improves patient survival over those cases 
presenting with unresectable metastatic disease (350, 351). Non-surgical options for pancreatic 
cancer include radiation, chemotherapy, or a combination of both. Some approved chemotherapies 
for the treatment of pancreatic cancer are the use of FOLFIRINOX, gemcitabine, albumin-bound 
paclitaxel, cisplatin, and oxaliplatin (as well as others) (352, 353). However, these drugs have had 
limited success in prolonging patient survival. Development of targeted therapies that specialize in 
blocking crucial molecular pathways of the pancreatic tumor and its microenvironment is becoming 
an increasingly attractive therapeutic option.”  
“Anti-angiogenic therapies were originally developed to starve tumors of important 
nutrients and oxygen and to reduce the number of potential routes for dissemination. However, 
clinical trials demonstrated that, when used alone, anti-angiogenic therapy was not sufficient to 
improve patient survival. Unexpectedly though, the results indicated that anti-angiogenic therapy 
significantly improved survival of patients with solid tumors when used in combination with  
conventional chemotherapies (354-356). These findings led to the evolution of the current vascular 
normalization theory: the use of anti-angiogenic therapy to block aberrant tumor angiogenesis and 
alleviate vessel dysfunction (357). By restoring the balance between pro- and anti-angiogenic 
factors, anti-angiogenic therapies improved vessel organization, stabilized cell-to-cell junctions, 
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increased pericyte coverage, and, consequently, reduced fluid leakage. All these factors, in turn, 
relieved blood flow irregularities resulting in improved delivery of chemotherapy to all parts of the 
tumor (358). Unfortunately, in the setting of pancreatic cancer, anti-angiogenic therapies have had 
either no effect or only transient effects on improving patient survival even when used in 
combination with standard chemotherapies (359-363). PDAC tumors are unusually hypovascular 
and desmoplastic negating the ability of even normalized vessels to deliver therapy (364). The 
failure of anti-angiogenic therapy in PDAC may also be the result of tumor cells circumventing the 
VEGF-A/VEGFR-1 blockade through autocrine or paracrine secretion of alternative angiogenic 
factors, such as the prototypical lymphangiogenic factors which have overlapping angiogenic 
functions (363, 365-367).”  
“Targeting the tumor lymphatic vasculature as a treatment for cancer is beginning to gain 
interest among both basic and clinical research groups with the primary focus on anti-
lymphangiogenic therapies. Lymphangiogenic growth factors are not critical for the maintenance 
of adult lymphatic vessels in homeostasis. This allows for extended treatment with anti-
lymphangiogenic therapies in tumor settings without disruption of pre-existing vessels and with 
minimal drug-induced toxicities (368, 369). Numerous pre-clinical in vivo studies have 
demonstrated that blocking pro-lymphangiogenic factors VEGF-C and VEGF-D and their receptor 
VEGFR-3 significantly reduces tumor lymphangiogenesis and lymph node metastases in many 
tumor types including pancreatic (108), breast (370-373), melanoma (369), renal (374), lung (156, 
375), gastric (376, 377), prostate (378), hepatocellular (379), and bladder (380). Other protein 
targets of lymphangiogenesis that have shown promise in inhibiting lymphatic metastasis in vivo 
include the VEGFR-3 co-receptor Nrp-2 (381, 382) and the angiopoietins Ang-1 and -2 (383, 384). 
Currently, two humanized neutralizing antibodies are in clinical trials for patients with solid 




“The blockade of a single VEGF/VEGFR pathway will likely be insufficient to inhibit 
tumor lymphangiogenesis and lymph node metastasis due to the multiple compensatory and 
overlapping roles of the VEGF ligands and receptors (52, 66, 366, 385). Other growth mechanisms 
outside of VEGF/VEGFR signaling may also regulate lymphangiogenesis in the tumor setting, such 
as PDGF-BB/PDGFR (76) and FGF/FGFR (386). Receptor tyrosine kinase inhibitors (RTKIs) 
often target multiple receptors allowing them to inhibit several signaling pathways 
simultaneously—including the VEGFR pathways. Both pre-clinical comparative studies and 
clinical trials have determined the safety and efficacy of numerous anti-angiogenic/-
lymphangiogenic RTKIs for the treatment of cancer including foretinib (387), cediranib (388, 389), 
and axitinib (390-392). Some of these RTK inhibitors have also been approved for clinical use. 
Sorafenib, which inhibits VEGFR-1 and -3, PDGFR-β, FGFR-1, and Raf proteins, has been 
approved for renal cell (RCC) and hepatocellular carcinomas (393-395); sunitinib, which inhibits 
VEGFR-1 and -3, and PDGFR-α and -β, has been approved to treat pancreatic neuroendocrine 
tumors, RCC, and gastrointestinal stromal tumors (396-399); and pazopanib, which inhibits 
VEGFR-1 and -3, PDGFR-α and -β, and FGFR, has been approved to treat RCC and soft tissue 
sarcoma (400-402) (RTKIs further reviewed in (42)). Vatalanib, which inhibits VEGFR-1, -2, and 
-3, and PDGFR-β, is currently in clinical trials for the treatment of various solid tumors including 
pancreatic, ovarian, and breast cancers. This RTKI has been shown to directly inhibit angiogenesis, 
lymphangiogenesis, and tumor growth in pre-clinical models of pancreatic cancer as well as other 
cancer models (403-407). In a recent clinical trial, vatalanib resulted in a partial or stable response 
for some metastatic pancreatic cancer patients who had initially failed gemcitabine treatment (408). 
Many of these lymphangiogenic receptor-targeting RTKIs hold promise for the treatment of early-
diagnosed and resectable cancers (52).  Unfortunately, these are not typical characteristics of 
pancreatic cancer, and, consequently, many of these drugs have failed to significantly improve 
pancreatic cancer patient survival (391, 409-411).”  
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“Lymphangiogenesis is not the only manner by which the lymphatic vasculature may 
promote tumor progression. As discussed previously, pre-existing lymphatic vessels can directly 
facilitate metastasis by transporting tumor cells to distant sites, and our studies with GMI-1271 and 
GMI-1359 indicate that is possible to target mechanisms of lymphatic invasion by tumor cells 
during dissemination. Lymphatic endothelia may also contribute to immune suppression by altering 
DC and T cell responses. However, the processes of lymphatic invasion and lymphatic-directed 
immune suppression are poorly understood and much more work needs to be done to determine if 
these functions can be specifically targeted in lymphatic vessels for effective treatment of PDAC 
as well as other cancers.” 
ii. Using lymphatic vessels to deliver therapies to lymph nodes 
“In pancreatic cancer, metastasis to lymph nodes and distant sites has often already 
occurred by the time of diagnosis. Anti-lymphangiogenic therapies may inhibit further tumor cell 
dissemination but will do little to reduce the growth of metastatic tumors that have already 
colonized distant sites (156, 389, 412). Successful treatment of tumor-invaded lymph nodes has 
been particularly difficult to achieve. Resection of invaded lymph nodes would intuitively seem to 
be a promising strategy; however, as discussed above, current clinical imaging technologies cannot 
reliably detect single cell or microscopic lymph node metastases (413, 414), and excision of an 
excessive number of lymph nodes is controversial due to conflicting evidence regarding its survival 
benefits and concerns about post-operative quality-of-life (415, 416). Also, conventional 
intravenously-administered therapies display poor access to lymphatic vessels and lymph nodes 
resulting in sub-optimal drug concentrations within lymph nodes (417). This enables tumor cells 
present within lymph nodes to evade treatment and potentiate future recurrence. Using the 
lymphatic vasculature as a delivery system for cancer therapies to the lymph nodes has gained 
increasing interest. For therapies to be effectively taken up by lymphatic vessels and not blood 
capillaries requires specific characteristics of drug formulations such as being of a particular size 
and molecular weight, lipophilicity and surface charge of the drug carrier, and concentrations of 
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the drug and carrier (reviewed in (418, 419)). A few anti-cancer drugs have been formulated to 
target the lymphatic system and have shown promise in vivo: a methyl poly(ethylene glycol)-
distearoylphosphatidylethanolamine micelle containing doxorubicin reduced the size of lymph 
node metastases in a melanoma model (420); a PEGylation of interferon-α2 demonstrated anti-
tumor efficacy in the lymph nodes of rats with breast cancer (421); cisplatin conjugated to a 
copolymer block of poly(ethylene oxide)-block-poly(lysine) successfully treated lymph node 
metastases in a model of squamous cell carcinoma (422); and gemcitabine loaded onto magnetic 
multiwalled carbon nanotubes (mMWNTs) resulted in better uptake of gemcitabine in the lymph 
nodes and regression of lymph node metastases in a subcutaneous model of pancreatic cancer (380). 
Recently, implantable intralymphatic ports have also been evaluated as a mechanism for delivering 
drugs and DC vaccines to lymph nodes (423, 424). The field of lymphatic-based drug delivery is 
still in its infancy and more studies are required to demonstrate efficacy and feasibility in patients.” 
VI. Conclusions and Perspectives 
The lymphatic system almost certainly plays a significant role in PDAC progression, as 
dissemination is seen early and frequently in PDAC patients. However, the specific mechanisms 
governing tumor-associated lymphangiogenesis, lymphatic invasion, and lymphatic-directed 
metastasis are sorely under-researched as are the contributions of the PDAC microenvironment to 
these processes. In this dissertation, we characterized the effects PDAC cells and pancreatic 
fibroblasts have on lymphatic endothelial cells in regards to recruitment, lymphangiogenesis, and 
invasion. Using novel small molecule inhibitors, we specifically focused on the roles of E-selectin 
and CXCR4 in regulating lymphatic invasion and metastasis. Blockade of E-selectin significantly 
impaired PDAC interactions with lymphatic endothelia resulting in decreased metastasis to the 
lymph nodes. Blockade of CXCR4 also impaired PDAC invasion of lymphatic endothelia as well 
as reshaped the PDAC tumor microenvironment. The work presented in this dissertation uncovers 
some the mechanisms by which lymphatic endothelial cells support PDAC progression 
(particularly invasion and metastasis) as well as how both PDAC tumor cells and pancreatic 
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fibroblasts influence lymphatic biology. Further investigation into the role of the lymphatic 
vasculature during PDAC progression and metastasis will undoubtedly improve our understanding 
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